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Introduction
Cardiovascular diseases are a major public health problem in affluent countries. In 1999
about 36% (or ~50,000) of all deaths in the Netherlands were due to cardiovascular diseases.
In comparison, about 27% was due to cancer, indicating that vascular diseases are the most
important cause of death in the Netherlands (1).
Cardiovascular diseases can roughly be classified into three categories: 1) coronary heart
disease (CHD), 2) cerebrovascular accidents (CVA), and 3) other vascular diseases. In CHD the
coronary arteries that supply blood to the heart, are blocked and in CVA the arteries that supply
blood to the brains are obstructed. The category “other vascular diseases” comprises occlusions
of peripheral arteries or veins, and congenital, infectious and rheumatoid heart diseases. Of all
cardiovascular diseases, CHD is the most prevalent one (1).
Blockage of the coronary arteries often begins with atherosclerosis. This is characterized by
the deposition of cholesterol, cellular waste products, calcium and other substances in the inner
layer of the arterial wall, together with the formation of connective fibrous tissue. This is called
an atherosclerotic plaque. If plaques grow large enough they significantly reduce or obstruct
the blood flow through an artery. They can also become fragile and rupture. Plaques that
rupture induce the formation of blood clots (thrombosis). These clots may locally block the
blood flow or break off and travel to other parts of the body where they may occlude other
arteries or veins (2).
A high blood pressure, an unfavorable cholesterol profile (i.e. high total or LDL and low HDL
cholesterol levels) and smoking explain the majority of all CHD cases. However, the search for
other risk factors remains, as not all CHD cases can be explained by these established risk
factors.
History of homocysteine as risk factor for vascular diseases
The process of identifying homocysteine as a possible risk factor for vascular disease already
started in 1964. By that time Mudd and co-workers (3) showed that the accumulation of
homocysteine in blood, and consequently in urine leading to homocystinuria, was due to
deficiency of the enzyme cystathionine b-synthase (CBS). After this discovery, McCully (4)
observed that a patient with CBS deficiency had comparable arterial damage as another patient
with a different enzymatic abnormality that also led to homocystinuria. Since both abnormalities
shared accumulation of homocysteine, McCully postulated that homocysteine, or one of its
derivatives, was responsible for the arterial damage (4). This formed the basis for the
hypothesis that moderate elevations of homocysteine in blood may be a risk factor for
atherosclerosis in the general population (5). The first to test this hypothesis were Wilcken and
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Wilcken in 1976 (6). They showed that patients with coronary artery disease suffered more
often from an abnormal homocysteine metabolism than controls.
After the initial investigations, numerous experiments focused on the question how
homocysteine might cause vascular damage. To date, no definitive mechanism has been
identified. However, mostly in vitro experiments with very high homocysteine concentrations
have identified the stimulation of atherosclerosis and thrombosis through adverse effects on
coagulation pathways, platelets, endothelial cells, and vascular smooth muscle cells (7).
Homocysteine metabolism
Homocysteine is a sulphur-containing amino acid that is not used for the synthesis of
proteins. Foods only contain traces of homocysteine. Homocysteine is formed when cells
metabolize the essential amino acid methionine. The intracellular homocysteine concentration is
precisely regulated and any excess is transported to plasma. In plasma approximately 99% is
oxidized to disulphides. The vast majority of these disulphides is bound to proteins, only about
1% is reduced “free” homocysteine, unbound to proteins. The term total plasma homocysteine
(conventionally abbreviated with tHcy) refers to all these forms of homocysteine in plasma (8).
Roughly, moderate elevations in the tHcy concentration refer to fasting plasma concentrations
>15-30 µmol/L, intermediate hyperhomocysteinemia refers to concentrations between 30-100
µmol/L, and severe hyperhomocysteinemia refers to concentrations >100 µmol/L (9).
Intracellular homocysteine can irreversibly be degraded to cysteine through the
transsulphuration pathway that is mainly limited to cells of the liver and kidneys. The enzymes
in this pathway, CBS and g-cystathionase, are both dependent on pyridoxal-5’-phosphate, a
biologically active form of vitamin B6, as co-factor. Homocysteine can also be remethylated to
methionine, by the enzyme methionine synthase (MS). This enzyme uses methyl-cobalamin (a
biologically active form of vitamin B12) as co-factor. The methyl-group for the latter reaction is
donated by 5-methyl-tetrahydrofolate (5-methyl-THF). This form of folate is produced by the
enzyme 5,10-methylene-tetrahydrofolate reductase (MTHFR). MTHFR in turn uses a biologically
active form of vitamin B2 (flavin adenine dinucleotide) as co-factor (10,11). In an alternative
remethylation route, which is also mainly restricted to the liver and kidney, betaine is used as
the methyl-donor by the enzyme betaine-homocysteine methyltransferase (BHMT) to
remethylate homocysteine (10). An overview of the homocysteine metabolism is presented in
figure 1.
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Figure 1 Simplified intracellular homocysteine metabolism
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Explanation of abbreviations: BHMT=betaine-homocysteine methyltransferase, CBS=cystathionine b-synthase, C=g-cystathionase,
MS=methionine synthase, MTHFR=5,10-methylene-tetrahydrofolate reductase, TH=tetrahydro, F=folate, B2=vitamin B2,
B6=vitamin B6, B12=vitamin B12.
Disturbances in intracellular homocysteine metabolism lead in most cases to elevated tHcy
levels. Genetically determined functional deficiencies of enzymes in homocysteine metabolism,
like deficiency of CBS, can have an extremely large impact on the tHcy concentration. On the
population level these inborn errors of homocysteine metabolism are not important causes of
elevations in tHcy concentrations, because they are rare; homozygous CBS deficiency is the
most common inborn error and has a prevalence of about 1:335,000 (12,13). Possible tHcy-
determinants on population scale are evaluated in the next section.
Determinants of homocysteine levels in the general
population
Knowledge of factors that determine the tHcy concentration in the general population enables
the identification of high-risk groups in which specific preventive measures can be taken. In
addition, some determinants may be modifiable, which offers the possibility for public health
messages describing how favorable changes in diet and/or lifestyle will lower tHcy levels. This
could have a beneficial effect on the incidence of vascular diseases, assuming a causal relation.
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One objective of this thesis is to identify tHcy-determinants in the general Dutch adult (20-65
years) population. We use the term “determinants” throughout this thesis to indicate factors
that are associated with the tHcy concentration, not necessarily to indicate causal relations.
The following paragraphs give the state of the art with regard to the knowledge on tHcy-
determinants in general populations at the beginning of this PhD-project.
Age and sex
Increasing age and male sex are associated with a higher tHcy concentration (14,15). The
difference between the sexes could be due to the influence of sex hormones. It may also be
due to larger muscle mass in men, since the formation of muscles is associated with the
simultaneous formation of homocysteine in connection with creatine/creatinine synthesis (16).
Part of the relation with age in women might be explained by the menopause, since the tHcy
concentration was found to be higher in post-menopausal women compared with pre-
menopausal women (14,17).
Dietary factors
In the early 90’s it was shown in intervention trials that supplemental folic acid, the synthetic
form of folate in supplements, protected pregnant women from having a child with a neural
tube defect (18,19). In the same period evidence accumulated that folic acid could lower tHcy
levels of subjects with moderately elevated concentrations (20,21).
Besides folate, other B-vitamins are involved in homocysteine metabolism (see figure 1). At
the time of the start of the project described in this thesis, inverse associations between the
dietary intake of vitamin B6, B12 and folate and plasma tHcy levels were reported in a general
population of elderly (22). However, no information was available on dietary intake of B-
vitamins and their relation with the tHcy concentration in adults (20-65 years). Furthermore, no
study investigated the relation between vitamin B2 intake and the tHcy concentration.
Genetic variants and gene-diet interactions
In addition to the rare inborn errors that lead to very high tHcy levels (12,13), there are
genetic variants (polymorphisms) that have a less pronounced effect on the activity of the
enzyme they encode for. The only polymorphism that has been linked to elevated tHcy
concentrations is the 677 C>T mutation in the gene encoding for MTHFR (23). The homozygous
mutant form (TT) is relatively prevalent in the Dutch general population (5-8% (24,25)). Higher
tHcy levels were especially seen in TT subjects with a sub-optimal plasma folate status (26).
This was the first identified gene-nutrient interaction influencing tHcy levels. Because of the role
of the MTHFR enzyme in homocysteine and folate metabolism, it is also of interest to
investigate whether the 677 C>T polymorphism has an effect on the relation between folate
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intake and the plasma folate concentration, and on the relation between folate intake and tHcy
level.
Lifestyle factors
One study based on a large population of adults from Norway investigated the association
between the tHcy concentration and several lifestyle factors. Smoking (27,28) and coffee
consumption (28,29) were associated with higher tHcy levels. Tea consumption was not
associated with the tHcy concentration (29). Physical activity (27) and alcohol consumption (30)
were inversely associated with the tHcy concentration. Confirmation of these results in other
population-based studies is needed. Furthermore, the finding of an inverse relation between
alcohol consumption and tHcy level is remarkable and needs further clarification, as there is
also evidence that alcoholics have very high tHcy levels (31).
Biological CHD risk factors
Several studies concluded that an elevated tHcy level is an independent risk factor for CHD
(32), though associations of the tHcy concentration with established biological risk factors have
been demonstrated. The study from Norway (27) mentioned above reported a positive
association of the tHcy concentration with total cholesterol level, diastolic and systolic blood
pressure. A U-shaped association between the body mass index (BMI) and tHcy level was no
longer present in multivariate models. Waist circumference might be a better indicator for
abdominal fat than BMI and thus might be more relevant for CHD (33). The relation between
HDL cholesterol level and the tHcy concentration was not investigated. To identify potential
confounding factors in studies that quantify the risk of raised levels of tHcy for CHD, more
knowledge on the associations between biological CHD risk factors and the tHcy concentration
is needed.
Epidemiological studies on homocysteine and CHD
In 1995, Boushey et al (32) reviewed the available studies on tHcy concentrations and
cardiovascular diseases. Most of these initial investigations had a retrospective or cross-
sectional study design and consistently suggested a strong positive relation between moderate
elevations in tHcy concentration and risk of cardiovascular diseases (32). A major limitation of
these study designs is that it can not be excluded that the increased tHcy levels are the result
rather than the cause of the disease, because blood samples for these studies are typically
taken after the diagnosis of the cardiovascular event. Prospective studies provide stronger
evidence for a causal role of elevated tHcy levels in the etiology of cardiovascular diseases, as
collection of blood took place before the event.
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When the present PhD-project started in 1997, there were only a few studies with a
prospective design relating elevated tHcy levels to cardiovascular diseases (34). Even fewer
studies considered CHD as an endpoint (35-39). The Physicians’ Health Study found that after 5
years of follow-up, men with a high tHcy concentration (defined as >95th percentile of the tHcy
distribution) had a three-fold higher risk to die of a myocardial infarction relative to men with
lower tHcy levels (defined as <90th percentile) (35). However, after extending the follow-up
period from 5 to 7.5 years, high tHcy levels were no longer associated with an increased risk of
myocardial infarction (36). In another study (37) patients with vascular diseases were followed
to investigate whether higher tHcy levels were related to recurrence of vascular diseases,
including CHD. This was found to be true, as patients with elevated tHcy concentrations more
often demonstrated clinical progression of CHD, when compared with patients with a tHcy level
considered normal (37). Of the 2 available population-based investigations (38,39), a Finnish
study of Alfthan et al (39) found that each 5 µmol/L increase in tHcy concentration was not
associated with an increased risk of myocardial infarction (relative risk (RR)=1.03, 95%
confidence interval (CI)=0.66-1.53 (40)). Conversely, a Norwegian study of Arnessen et al (38)
found that each 5 µmol/L increase in tHcy concentration was progressively associated with the
risk of myocardial infarction (RR=1.41, 95% CI=1.06-1.88 (40)). Both studies included adult
men and women free of baseline myocardial infarction. An important difference may be that the
follow-up period of the Finnish study was 9 years, whereas the follow-up period in the
Norwegian study was only 4 years.
Since 1997 the results of more prospective studies have become available (40-43). The RR
estimates from these studies are smaller, and often not statistically significant, than the RRs
found in earlier cross-sectional and retrospective studies (44). This has increased the doubt on
whether an increase in tHcy concentration is causally related to the development of CHD
(44,45). Nevertheless, a meta-analysis taking the results of most prospective studies together,
shows an overall positive association between the tHcy concentration and the risk of CHD (40).
Yet, the inter-study differences are sometimes large, which may derive from different lengths of
follow-up and from differences in the composition of the study populations. In this thesis we will
further explore the prospective relation between the tHcy concentration and the risk of CHD
mortality in men and women aged 20-59 years.
Outline of the thesis
The main objectives of this thesis are to provide information on the determinants of plasma
total homocysteine (tHcy) concentrations, and to prospectively quantify the risk of elevated
tHcy levels for CHD mortality. Given the tHcy-lowering effect of folate in supplemental form, we
considered folate an important potential tHcy-determinant. Therefore we start this thesis with a
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review on folate intake (CHAPTER 2). In this review we describe the 1997 knowledge with
regard to actual, recommended and desired folate intake in relation to obtaining and
maintaining optimally low tHcy levels.
In CHAPTER 3 we describe the tHcy distribution of the general Dutch adult population. This
information is of value for public health authorities that want to estimate the possible public
health burden of the tHcy concentration in the population. To accurately estimate this burden,
the tHcy measurement needs to be valid and precise, thus issues that affect accuracy are
described. Finally, the effects of age and sex on the tHcy distribution are shown.
As will become clear from chapter 2, the knowledge on the relation between B-vitamin intake
and the tHcy concentration is mainly restricted to results from intervention trials using
supplements. In CHAPTER 4 we will investigate the relation between dietary intake of folate, and
also of the other B-vitamins involved in homocysteine metabolism, and the tHcy concentration
in detail.
Like described earlier, the MTHFR 677 C>T genotype modifies the relation between plasma
folate and tHcy concentrations. In CHAPTER 5 we complement this available information with
the effect of the genotype on the relations between 1) folate intake and plasma folate
concentration and 2) folate intake and tHcy concentration.
To clarify and to confirm or reject some of the relations between lifestyle and tHcy level we
describe the relation between reported smoking, physical activity, coffee, tea and alcohol
consumption and the tHcy concentration in CHAPTER 6. To explore whether one particular type
of alcohol beverage was especially associated with the tHcy concentration, we analyzed its
relation with beer, wine and spirits in CHAPTER 7.
To indicate potential confounders for the relation between tHcy level and the risk of CHD, we
describe how total and HDL cholesterol level, diastolic and systolic blood pressure, and waist
circumference, are associated with the tHcy concentration in CHAPTER 8.
We prospectively examined whether an elevated tHcy concentration is a risk factor for CHD
mortality in the general Dutch population aged 20-59 years in CHAPTER 9. This thesis concludes
with a general discussion of our findings in CHAPTER 10.
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Folate intake and the relation with homocysteine: 
the 1997 state of the art
Objectives: To describe and compare recommended, actual and desired folate intake in light of obtaining and
maintaining optimally low plasma total homocysteine (tHcy) concentrations in European adult populations.
Design: Review of dietary recommendations for folate, food consumption surveys providing information on folate
intake, and intervention and observational studies relating folate intake to tHcy concentrations.
Results: The recommended intake in different countries varies between 200-300 µg/d (men) and 170-300 µg/d
(women). In Europe, mean dietary folate intake in adults is 291 µg/d (range 197-326) for men and 247 µg/d (range
168-320) for women. A daily dose of 650 µg supplemental folic acid is desired to normalize elevated tHcy levels and
a dietary folate intake of at least 350 µg/d is desired to obtain and maintain optimally low tHcy levels in the adult
population in general.
Conclusions: Mean dietary folate intake in Europe is in line with the recommendations, but is not in agreement
with the desired dietary intake of >350 µg/d. This level of intake is only reached by a small part of the studied
European populations. More research is required 1) to establish the lowest effective dose of supplemental folic acid
to normalize high tHcy levels, 2) to determine the lowest effective dose of dietary folate to optimize tHcy levels in the
normal range, and 3) on the bioavailability of folate either naturally or artificially present in foods, which will enable
the choice of a strategy to achieve desired folate intakes in the general population.
Based on: A. de Bree, M. van  Dusseldorp, I.A. Brouwer, K.H. van het Hof and R.P.M. Steegers-Theunissen. Folate
intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997;51:643-660.
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Introduction
Folate is a B-vitamin, which acts as a coenzyme in several single carbon transfer reactions to
synthesize components of DNA, RNA, and amino acids. The term folate describes the group of
derivatives containing the parent molecule pteroylmonoglutamic acid, which exhibits biological
activity. In food, folates are mainly present as reduced tetrahydrofolate polyglutamates. Folic
acid is the synthetic fully oxidized form of pteroylmonoglutamic acid, which is present in
supplements and does not occur naturally in significant quantities.
Folic acid is classically used to treat deficiency symptoms like megaloblastic anemia arising
during pregnancy or infancy. Folate deficiency can also originate from a poor dietary intake or
from absorption disorders like celiac disease. Folic acid should never be used to correct the
macrocytic anemia due to vitamin B12 deficiency (1). During the past 30 years new functions of
folate have been discovered. In 1965 Hibbard and Smithells postulated that folate deficiency
might be associated with imperfect closure of the neural tube (2). At present there is solid
evidence that folic acid supplementation during the periconceptional period significantly reduces
the risk of giving birth to a child with a neural tube defect (3). More recent findings indicate that
supplementation with folic acid decreases plasma total homocysteine levels (tHcy) (4-7).
Furthermore, there are indications that a high dietary folate intake is associated with lower tHcy
levels (8,9). These are significant findings, since elevations in tHcy levels have been associated
with a graded increased risk of vascular diseases, independently of established cardiovascular
risk factors (10). Finally, there is a growing number of studies showing that a high folate intake
is related to a reduced risk of certain types of cancer, like colorectal cancer (11) but thus far no
conclusive evidence on this relation is available (12).
From a public health perspective these new insights on the role of folate are important.
Consequently, this has raised concern about the folate intake of the general population both by
the scientific community (10,13,14) and health authorities (15-20). Scientists have proposed to
increase the current recommended intake levels for folate (8,9,21,22) and this has resulted in a
discussion on possible strategies to raise the folate intake of the general population
(10,14,23,24).
This review describes and compares the recommended, actual and desired folate intake with
regard to obtaining and maintaining optimally low tHcy levels. We concentrate on the general
adult population (age 18-64 years).
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Folate recommendations
Recommended dietary intake (RDI) is a general term to describe the intake level estimated to
be sufficient to cover the needs of the majority (97.5%) of the healthy population. The
recommendation should provide a margin of safety to allow for periods of decreased intake,
increased utilization, individual variability and bioavailability of folates in foods. The RDI can be
used to evaluate intake figures derived from nutritional surveys e.g., to detect groups with a
low intake (25).
Within the European Community, France, Germany, Italy, Ireland, the Netherlands, Portugal,
Spain and the UK have composed their own set of RDIs. Belgium uses the recommendations of
several countries (the USA, the UK, the Netherlands and France) and Greece uses those of the
FAO/WHO and the USA. The Northern European countries Denmark, Sweden, Norway, Finland
and Iceland have established the Nordic Nutrition Recommendations. Beyond the European
community, Bulgaria, the Czech and Slovak republic, Hungary, Poland, and Russia all have their
own recommendations (26).
The most up to date recommendations for dietary folate intake in Europe are those of France,
Germany, the Netherlands, and the UK. These recommendations and those of the FAO/WHO
and the USA are summarized in table 1. The recommendations for males vary from 200 to 300
µg/d and for females from 170 to 300 µg/d. Despite this variation between countries, the most
frequently recommended level of dietary folate intake is 200 µg/d for men and women.
The variation in recommended intake levels is due to the fact that each country has its own
approach, correction factors, and publications on which the recommendations are based. In
general, two manners to establish the RDI for folate can be distinguished. The first approach is
to determine a minimum requirement that is necessary to maintain normal metabolic processes
or to cure clinical and biochemical symptoms of folate deficiency. This minimum amount is then
increased in order to correct for bioavailability and individual variation. The second method is to
evaluate the average dietary folate intake of a population with a known biochemical folate
status. With the information on folate intake and the prevalence of e.g. low red blood cell folate
status, an RDI value can be established which assures a sufficient folate intake for the whole
population. The committees which constituted the RDI for the FAO/WHO, the USA, the UK, and
France combined both approaches. The RDIs of the Netherlands and Germany were solely
based on the first approach. The estimated minimum requirements and the correction factors
are also given in table 1.
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Table 1 Minimum requirements, correction factors and recommended dietary folate intakes (in µg/d) for adults (³ 18
years)
Organization/
Country
Minimum
requirements
Correction for: Recommendations
individual
variation
bioavailability Men Women
FAO/WHO (27) 60 +15% +70% 200 170
USA (28) 60 +30% +50% 200 180
UK (29) 100 +? +50% 200 200
The Netherlands
(30)
50 +200-300% +50% 200-300 200-300
France (31) 50-100 ? ? 300 300
Germany (32) 150 nc +50% 300a 300a
Explanation of abbreviations and symbols: +?=corrections were made, but it is unknown to which extent; ?=unclear whether
corrections were made; nc=no corrections were made; a=the actual German recommendation, for both men and women, is 460
µg/d. This amount is based on the folate content of "raw" material. In this table the actual recommended folate intakes are
summarized, these have been corrected for the estimated 35% loss of folate during preparation and cooking (32).
Folate intake
Folate is present in a wide range of foods. Particularly rich in folate are liver, yeast, green
leafy vegetables, legumes, and fruits like mandarins and grapefruits (33). These foods are not
necessarily the predominant contributors to the folate intake. Major contributors to the folate
intake in the Netherlands, the UK, and Ireland are vegetables, bread and potatoes, responsible
for respectively 15-22%, 12-22%, and 10-15% of the total daily intake (34-36).
Folate intakes of adult populations in Europe are shown in table 2. For this table large recent
national and regional nutritional surveys have been used. When more than one survey per
country was available, the most representative study is shown. The age categories are
tabulated in the format in which they were shown by the original survey. This means that for
some countries the folate intake of subjects under 18 years are presented as well.
The highest folate intake was reported in the Parisian area in France i.e., median folate
intake of men was higher than 400 µg/d, and that of women was higher than 350 µg/d (37).
The lowest folate intakes were found in British, Swedish, and Irish females, and in Irish men
aged 40 years and older. In these populations the median or mean folate intakes were lower
than 200 µg/d (35,36,38). Overall, the weighed mean folate intake was 291 µg/d (range:
197-326 µg/d) for men and 247 µg/d (range: 168-320 µg/d) for women.
Differences in folate intake may partly reflect differences in dietary habits among the
European countries. For example, the higher folate intake in France, but also in Spain and
Portugal, might originate from the Mediterranean diet consumed in these populations. This diet
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consists of a higher portion of folate-rich foods such as vegetables, fruits, and whole grains
compared with Northern European diets (39).
Methodological differences between studies are another source of variation in folate intake.
The different methods used to collect dietary information all have their own advantages and
disadvantages that can potentially have led to an over- or underestimation of the habitual
intake (24). Another methodological issue is the unreliability, or even the lack, of folate content
data in food composition tables. This problem is thought to lead to an underestimation of the
actual folate intake (40). Most surveys did not use food composition tables based on
internationally standardized methods to determine the folate concentration in food, instead
tables based on various techniques to determine the folate content of foods commonly eaten
within that country were used. An exception is the Dutch survey, which used the recent edition
of the McCance and Widdowson's (33). This food composition table gives a complete overview
of the folate content of a broad range of foods and all food samples have been analyzed with
the same method. The analysis of the folate content of food is difficult. The principle forms of
folate in food are reduced pteroylpolyglutamates. High-performance liquid chromatography
(HPLC), ligand binding methods or microbiological assays with the Lactobacillus casei, can
measure these (41). The accuracy of the analysis is highly dependent on the preparative steps,
consisting of the enzymatic deconjugation and the extraction of the polyglutamates. Some
previously used extraction techniques might not have yielded a complete extraction of folates
from the food sample matrix (42). All these methodological differences may partly account for
the different folate intake estimates in the presented studies.
Factors that do not seem to explain differences in average folate intake level among the
surveys are vitamin supplement use and fortification with folic acid. For instance, although
foods fortified with folic acid and vitamin preparations were included in the intake values of the
Irish survey, folate intake was still low (36). In contrast, the intake of folate was much higher in
France excluding vitamin supplements and fortified products (except for some special formulas
like dietetic products) (37).
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Table 2 Daily intake of folate (µg/d) in adult populations in Europe
Men
Intake
Country, reference Method Age N Mean Median
France
Hercberg et al, 1993
(37)
dietary history 18-29 y
30-39 y
40-49 y
50-64 y
total, 18-64 y
84
94
72
76
326
-
-
-
-
389
408
399
453
R:236-674
Spain
Serra Majem et al, 1996
(43)
24 hr recall & food
frequency
questionnaire
18-34 y
35-49 y
50-64 y
total, 18-64 y
360
242
218
820
312
326
315
317
290
289
288
R:130-615
Portugal
Gonçalves Ferreira et al, 1988
(44)
24 hr recall 15-19 y
20-49 y
50-64 y
total, 15-64 y
631
2188
1016
3835
306
295
307
300
-
-
-
The UK
Gregory et al, 1990
(35)
7 d weighed
record
16-24 y
25-34 y
35-49 y
50-64 y
total, 16-64 y
214
254
346
273
1087
302
317
321
300
311
285
303
308
289
R:138-600
Denmark
Andersen et al, 1996
(45)
7 d dietary record 15-18 y
19-24 y
25-34 y
35-44 y
45-54 y
55-64 y
total, 15-64 y
68
85
142
135
147
140
717
295
313
282
329
291
313
304
295
281
290
286
288
287
R:142-603
The Netherlands
Bausch-Goldbohm et al, 1995 (34)
2 d dietary record 16-18 y
19-21 y
22-49 y
50-64 y
total, 16-64 y
128
111
1306
405
1950
274
289
293
299
293
255
281
281
282
R:131-510
Germany
Adolf et al, 1994, 1995 (46)
7 d dietary record 15-18 y
19-24 y
25-50 y
51-65 y
total, 15-65 y
592
1182
4974
1699
8447
320
301
282
284
288
285
269
256
261
R:123-714
Explanation of abbreviation: R=range, derived from lower (2.5 or 5th) and upper (95 or 97.5th) percentile figures.
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Women
Intake Conducted in Comments
N Mean Median
127
102
90
97
416
-
-
-
-
350
379
375
391
R:196-652
1998 Representative sample for Parisian area in France.
Intake from dietary sources only.
Fortifying general food products with folate is not allowed in France,
except for infant formulas and specialized dietetic products.
431
323
260
1014
282
317
320
303
257
291
301
R:116-584
1992-1993 Representative sample for Catalan area in Spain.
Not clear if supplement use is included.
In 1997, fortification with folic acid was not allowed in Spain.
640
2571
1237
4448
257
263
273
265
-
-
-
1980 Representative sample for Portugal.
Not clear if supplement use is included.
Fortification of breakfast cereals was allowed in 1997, but fortified
products were not included in this study.
189
253
385
283
1110
198
206
220
218
213
194
198
212
214
R:84-383
1986-1987 Representative sample for the UK.
Intake from dietary sources only.
Fortification of foods was allowed in 1997, but fortified products
were not included in this study as fortification was just being
introduced: 1986-1987.
84
100
161
158
155
128
786
265
244
266
234
248
241
249
234
220
232
239
248
240
R:138-469
1995 Representative sample for Denmark.
Intake from dietary sources only.
In 1997, fortification with folic acid was not allowed in Denmark.
125
107
1493
545
2270
227
243
234
249
238
215
236
224
242
R:108-390
1992 Representative sample for the Netherlands.
Intake from dietary sources only.
In 1997, fortification with folic acid was not allowed in the
Netherlands.
730
1504
5304
2103
9641
260
251
242
249
246
233
227
219
230
R:98-600
1985-1988 Representative sample for Germany
Not clear if supplement use is included.
In 1997, fortification with folic acid was not allowed in Germany.
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Table 2 continued
Men
Intake
Country, reference Method Age N Mean Median
Sweden
Becker, 1992 (38)
7 d dietary
record
15-18 y
19-29 y
30-44 y
45-64 y
total, 15-64 y
56
152
243
251
702
265
250
225
215
230
-
-
-
-
Ireland
Lee & Cunningham, 1990 (36)
dietary history 18-24 y
25-39 y
40-59 y
total, 18-59 y
51
85
87
223
255
244
197
228
237
238
190
Explanation of abbreviation: R=range, derived from lower (2.5 or 5th) and upper (95 or 97.5th) percentile figures.
Desired folate intake in light of obtaining and maintaining
normal homocysteine levels
B-vitamins play an important role in homocysteine metabolism. Folate is the methyl-donor for
the remethylation of homocysteine to methionine. Furthermore, vitamin B2, B6 and B12 are
cofactors of enzymes in homocysteine metabolism (47). In case of a B-vitamin shortage,
intracellular homocysteine will accumulate and the excess is transported to plasma. Elevations
in the plasma tHcy concentration are associated with an increased risk of vascular diseases
(10). The mechanism underlying this association is not completely understood, but
homocysteine presumably stimulates atherosclerotic as well as thrombotic processes (48).
Because of the substrate donor function of folate in homocysteine metabolism, it may have
the potential to prevent vascular diseases. This hypothesis is supported by the observations that
low serum folate levels were associated with an increased risk of ischemic stroke (49) and
coronary heart disease (50). However, randomized trials are needed to provide definitive proof
for this association (51).
There is no consensus considering the definition of normal or elevated tHcy levels. Reported
normal plasma values in healthy blood donors ranged from 7.9 to 9.3 µmol/L (48). Values
>16.3 µmol/L are commonly considered indicative of mild hyperhomocysteinemia (5-7)
although others have used levels >13.6 µmol/L (52), >14 µmol/L (8), and >15 µmol/L (53).
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Women
Intake Conducted in Comments
N Mean Median
 69
193
251
253
766
192
205
185
195
194
-
-
-
-
1989 Representative sample for Sweden.
Not clear if supplement use is included.
In 1997, fortification with folic acid was not allowed in Sweden.
54
122
111
287
169
182
168
174
157
175
160
-
1990 Representative sample for Ireland.
Supplement use is included.
Fortified products like breakfast cereals were included in this study,
as fortification was allowed since 1987.
In the following paragraphs we evaluate studies that provide evidence on the amount of
folate necessary to obtain and maintain normal tHcy levels. One of the first intervention trials,
in which the effect of folic acid supplementation on tHcy levels was investigated, was performed
in 1988 (4). The authors showed that daily supplementation with 5000 µg folic acid for two
weeks, reduced the tHcy concentration with 52% in a group of men and women (n=42) with
slightly elevated tHcy concentrations. This reduction was not observed in the groups
supplemented with vitamin B6 (40 mg/d) or B12 (1 mg/d). Unfortunately, this study did not
include a control group (4).
A daily combined vitamin supplement containing folic acid (1000 µg), vitamin B6 (12.2 mg),
and vitamin B12 (0.4 mg) for six weeks in mild hyperhomocysteinemic men (n=26), normalized
tHcy levels (<16.3 µmol/L). Doubling the vitamin doses for two weeks, after the initial six
weeks, did not result in a further decrease in tHcy levels (5). The same supplement was used in
another trial (6) with 20 hyperhomocysteinemic men. After 6 weeks of supplementation, an 18-
week washout period followed. Based on the tHcy concentration in week 24, the group was
divided in men with normal (<16.3 µmol/L) and elevated tHcy levels (>16.3 µmol/L). In the
subsequent experimental period, the group with the normal levels received advice to include
more folate-rich foods in their diet. Adherence to these guidelines should have provided 200 µg
folate/d. At the end of the experiment (week 48) these men still had normal tHcy levels (6).
Ubbink et al (7) also conducted a placebo-controlled trial in which the individual effects of
vitamin B6 (12.2 mg), B12 (0.4 mg) and folic acid (650 µg) on mild hyperhomocysteinemia
were compared with the effects of a combined supplement and a placebo. The study comprised
91 men with mild hyperhomocysteinemia (>16.3 µmol/L). No significant reduction in mean tHcy
level was found in the placebo group or in the vitamin B6 group. In contrast, the groups
supplemented with vitamin B12 or with folic acid, or with the three vitamins combined showed
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reductions of 15, 42 and 50%, respectively. The reduction in mean tHcy level with the
combined supplement did not significantly differ from the reduction established with folic acid
alone. From these results the researchers concluded that the tHcy-lowering effect of the
combined supplement was mainly due to folic acid.
Jacob et al (21) performed a controlled depletion-repletion-depletion-repletion study for 108
days in 12 non-smoking apparently healthy men. During the depletion periods the subjects
were fed a diet providing ~25 µg/d of dietary folate. The tHcy levels increased significantly
during depletion and did not normalize in the repletion phases, when the participants were
given 74 µg supplemental folic acid/d and 25 µg dietary folate/d. The authors assumed that 74
µg folic acid equaled ~148 µg dietary folate (bioavailability of food folates is ~50% relative to
folic acid). Thus, the total folate intake of ~173 µg/d was only slightly less than the USA RDI of
200 µg/d (table 1). Based on the lack of normalization of tHcy levels during the repletion
periods, it was concluded that the RDI is not sufficient to obtain a normal tHcy concentration
(21).
This conclusion is complemented with results of a controlled dietary trial in which was shown
that an RDI of 200 µg/d is not sufficient to maintain normal tHcy levels (22). For a period of 70
days, a daily diet providing 30 µg dietary folate plus 170 µg supplemental folic acid (n=5),
significantly increased tHcy levels as compared with baseline levels in apparently healthy
women. The tHcy levels remained normal in the groups with a daily intake of 30 µg dietary
folate plus 270 µg (n=6) and 370 µg (n=6) of supplemental folic acid.
In observational studies with population-based elderly (8) and population-based controls (9),
the curve describing the relation between folate intake and the tHcy concentration, reached its
nadir at a total dietary folate intakes of 350-400 µg/d (8,9). Total refers to folate from the diet
and from supplements. Nevertheless, when only food folates were plotted against tHcy levels,
the nadir was reached at the same amount of folate (P. Verhoef, unpublished data).
Taking all the evidence together, the lowest dose of folic acid that normalized elevated tHcy
levels, was 650 µg/d (7). Once tHcy levels are normalized a daily dietary folate intake of 200 µg
maybe sufficient to maintain this level (6). However, this contrasts the results of the trial in
which 200 µg folate/d (of which 170 µg folic acid and 30 µg dietary folate) was not enough to
prevent an increase in tHcy concentration (22). As these results were obtained with small
numbers of subjects, in an uncontrolled setting (6) and without control groups (6,22), it might
be safer to rely on the results of the observational studies. These indicate that a dietary folate
intake of at least 350 µg/d is probably enough to maintain optimal low tHcy levels (8,9).
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Discussion
Most health authorities recommend a daily intake of 200 µg dietary folate for both men and
women (table 1). Nutrition surveys providing information on mean folate intake and the
standard deviations, offer the possibility to estimate the proportion of the population with an
intake below the generally recommended level of 200 µg/d. However, this is only allowed when
folate intake is normally distributed, which is not the case evaluating medians and percentile
figures. Nevertheless, it is still possible to make a rough estimate. For example, when median
folate intake of a population equals the RDI, 50% of the population has an intake below the
RDI. Using this strategy, table 2 indicates that the majority of the adults in the studied
European countries meet the average RDI of 200 µg/d; weighed mean intake is 291 µg/d for
men and 247 µg/d for women and median values lower than 200 µg/d are not frequently seen.
There appears to be a North-South gradient in dietary folate intake as the highest folate
intake is observed in the Mediterranean area, and the lowest intakes are found in the UK,
Sweden, and Ireland. In the latter countries a substantial part of the population does not meet
the average recommended folate intake of 200 µg/d, which could indicate that the folate
requirements for some individuals are not completely covered. However, it remains possible
that the folate intake is underestimated due to unreliable food composition tables (40-42).
Comparison of actual intakes with the recommended intakes cannot be used to diagnose
under-, mal- or over-nutrition of groups or individuals. This can only be done after the
assessment of the clinical or biochemical status (26). The folate status can be determined by
measuring the concentration of folate either in plasma or serum (reflecting recent folate
intake), or in red blood cells (reflecting intake of the past 2-3 months) (54). Herbeth et al (55)
determined the plasma and red cell folate concentration of a population of 710 adult men and
women. They observed that of the subjects with a folate intake below the RDI (<200 µg/d),
only 25% also had a low plasma folate concentration (<5 µg/L) or a low red blood cell folate
concentration (<200 µg/L). One target of the RDI is to provide a margin safety to allow for
periods of decreased intake, increased utilization, individual variability and bioavailability of
folates in food (25). Therefore, these results (55) are in line with this margin.
RDIs are not established to indicate a level of desired intake. In this review we investigated a
desired folate intake with respect to obtaining and maintaining an optimally low tHcy
concentration. Optimally low tHcy levels are desired in light of the continuous positive graded
association of the tHcy concentration with the risk of vascular diseases. However, the causality
of this association is not yet proven, thus, we can not substantiate that the desired intake that
we established would lead to a lower incidence of vascular diseases. Nevertheless, we have
distinguished two levels: 1) 650 µg/d of supplemental folic acid for adults with elevated plasma
tHcy levels; and 2) a dietary folate intake of at least 350 µg/d for the general adult population.
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Achieving a dietary folate that is equally effective as 650 µg of folic acid would mean a
dietary folate intake of 1300 µg/d, assuming that food folates are only for 50% bioavailable
(relative to folic acid (56,57)). As the average actual folate intake is ~400% lower (table 2), it
seems more realistic to achieve this desirable intake with supplements. There are, however,
preliminary indications that lower doses of folic acid may also effectively lower tHcy levels
(58,59).
To maintain normal tHcy levels, food folates alone may be effective (8,9). Table 2 indicates
that only in the French survey, the majority of the population reached the desired dietary folate
intake of at least 350 µg/d (median intake men ~410 µg/d, women ~370 µg/d) (37). We have
to bear in mind, however, that the evidence for maintaining normal tHcy levels with dietary
folate was derived from only two observational studies (8,9). Future results from randomized
intervention trials might be able to provide evidence considering the lowest dose of dietary
folate to obtain and maintain optimally low tHcy levels.
The discrepancy between the average actual folate intake and the desired folate intake asks
for strategies to increase the folate intake. Is it realistic to stick to dietary advises, while the
bioavailability of supplements is much higher? The difference in bioavailability of supplements
and food is largely due to the fact that folic acid (pteroylmonoglutamic acid) can be absorbed
directly, whereas food folates (mainly polyglutamyls) need to be enzymatically hydrolyzed to
the monoglutamyl form before absorption (60).
The easiest way to increase folate intake may be consuming foods fortified with folic acid.
Compared with folic acid supplements, fortified products are somewhat less bioavailable,
depending on the characteristics of the carrier food (e.g., food matrix, food compounds that
inhibit absorption, etc.). For example, relative to folic acid the bioavailability of fortified bread
was 30%, of fortified maize 50%, and of fortified rice 60% (61). Nevertheless, the
bioavailability of fortified products is higher than that of folates naturally present in foods, as
indicated by preliminary results of an intervention trial performed by Cuskelly et al (62). They
used five intervention groups all targeted to provide an extra 400 µg of folate/d, and one
control group. After 3 months intervention, red blood cell folate increased only in the groups
receiving supplements and fortified foods, compared with the control group. The group supplied
with folate rich foods and the group receiving dietary advice did not show an increase in red cell
folate. Weaknesses of this study were that the design did not allow control of the dietary intake
and of food preparation methods, during which folate losses can easily occur (56). In addition,
the intervention groups were very small: between 6 and 10 subjects per group (62). In
conclusion, fortified foods are effective in optimizing the folate status, nevertheless, the
shortcomings of the study design hamper the conclusion that natural food cannot effectively
optimize the folate status. Consequently, more data on bioavailability of folate in foods is
needed.
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Conclusions
Current dietary folate intake of adults (291 µg/d for men and 247 µg/d for women) is in line
with the average recommended level i.e., 200 µg/d. Elevated tHcy levels can be normalized
with 650 µg supplemental folic acid/d. To maintain optimally low tHcy levels a dietary folate
intake of at least 350 µg/d may be sufficient.
None of the most recent folate intake recommendations (table 1), proposes a desired dietary
folate intake level of 350 µg/d. In light of optimally low tHcy levels, which may be associated
with a lower incidence of cardiovascular diseases, a reconsideration of the current
recommendations might be appropriate. Furthermore, the dietary surveys (table 2) show that
only in the French population more than 50% of the population reaches a dietary folate intake
>350 µg/d.
More research should focus on the lowest effective dose of supplemental folic acid to
normalize initial high tHcy levels and on the lowest effective dose of dietary folate to maintain
an optimally low tHcy level. In addition, more data is needed on the bioavailability of folate
either naturally or artificially present in foods. This research will enable the choice of the
optimal strategy to achieve desired folate intakes in the general population. In the meantime, it
will be worthwhile to stimulate the consumption of foods naturally rich in folate, especially in
Northern European countries where the folate intake is lower than 200 µg/d for more than 50%
of the women of childbearing age and in men ³40 years. Increasing the consumption of foods
of plant origin is safe and will increase the intake of other beneficial nutrients and non-nutrients
simultaneously.
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The plasma homocysteine distribution in the general
Dutch adult population
The non-fasting plasma total homocysteine (tHcy) concentration was measured in a random sample of 3025 Dutch
adults aged 20-65 years (main study). The positively skewed distribution had a geometric mean of 13.9 µmol/L in
men and 12.6 µmol/L in women. Blood of the main study was not cooled or centrifuged immediately after drawing. A
stability study (n=26) indicated that this could have resulted in a small (0.4 µmol/L) overestimation of the means. A
comparative study (n=88), and a reproduction of these results in an entirely different population (n=213), showed a
systematic difference in tHcy concentration of –2.4 µmol/L between our laboratory (Nijmegen, the Netherlands) and
that in Bergen, Norway. With the information of the additional studies we provided precise and valid data of the
Dutch tHcy distribution, from which we conclude the status in the Netherlands is worse than in other European
countries. Furthermore, we showed that comparison of tHcy data is complicated unless the interlaboratory
differences are known.
Published as: A. de Bree, W.M.M. Verschuren, H.J. Blom, A. de Graaf-Hess, F.J.M. Trijbels and D. Kromhout. The
homocysteine distribution: (Mis)judging the burden. J Clin Epi 2001;54:462-469.
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Introduction
Accumulating evidence indicates that the plasma total homocysteine (tHcy) concentration is
an independent risk factor for cardiovascular diseases (CVD) (1-8). Therefore, it is important
that health authorities are provided with information on the possible burden that it might
constitute in the general population. For this purpose knowledge on the tHcy distribution is
necessary. This seems straightforward: provide a laboratory with plasma from a representative
population and describe these data. However, some frequently disregarded problems can lead
to an incorrect interpretation of the tHcy status.
The first problem emerges when a study is not designed to measure the tHcy concentration.
Optimal blood sampling conditions, i.e. cooling or centrifuging whole blood directly after
drawing (9), are necessary to obtain a valid tHcy measurement. Leaving whole blood at room
temperature might artificially increase the tHcy concentration, which is already detectable after
1 h (10,11).
A second commonly overlooked problem is that the tHcy status cannot simply be evaluated
by using reference values established in laboratories other than the laboratory where it was
measured. This difficulty is due to the lack of a gold standard and of a (inter-)national
standardization program for the measurement, which can result in large differences (9-15%) in
the tHcy concentration of one sample measured in different laboratories (12,13).
The goal of this paper is to provide information on the tHcy distribution in the general Dutch
adult population (main study), which has been unavailable up until now. To critically judge this
distribution we performed a stability study and a comparative study, also described in this
article.
Subjects and methods
Subjects
For the main study we used data from the population-based MORGEN study. This is a cross-
sectional investigation into the prevalence of risk factors for chronic diseases as well as the
prevalence of some specific chronic conditions, using self-administered questionnaires and a
physical examination in a randomly selected sample of the Dutch population aged 20-65 years
in three Dutch cities (Amsterdam, Doetinchem, and Maastricht) (14).
From the 19,066 subjects that participated in the MORGEN study during 1993-1996, 14,356
met our inclusion criteria (i.e. completed questionnaires, blood available for all aimed
biochemical analyses, recorded time of drawing and centrifugation of blood). Of these, 7992
subjects were excluded because their whole blood had been stored at room temperature for
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more than 1 h. This left us with a sample of 6364 subjects, out of which we drew an age and
sex stratified sample of 3025 subjects. This sample did not differ from the total 1993-1996
MORGEN population with respect to established cardiovascular risk factors like total and HDL
cholesterol level, blood pressure, social economic status, body mass index and smoking.
The stability study was performed in 1998 with 26 apparently healthy volunteers (14 men, 12
women, aged 24-57 years), working at the National Institute of Public Health and the
Environment.
The comparative study was done in 1999 after the tHcy concentrations (measured in the
Laboratory of Pediatrics and Neurology of the University Hospital in Nijmegen, the Netherlands)
of the main study were available. We made sex-specific deciles and randomly drew 30 subjects
(15 men and 15 women) out of the highest decile, the middle two deciles, and the lowest
decile. From 2 subjects there was not enough plasma, for the remaining 88 subjects the tHcy
concentration was also analyzed in the Laboratory of the Department of Pharmacology at the
University of Bergen, Norway. To reproduce the results of our comparative study we used data
(n=213) from another previously described study population (15). The fasting tHcy
concentration of this population was measured in Bergen between 1992 and 1994, and re-
analyzed in Nijmegen in 1999.
The external Medical-Ethical Committee of the TNO Toxicology and Nutrition Institute, which
follow the guidelines of the Helsinki Declaration, has approved the studies described in this
paper. All subjects gave their informed consent.
Blood sampling and biochemical determinations
All venous blood samples for the MORGEN study were collected in sitting position between
9.00 a.m. and 2 p.m. with no requirements for fasting. Information on the time of the last meal
or beverage was recorded. The samples used for the preparation of plasma were collected in
vacutainers containing 7.5% tri potassium EDTA (Safety-Monovette tubes, Sarstedt, Tilburg, the
Netherlands) and centrifuged at room temperature for 10 minutes at 3000 x g. All samples for
the main study were centrifuged within 1 h. After centrifugation the plasma was separated from
blood cells, and stored at -20°C or -80°C until the homocysteine determination.
Blood collection for the stability study was accomplished in the same manner as in the
MORGEN study; however, the samples were handled differently after drawing. Of each subject
2 vacutainers were collected with one venapuncture. One sample (2.6 ml) was centrifuged
immediately at room temperature to obtain the baseline sample and one (9 ml) was stored at
room temperature, which during the study varied between 18.2 and 21.8°C.
Each 15 minutes after centrifuging of the baseline sample (T0), we aspired 1.5 ml of whole
blood out of the 9 ml tube and centrifuged it to obtain plasma to monitor the change in tHcy
concentration after 15, 30, 45 and 60 minutes. We also measured the change at 75 and 90
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minutes to enable comparisons with other stability studies, which did not report on the change
within 1 h (9-11,16). The plasma samples of each subject were left at room temperature until
all samples (T0 - T90) were acquired. Subsequently the plasma samples were stored at -20°C
until the tHcy determination. Samples of each subject were batched together to be analyzed in
the same run, encoded in such a manner that the laboratory technician was unaware of the
processing time.
The biochemical analyses in Nijmegen were done with an automated high-performance liquid
chromatography with reverse phase separation and fluorescent detection (Gilson 232-401
sample processor (Gilson Medical Electronics Inc., Middleton, WI), Spectra-Physics 8800 solvent
delivery system and Spectra-Physics LC 304 fluorometer (San Jose, CA)), as described by
Fiskerstrand (17), with some modifications (18). The within- and between-run coefficients of
variation (CV) for reference plasma with this method were 3.3% and 8.9%, respectively. The
samples measured in Bergen were analyzed with essentially the same method (17). The within-
and between- day CV of this determination were reported to be <5% (17).
Statistical analysis
In the stability study the change in mean tHcy concentration was calculated by subtracting
the tHcy concentration at baseline from the value at T15 to T90. Evaluation of a significant
change was performed with the signed rank test. The ranking of subjects according to their
baseline tHcy concentration and their tHcy concentration at T15 to T90 was assessed with the
Spearman rank correlation. The mean change in tHcy concentration per minute was estimated
using linear regression analysis with mean change in tHcy concentration at T15 to T90 as the
dependent variable and time as the independent variable. The intercept of this regression line
was set at 0, as at baseline there can neither be an increase nor a decrease in the tHcy
concentration.
In the comparative study (and for the reproduction of these results) we used the tHcy
concentration as measured in Bergen to predict the tHcy concentration as measured in
Nijmegen by means of linear regression. The difference in mean tHcy concentration was
assessed with the signed rank test. The Spearman rank correlation was used to compare the
ranking of subjects according to their tHcy concentration as measured in Nijmegen and in
Bergen.
Linear regression analyses with the data from the main study were performed after
logarithmic transformation of tHcy levels, as this normalized the distribution. When logarithmic
transformations were applied, geometric means are given (antilogarithms of the transformed
means). The effect of the menopause was studied in women aged 45-54 years, as the number
of pre-menopausal (n=183) and post-menopausal (n=175) women was almost equal in this
group. The age-adjusted mean geometric tHcy concentration of pre- and post-menopausal
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women was calculated and tested for differences by means of analysis of covariance. With the
results of the stability study and the information on storage time at room temperature (in
minutes) of the samples of our main study, we estimated what the mean tHcy concentration
would have been if the samples were centrifuged immediately after drawing (i.e. the corrected
value). In addition, we calculated the Spearman rank correlation coefficient between the
measured and the corrected value. Finally, we compared our data with data of the Bergen
laboratory using the results of the comparative study.
Findings were considered statistically significant if the two-sided P value was <0.05. We used
the SAS statistical software (version 6.12) for all statistical analyses (SAS institute Inc., Cary,
North Carolina, USA).
Results
Stability study: the effect of blood sampling conditions on the tHcy concentration
Figure 1 shows the time-dependent change in tHcy concentration from baseline, in whole
blood stored at room temperature. Already 30 minutes after baseline, we observed a significant
mean increase in tHcy concentration of 0.41 µmol/L (P=0.04). After 90 minutes the increase in
tHcy concentration was on average 0.80 µmol/L (P=0.0001).
The correlation between the tHcy concentration at baseline and at T15, T30, T45, T60, T75
and T90 ranged between 0.95 and 0.97. This indicates that the ranking of the 26 subjects
according to their tHcy concentration at baseline, was essentially the same at T15 to T90.
Comparative study: interlaboratory differences in the tHcy measurement
The mean tHcy concentration of the 88 samples was 15.4 µmol/L in Nijmegen and 13.2
µmol/L in Bergen (P=0.0001). The difference in tHcy concentration was systematic: predicting
the tHcy level of Nijmegen with the tHcy level of Bergen with linear regression revealed an
intercept of 2.4 µmol/L and a beta of 0.98. The correlation between the 2 measurements was
0.93, indicating that ranking subjects according to their tHcy concentration as measured in
Nijmegen is in accordance with the ranking of the subjects in Bergen. These results were
reproduced with an entirely different population (n=213) (15): the mean tHcy concentration
was 15.0 µmol/L in Nijmegen and 12.7 µmol/L in Bergen (P=0.0001). The regression equation
revealed a beta of 1.003 and an intercept of 2.2 µmol/L. The correlation between the 2
measurements was 0.86 indicating a similar ranking of the subjects according to the two
laboratories. In figure 2 the Nijmegen and Bergen tHcy values are plotted against each other.
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Figure 1 The time dependent mean change in tHcy concentration in whole blood stored at room temperature
The figure is based on data of 26 subjects (14 men and 12 women). Bars indicate mean absolute change (and 95% confidence
intervals).
Main study: tHcy distribution in the general Dutch population
Figure 3 shows the positively skewed cumulative frequency distribution of the tHcy
concentration for men and women separately. Subjects with a tHcy concentration >30 µmol/L
(33 (2%) men and 14 (0.9%) women) are not shown in this curve. The arithmetic mean for all
men was 14.6 (range 5.9-94.6) µmol/L and for all women 13.1 (6.1-72.2) µmol/L.
The geometric mean (and median) tHcy concentration by age and sex is given in table 1. For
all age categories the tHcy level was higher in men than in women. In both sexes we observed
an age-related increase in the tHcy concentration, which was statistically significant in women,
but not in men.
In women, the largest increase in mean tHcy concentration was observed at the transition
from the age category 40-49 to 50-59 years. To evaluate whether this effect was due to the
occurrence of the menopause, we studied the separate effect of menopause in women aged
45-54 years. Within this group, menopausal status was not a significant predictor of the tHcy
concentration. Furthermore, the age-adjusted mean tHcy concentration did not differ between
pre and post-menopausal women (geometric means: 12.7 vs. 12.9 µmol/L, P=0.4).
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Figure 2 Relation between tHcy concentration as measured in Nijmegen compared with the tHcy concentration as
measured in Bergen
Combined results of the main study and the stability study
Linear regression analyses with data of the stability study predicted an increase in tHcy
concentration of 0.0094 µmol/L per minute. With the information on storage time (in minutes)
at room temperature of the samples of our main study, we could estimate the artificial increase
in tHcy concentration for each sample, and correct for it. The corrected mean geometric tHcy
level for men in the main study was 13.5 µmol/L compared with 13.9 µmol/L uncorrected
(arithmetic: 14.3 vs. 14.6 µmol/L) and for women 12.2 µmol/L compared with 12.6 µmol/L
uncorrected (arithmetic: 12.8 vs. 13.1 µmol/L).
Storage time at room temperature varied between the samples (0-60 minutes, with a mean
time of 36 minutes), which resulted in differences in increases. However, the correlation
between the corrected and measured tHcy concentration was 0.99 for both men and women,
indicating that the artificial increase had not affected the ranking of subjects.
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Explanation of symbols:
The circles are the values of 88 subjects
participating in our main study. The tHcy
concentration for these subjects was
measured first in Nijmegen and re-measured
in Bergen (comparative study).
The triangles are the values of 213 subjects
described in an earlier study (15). The tHcy
concentration for these subjects was
measured first in Bergen and re-measured
in Nijmegen.
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Figure 3 Cumulative frequency distribution of the tHcy concentration in Dutch men and women aged 20-65 years
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Combined results of the main study and the comparative study
As the systematic difference between the tHcy concentration of Nijmegen and Bergen was -
2.4 µmol/L, we adapted the definition of hyperhomocysteinemia from Bergen (i.e. tHcy >15
µmol/L (19)) to 17.4 µmol/L. The prevalence of hyperhomocysteinemia in our main study with
the adapted definition was 14.4% in men and 8.9% in women. With the >15 µmol/L definition
of hyperhomocysteinemia, 30.9% of the men and 19.9% of the women would have been
diagnosed as hyperhomocysteinemic.
Table 1 Mean (median) geometric tHcy (and 95% confidence interval) concentration in µmol/L in the main study by
age and sex
Men Women
Age N tHcy N tHcy
20-65 y 1493 13.9 (13.5) (13.7-14.1) 1532 12.6 (12.2) (12.4-12.8)a
20-29 y 359 13.7 (13.1) (13.3-14.1) 358 12.2 (11.8) (11.8-12.5)a
30-39 y 360 13.9 (13.3) (13.5-14.3) 360 12.5 (12.3) (12.2-12.9)a
40-49 y 360 13.7 (13.4) (13.3-14.1) 358 12.4 (12.1) (12.0-12.7)a
50-59 y 358 14.2 (13.9) (13.7-14.6) 360 13.1 (12.9) (12.7-13.4)a
60-65 y 56 14.6 (14.3) (13.6-15.7) 96    13.5 (13.0) (12.8-14.3)
P for trend by age 0.1 0.0001
Explanation of symbols: a=Significantly different from men in same age category, P=0.0001.
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Table 2 shows the non-fasting tHcy percentiles of our Dutch study population compared with
the fasting tHcy percentiles of the control group of the European Concerted Action Project on
vascular disease (COMAC) (20). The controls of this project originate from 9 European
countries. As the tHcy measurements for the COMAC study were centrally performed in Bergen,
we subtracted 2.4 µmol/L of our original percentile values, in order to make a valuable
comparison. The comparison shows that the tHcy values in this Dutch study were higher in
younger as well as older men and women, compared with the values of the COMAC study.
Furthermore, at higher percentiles the difference between the Dutch and the COMAC
concentrations became larger. For example, in women younger than 45 years, the difference
was 0.4 µmol/L at the 2.5th percentile, 1.6 µmol/L at the 50th percentile and 5.3 at the 97.5th
percentile.
Table 2 The non-fasting tHcy concentration in Dutch adults compared with the fasting tHcy concentration in the
control group of the European Concerted Action Project on homocysteine and vascular disease (COMAC study)
Percentilea
2.5 20 50 80 97.5
Dutch study, all (n=3025) 6.0 8.4 10.5 13.3 22.2
COMAC, all (n=800) 5.9 7.7 9.5 12.1 18.5
Dutch men <45 years (n=899) 6.3 8.7 10.9 14.0 27.5
COMAC men <45 years (n=232) 6.3 7.8 9.6 11.9 18.8
Dutch women <45 years (n=898) 5.2 7.7 9.7 12.2 22.2
COMAC women <45 years (n=135) 4.8 6.6 8.1 10.4 16.9
Dutch men ³45 years (n=594) 7.1 9.4 11.3 14.0 20.3
COMAC men ³45 years (n=338) 6.8 8.5 10.3 12.6 18.6
Dutch women ³45 years (n=634) 6.2 8.3 10.1 13.1 20.9
COMAC women ³45 years (n=95) 5.8 7.1 9.1 11.4 15.1
Explanation of symbols: a=To make a comparison with the COMAC study (20) possible, we subtracted 2.4 µmol/L of our original
percentile values.
Discussion
The goal of our study was to provide data on the tHcy distribution in the Dutch adult
population. Two problems that could hinder a correct judgement of the tHcy status were
evaluated in the stability and the comparative study. The tHcy concentration was skewed
towards higher values, the geometric mean tHcy level was higher (13.9 µmol/L) in men than in
women (12.6 µmol/L) and increased with age. The stability study indicated that our sampling
conditions might have caused a mean artificial increase of 0.4 µmol/L in tHcy concentration, for
both sexess. The comparative study showed a systematic difference of 2.4 µmol/L between the
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laboratory in Nijmegen and Bergen. Taking this difference into account revealed a higher tHcy
concentration in the Netherlands than in other European countries.
Factors that might have contributed to random and systematic errors in our data will now be
discussed. First, it is generally recommended that the subjects should be fasting for the tHcy
measurement (21). Consumption of a normal breakfast is associated with a lower tHcy
concentration (9) and a protein rich meal result in a higher tHcy concentration up until 8 h after
consumption (22). Our data showed no significant difference in tHcy concentration in subjects
who had fasted before the blood collection (n=89), compared with subjects who where non-
fasting (geometric means in men: 14.5 vs. 13.9 µmol/L, P=0.4; in women: 13.3 vs. 12.6
µmol/L, P=0.1).
Second, the tHcy concentration in samples stored at -20°C remains stable over at least 2
years (9,10,23,24). Our samples were stored at this temperature for a median period of 4
(range 0-17) months, while the major part of the total storage time was at -80°C (median 30,
range 11-51 months). As the stability at -80°C is even better than at -20°C, frozen storage time
will not have affected the tHcy concentration.
Third, the intra-individual variation in the tHcy concentration is ~9% over a year, with little
seasonal variation (25-28), resulting in reliability coefficients (the between person variance as a
proportion of the total variance) between 0.82 and 0.90 (26-28). Therefore, a single
measurement characterizes a person with respect to his/her tHcy concentration reasonably well.
Fourth, all samples of the main study were measured between July 1997 until January 1999.
Over this period the within- (repeatability) and between-run (reproducibility) coefficients of
variation for reference plasma (³2 samples in each run) with this method were respectively
3.2% and 8.6%, indicating that the precision of the method is good. The extent of a systematic
error is difficult to establish for the tHcy analysis, as there is no gold standard. Nevertheless,
Fiskerstrand et al (17), who used essentially the same method as we did, observed that known
concentrations of homocysteine added to water or to plasma showed an average recovery of
95%, demonstrating that the validity of this method is appropriate.
Finally, our study population consisted of a random sample from the MORGEN study. All
subjects invited for the MORGEN study received a response card enclosed in their invitation
letter. This card was returned by ~70%, and ~50% completed the full assessment. A non-
response study indicated that non-responders were more likely to be men and to be smokers.
As men and smokers, on average, have a higher tHcy concentration (29), this bias will influence
our tHcy distribution into the direction of lower values. However, the percentage of males
(49%) and smokers (36%) in our study was similar as in a nationwide study (30). Furthermore,
other characteristics of our study population (education and employment) were also comparable
to nationwide data (30). Therefore, we conclude that selective response most likely did not
largely influence our results.
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Taken together, all factors evaluated above do not appear to have seriously affected the
internal validity and precision of our estimate of the tHcy distribution in the Dutch population.
However, our blood sampling conditions introduced a bias due to a continuous synthesis and
transport of homocysteine in blood cells at room temperature (11,31). The stability study
indicated that the MORGEN sampling protocol increased the tHcy concentration with 0.6 µmol/L
per h, which is in line with other stability studies (9-11,16). The increase was independent of
the baseline tHcy concentration and of the amount of blood cells (data not shown). Estimating
the increase for each subject and subtracting that from the measured concentration showed
that the corrected mean concentration might have been 0.4 µmol/L lower. Fortunately, the
increase did neither affect the ranking of the subjects according to their tHcy concentrations nor
appreciably change the prevalence of hyperhomocysteinemia.
The tHcy status of our population was evaluated by comparing our data with those from
other populations. The largest problem in this evaluation, apart from differences in ethnicity,
dietary habits, genotype distribution, etc., is the large interlaboratory variability in the tHcy
measurement. For example, the coefficient of variation of 1 sample sent to 5 laboratories was
15% (13) and 9% for 9 laboratories (12). Therefore, data derived from different laboratories
cannot be compared unless the interlaboratory differences are known.
The comparative study, and the reproduction of these results in an entirely independent
population (15), indicated a systematic difference of -2.4 µmol/L in the measured tHcy
concentration between the laboratory in Bergen and our laboratory. This difference cannot be
attributed to differences in the sampling conditions, as they were exactly the same. The only
difference was that the samples that were sent to Bergen had already been thawed twice for
other biochemical measurements, whereas the vast majority of the samples measured in
Nijmegen were thawed for the first time when they were analyzed. This, however, should not
have influenced the results as repeated freezing and thawing cycles do not affect the tHcy
concentration (19). Therefore, the only plausible explanation for the systematic difference is a
difference in the calibration of the tHcy concentration.
Comparing the adapted non-fasting tHcy percentiles of our study with fasting percentiles
from the controls of the COMAC study (20) (table 2), and with non-fasting tHcy levels
(determined in Bergen) of the population-based Hordaland Homocysteine Study in Norway (32),
showed that the tHcy concentrations in our study were higher and more skewed towards higher
values. The difference between the Dutch and European values may in theory even be larger,
as fasting levels (COMAC study) might be higher than non-fasting levels (9). In this evaluation
we assume a negligible effect of the Dutch (3%) (15) and hospital based (2%) (4) controls that
were included in the COMAC study.
In accordance with the Hordaland Homocysteine Study (32), we observed a higher tHcy
concentration in older subjects. In women, we did not observe an effect of the menopause on
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top of the age related increase. Despite the evidence that the response in tHcy concentration
after a methionine load is larger in post-menopausal women compared with pre-menopausal
women (33,34), the lack of a significant effect of the menopause on the fasting tHcy
concentration has been observed before (35,36).
In conclusion, this study provides precise and valid data of the tHcy status in the Dutch
population aged 20-65 years. We plead for an international standardization or calibration of the
tHcy measurement by an external quality assurance program. This will improve the quality of
the tHcy measurement and will enable comparisons of tHcy data between studies, resulting in
better estimates of the prevalence of hyperhomocysteinemia. For example, if we had used 15
µmol/L as a cut-off level (19), the prevalence of hyperhomocysteinemia in the Netherlands
would have been twice as high. The correct use of the cut-off level decreased the number of
hyperhomocysteinemic subjects, nevertheless, the average tHcy concentration in this population
is worse than in other European countries. Future studies must provide knowledge into factors
that cause this unfavorable tHcy concentration in order to develop optimal public health
strategies to lower the tHcy concentration in the general Dutch population and thereby possibly
reducing the risk for the development of CVD.
Acknowledgements
We thank M.E.P. Hemert-Janssen and S. Houterman for their excellent technical assistance in
the stability study. Furthermore, Prof. H. Refsum and Prof. P.M. Ueland and Dr. A.L. Bjørke-
Mønsen for the measurement of the tHcy concentrations for the comparative study. In addition
we are grateful to Dr. P. Verhoef and K. Lievers for providing data for the reproduction of the
comparative study. We thank the field workers of the Municipal Health Services in Amsterdam,
Doetinchem and Maastricht for their important contribution to the data collection of this study.
References
1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for
vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
2. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC.
Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol
1996;143:845-859.
3. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as
a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
4. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, PalmaReis RJ, Boers GHJ, Sheahan RG, Israelsson
B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, deValk HW, Luis
ACS, ParrotRoulaud FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma
homocysteine as a risk factor for vascular disease: The European concerted action project. JAMA 1997;277:1775-
1781.
5. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-462.
The Homocysteine Distribution
47
6. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal
stroke: Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998;29:2473-
2477.
7. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: Results of a
prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-867.
8. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total
homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch
Intern Med 1999;159:1077-1080.
9. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. The effect of blood sample aging and food consumption on plasma
total homocysteine levels. Clin Chim Acta 1992;207:119-128.
10. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of
homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991;29:549-554.
11. Andersson A, Isaksson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin
Chem 1992;38:1311-1315.
12. Moller J, Christensen L, Rasmussen K. An external quality assessment study on the analysis of methylmalonic acid and total
homocysteine in plasma. Scand J Clin Lab Invest 1997;57:613-619.
13. Eliason SC, Ritter D, Chung HD, Creer M. Interlaboratory variability for total homocysteine analysis in plasma. Clin Chem
1999;45:315-316.
14. Smit HA, Verschuren WMM, Bueno de Mesquita HB, Seidell JC. The monitoring project on risk factors for chronic diseases in
the Netherlands (MORGEN-project): Aim and method. 1994;report number:263200001:1-93 [In Dutch].
15. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, Refsum H. Plasma total
homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-995.
16. Willems HPJ, Bos GMJ, Gerrits WBJ, denHeijer M, Vloet S, Blom HJ. Acidic citrate stabilized blood samples for assay of total
homocysteine. Clin Chem 1998;44:342-345.
17. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated
determination and sample stability. Clin Chem 1993;39:263-271.
18. te Poele Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ. Three
different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995;32:218-220.
19. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods
and clinical applications. Clin Chem 1993;39:1764-1779.
20. Refsum H, Ueland P, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998;49:31-62.
21. Refsum H, Fiskerstrand T, Guttormsen AB, Ueland PM. Assessment of homocysteine status. J Inherit Metab Dis
1997;20:286-294.
22. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations of homocysteine and other
aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994;124:1934-1941.
23. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid--an innocuous means to reduce plasma homocysteine.
Scand J Clin Lab Invest 1988;48:215-221.
24. Dierkes J. Vitamin requirements for the reduction of homocysteine blood levels in healthy young women. Thesis. Bonn:
University of Bonn,1995.
25. Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge N, Lindemans J. Significance of various parameters derived from
biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clin Chem 1997;43:1958-
1964.
26. Rossi E, Beilby JP, McQuillan BM, Hung J. Biological variability and reference intervals for total plasma homocysteine. Ann
Clin Biochem 1999;36 Part 1:56-61.
27. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH. Short-term and long-term variability of plasma
homocysteine measurement. Clin Chem 1997;43:141-145.
28. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT. Variability and determinants of total
homocysteine concentrations in plasma in an elderly population. Clin Chem 1998;44:102-107.
29. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the
Hordaland homocysteine study. Am J Clin Nutr 1998;67:263-270.
30. Central Bureau for Statistics. Statistical Yearbook of the Netherlands. The Hague, The Netherlands: Central Bureau for
Statistics, 1996;1-602 [In Dutch].
31. Malinow MR, Axthelm MK, Meredith MJ, MacDonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood.
J Lab Clin Med 1994;123:421-429.
Chapter 3
48
32. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. Total plasma homocysteine and
cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-1533.
33. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;34:1073-
1077.
34. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in
premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-
1976.
35. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after
methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
36. Verhoef P, Meleady R, Daly LE, Graham IM, Robinson K, Boers GHJ. Homocysteine, vitamin status and risk of vascular
disease - Effects of gender and menopausal status. Eur Heart J 1999;20:1234-1244.
4
Dietary intake of B-vitamins and plasma homocysteine in
the general Dutch adult population
Background: An elevated plasma total homocysteine (tHcy) concentration is associated with an increased risk of
cardiovascular diseases. Folate, vitamin B2, B6 and B12 are essential in homocysteine metabolism.
Objective: To describe the association between dietary intakes of folate, riboflavin (vitamin B2), vitamin B6, and
vitamin B12 and the non-fasting plasma tHcy concentration.
Design: A random sample of 2435 men and women aged 20-65 years, from a population- based Dutch cohort
were analyzed cross-sectionally.
Results: Univariately, intakes of all B-vitamins were inversely related to the plasma tHcy concentration. In
multivariate models, only folate intake remained inversely associated with the plasma tHcy concentration. Mean
plasma tHcy concentrations (adjusted for intakes of riboflavin, vitamin B6, vitamin B12, and methionine and for age,
smoking, and alcohol consumption) in men with low (first quintile: 161 µg/d) and high (fifth quintile: 254 µg/d) folate
intakes were 15.4 and 13.2 µmol/L, respectively; in women plasma tHcy concentrations were 13.7 and 12.4 µmol/L
at folate intakes of 160 and 262 µg/d, respectively. In men, the difference in the mean plasma tHcy concentration
between men with low and high folate intakes was greater in smokers than in non-smokers (2.8 compared with 1.6
µmol/L), and greater in non-drinkers than in drinkers of >2 alcoholic drinks/d (3.5 compared with 1.4 µmol/L). In
women, the association between folate intake and plasma tHcy concentration was not modified by smoking or
alcohol consumption.
Conclusions: In this Dutch population, folate was the only B-vitamin independently inversely associated with the
plasma tHcy concentration. Changing dietary habits may substantially influence the plasma tHcy concentration in the
general population.
Published as: A. de Bree, W.M.M. Verschuren, H.J. Blom and D. Kromhout. Association between B vitamin intake and
plasma homocysteine concentration in the general Dutch population aged 20-65 y. Am J Clin Nutr 2001;73:1027-
1033.
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Introduction
The relation between elevated plasma homocysteine concentrations and cardiovascular
diseases has been suspected since the 1960s. Extremely high plasma homocysteine
concentrations in patients with homocystinuria, a rare genetic disorder of impaired
homocysteine metabolism, are associated with the development of atherosclerosis (1,2). More
recently, numerous studies showed that a moderate elevation of the plasma total homocysteine
(tHcy) concentration is also associated with an increased risk of vascular diseases (3,4).
Although the exact mechanism underlying this association is unidentified, it is suggested that
homocysteine or one of its metabolites contributes to the development of vascular diseases (5-
8).
Homocysteine is a sulfur-containing amino acid derived from the metabolism of the essential
amino acid methionine, which is the only dietary precursor of homocysteine. Several B-vitamins
are involved in homocysteine metabolism. Vitamin B6 is the cofactor of cystathionine b-
synthase, the enzyme that irreversibly converts homocysteine to cystathionine. Vitamin B12 is
the cofactor of methionine synthase, which remethylates homocysteine to methionine. Folate, in
the 5-methyltetrahydrofolate form, donates the methyl-group in this reaction. For one of the
recycling steps to reform 5-methyltetrahydrofolate, the enzyme methylenetetrahydrofolate
reductase is necessary. This enzyme, in turn, uses riboflavin (vitamin B2) as a cofactor (9,10).
Several intervention studies have provided evidence for the importance of B-vitamins in
homocysteine metabolism. Supplements containing folic acid (synthetic form of folate) and also
combinations of folic acid, riboflavin, vitamin B6 and B12 effectively reduced the plasma tHcy
concentrations in subjects with normal (11,12) and elevated (13-16) baseline concentrations.
Although information on the relation between dietary intakes of folate, riboflavin, vitamin B6
and B12, and the plasma tHcy concentration is available for middle aged (17) and elderly
(18,19) populations, it is scarce for the general adult population. This information is essential
for an understanding of to what extent the plasma tHcy concentration can be lowered in the
general population through dietary interventions. The only available large population-based
study of adults (40-67 years), the Hordaland Homocysteine Study, unfortunately did not provide
this information because it lacked detailed information on dietary intakes (20). The present
study contains detailed information on intakes of folate, riboflavin, vitamin B6 and B12 and
describes the association between these vitamins and plasma tHcy concentrations in a random
sample (n=2435) of the general Dutch population aged 20-65 years.
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Subjects and methods
Study population
Data were used from the MORGEN study (21), a cross-sectional investigation into the
prevalence of risk factors for chronic diseases and certain chronic conditions. The population of
this study consisted of a random sample of subjects aged 20-65 years from 3 cities in the
Netherlands: Amsterdam, Doetinchem, and Maastricht. The external Medical-Ethical Committee
of the TNO Toxicology and Nutrition Institute, which follows the guidelines of the Helsinki
Declaration, approved the protocol of the MORGEN study.
Of the 19,066 subjects who participated in the MORGEN study during 1993-1996, 14,356
were considered eligible for the present study because they had completed questionnaires, had
blood available for all aimed biochemical analyses, and had recorded time of drawing and
centrifugation of blood. Of those subjects, 7992 subjects were excluded because their whole
blood samples had been stored at room temperature for >1 h, which may have artificially
increased the plasma tHcy concentration (22,23). A sample of 6364 subjects remained, from
which an age- and sex- stratified random sample of 3025 subjects was drawn. Demographic
variables and cardiovascular disease risk factors of this sample did not differ significantly from
those of the MORGEN study (1993-1996). Furthermore, the distribution of demographic
characteristics (e.g., sex, employment, and education) of our sample was comparable with
nationwide data (23).
Data collection
Respondents answered 2 self-administered questionnaires: a general and a semi-quantitative
food-frequency questionnaire. Subsequently, trained research assistants performed a physical
examination of each subject at the Municipal Health Service.
From the general questionnaire we extracted information on sex, age, smoking and alcohol
consumption. The food-frequency questionnaire assessed the habitual consumption of 178 food
items and vitamin supplements during the previous year. The frequency of consumption of main
items could be indicated in 1) times per day, 2) times per week, 3) times per month, 4) times
per year or 5) never. The amount eaten was estimated in commonly used units by using
household measures or colored photographs of foods showing different portion sizes (24).
Average daily intakes of folate, riboflavin vitamin B6, B12, methionine and total energy were
estimated by multiplying the frequency of consumption of the food items by the portion size
and the nutrient content per gram. Riboflavin, vitamin B6 and energy intakes were calculated
by using an extended version of the 1996 computerized Dutch food composition table (25). This
table does not contain data on folate, vitamin B12 or methionine. Therefore, folate data were
derived from a validated HPLC method with which Dutch foods were analyzed (26,27). Vitamin
Chapter 4
52
B12 and methionine data were compiled from food composition tables from the United States,
United Kingdom, Germany, and Sweden.
The food-frequency questionnaire did not collect information on the doses and contents of
vitamin supplements. Hence, we excluded from all analyses subjects who used supplements
that might have contained B-vitamins (217 men and 371 women), to reduce misclassification of
B-vitamin intake. In addition, one man and one woman were excluded because of unreliable
data in the food-frequency questionnaire.
Blood sampling and biochemical determinations
During the physical examination non-fasting venous blood samples were obtained from
subjects in a sitting position. The samples used for the preparation of plasma were collected in
evacuated tubes containing vacutainers containing 7.5% tripotassium EDTA (Safety-Monovette
tubes, Sarstedt, Tilburg, Netherlands) and were centrifuged at room temperature for 10
minutes at 3000 x g within 1 h of collection. After centrifugation the plasma was separated from
blood cells immediately and stored at -20°C or -80°C until homocysteine was measured.
The plasma tHcy concentration, which includes both the unbound and bound fractions of
homocysteine, was measured by HPLC with fluorescence detection as described by Fiskerstrand
et al (28), with some modifications (29). All samples were measured between July 1997 and
January 1999; the within- and between-run CVs for reference plasma (³2 samples in each run)
were 3.2% and 8.6%, respectively.
Statistical analysis
Because users of B-vitamin supplements were excluded, all analyses were based on the data
of 1275 men and 1160 women.  Differences in characteristics between men and women were
tested with Wilcoxon’s two-sample test. The distributions of nutrient and energy intakes, and
plasma tHcy concentrations were positively skewed; therefore, we used natural logarithmic
transformations to normalize their distributions. Thus, geometric means (antilogarithms of the
transformed means) are presented unless stated otherwise.
To assess the association between intake of B-vitamins and the plasma tHcy concentration,
the nutrients (B-vitamins and methionine) were energy-adjusted by regressing nutrient intake
on total energy intake for each individual. The energy independent residuals of this analysis
were standardized to the predicted nutrient intake at the average energy intake (9391 kJ/d) in
our population (30). Energy adjustments were applied to prevent multicollinearity in the
multivariate models. The adjustments reduced the Spearman correlation between the nutrients
from 0.46-0.81 to 0.12-0.69 and resulted in a maximum variance inflation factor (VIF) of 2.7.
Multicollinearity is a concern when the VIF is larger than 10.0 (31).
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Sex-specific quintiles of B-vitamin intake were created after the logarithmic transformations
and energy adjustments. Each relation between B-vitamin and plasma tHcy was evaluated by
calculating the mean plasma tHcy concentration per quintile of B-vitamin intake. Adjusted mean
plasma tHcy concentrations were estimated by analysis of covariance. Adjustments were made
for age (y), methionine intake (mg/d), smoking (no or yes), and alcohol consumption. Alcohol
consumption was included as 2 indicator variables: £2 drinks/d and >2 drinks/d, with non-
drinkers with as a reference. Non-drinkers comprised abstainers (128 men and 273 women) and
those drinking <1 drink/wk (209 men and 397 women). These variables were associated with
B-vitamin intake and with the plasma tHcy concentration. We also adjusted for the intake of the
3 other B-vitamins under study (included continuously in the model when considered as
confounders) to assess the independent effect of each B-vitamin on the plasma tHcy
concentration.
Trends across the quintiles were evaluated with linear regression, in which the quintiles were
modeled as continuous variables. For the multivariate models similar adjustments were made as
in the analyses of covariance. The regression coefficients of these analyses express a
proportional change, because the plasma tHcy concentration was logarithmically transformed.
The relation between folate intake and the plasma tHcy concentration was visualized by
plotting the adjusted mean plasma tHcy concentration against the mean folate intake in gender
specific deciles of folate intake. The adjusted means were calculated in a manner similar to that
described for the quintiles.
Because both smoking and alcohol consumption are known to interfere with B-vitamin
metabolism (32-35), they were also evaluated as effect modifiers. For this evaluation the P
value of the interaction terms (e.g. smoking ´ folate intake) was assessed for significance in the
multivariate linear regression models.
Differences in the mean plasma tHcy concentration compared with a referent category were
tested by using Bonferroni’s adjustment for multiple comparisons. Findings were considered
statistically significant if the two-sided P value was <0.05. We used the SAS statistical software
(version 6.12) for all statistical analyses (SAS Institute Inc., Cary, NC).
Results
Population characteristics
Selected characteristics of the study population are shown in table 1. Because B-vitamin
supplements are used more frequently by women than by men, the exclusion of B-vitamin
supplement users resulted in a greater number of men in the study. However, the age range of
the men and women was similar. The plasma tHcy concentration was significantly higher in
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men than in women, as were B-vitamin and methionine intakes, and alcohol consumption. The
percentage of smokers was similar between the sexes.
Table 1 Selected characteristics of the study population
Characteristics Men (n=1275) Women (n=1160)
Mean SD Mean SD
Age (years) 40.5 12.1 40.8 12.5
tHcy (µmol/L)a 14.8 6.2 13.4b 4.8
Folate intake (µg/d)a 239 73 192b 54
Vitamin B2 (Riboflavin) (mg/d)a 1.8 0.7 1.5b 0.5
Vitamin B6 (mg/d)a 2.1 0.6 1.6b 0.4
Vitamin B12 (µg/d)a 5.7 2.8 4.3b 2.1
Methionine (mg/d)a 2.1 0.6 1.7b 0.5
Alcohol (drinks/d) 1.7 2.2 0.5b 1.0
Current smokers (%) 35.1 36.5
Explanation of symbols: a=Arithmetic values, b=Significantly different from men, P=0.0001.
Association between B-vitamin intake and the plasma tHcy concentration
Mean plasma tHcy concentrations by quintiles of B-vitamin intake are shown in table 2.
Univariately, the intake of all B-vitamins was inversely associated with the plasma tHcy
concentration in both men and women. An increase in intake of the different B-vitamins from
the lowest (first) to the highest (fifth) quintile was associated with decreases in plasma tHcy
concentration of 0.7 to 2.8 µmol/L. The largest decrease was observed across quintiles of folate
intake; plasma tHcy concentration decreased from 15.8 to 13.0 µmol/L in men and from 14.2 to
12.2 µmol/L in women.
Multivariate regression analyses showed that, after adjustment for age, intake of the other B-
vitamins and methionine, smoking and alcohol consumption, only folate intake remained
inversely associated with the plasma tHcy concentration (table 2). The mean plasma tHcy
concentration decreased from 15.4 µmol/L in the first quintile of folate intake to 13.2 µmol/L in
the fifth quintile in men and from 13.7 to 12.4 µmol/L in women. Each quintile increase in folate
intake was associated with a 3.2% decrease in plasma tHcy in men and a 2.5% decrease in
women.
The association between folate intake and the plasma tHcy concentration in both sexes
described a curve, especially in women, with a steeper slope in the low folate intake range
(140-210 µg/d), which gradually became flatter at higher folate intakes (figure 1). Across the
range of folate intakes, the curve continued to describe an inverse association.
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Table 2 Mean plasma total homocysteine (tHcy) concentrations by quintiles of B-vitamin intake
Men (n=1275)a
Q1 Q2 Q3 Q4 Q5 P for trend
Folate (µg/d)b 161 187 204 223 254
tHcy 15.8 14.4e 13.5e 13.8e 13.0e <0.001
Adjustedc tHcy 15.4 14.3d 13.6e 13.9e 13.2e <0.001
Vitamin B2 (mg/d)b 1.1 1.3 1.5 1.7 2.1
tHcy 14.5 14.5 13.9 13.8 13.7 <0.01
Adjustedc tHcy 13.8 14.4 14.0 14.0 14.2 0.6
Vitamin B6 (mg/d)b 1.5 1.7 1.8 2.0 2.2
tHcy 15.4 14.0e 13.9 e 13.8e 13.3e <0.001
Adjustedc tHcy 14.6 13.9 13.9 14.1 13.8 0.2
Vitamin B12 (µg/d)b 2.9 3.9 4.6 5.5 7.2
tHcy 14.7 14.5 14.2 13.5e 13.4e <0.001
Adjustedc tHcy 14.0 14.3 14.1 13.6 14.3 0.8
Women (n=1160)a
Q1 Q2 Q3 Q4 Q5 P for trend
Folate (µg/d)b 160 188 206 224 262
tHcy 14.2 13.0e 12.6e 12.3e 12.2e <0.001
Adjustedc tHcy 13.7 13.1 12.7e 12.5e 12.4e <0.001
Vitamin B2 (mg/d)b 1.1 1.4 1.6 1.8 2.2
tHcy 13.4 13.2 12.8 12.5d 12.5d <0.001
Adjustedc tHcy 12.8 12.9 12.7 12.7 13.2 0.6
Vitamin B6 (mg/d)b 1.4 1.6 1.7 1.9 2.1
tHcy 14.0 12.8e 13.0d 12.6e 12.1e <0.001
Adjustedc tHcy 13.1 12.6 13.1 12.9 12.6 0.6
Vitamin B12 (µg/d)b 2.9 3.7 4.4 5.3 6.8
tHcy 13.6 13.0 12.6d 12.5d 12.6d <0.001
Adjustedc tHcy 12.8 12.8 12.6 12.7 13.4 0.3
Explanation of symbols: a=Due to missing values the adjusted analyses are based on 1254 men and 1148 women; b=Median
geometric intake per quintile standardized to average energy intake in our population (i.e. 9391 KJ/d); c=Adjusted for intake of
other B-vitamins, intake of methionine, age, smoking (no/yes) and alcohol consumption [drinkers (£2 and >2 alcoholic drinks/d) vs.
non-drinkers]; d and e=Significantly different compared from the lowest folate intake quintile: d=P<0.05, e=P<0.01.
In men the relation between folate intake and the plasma tHcy concentration differed by
smoking status (figure 2). An increase in folate intake of one quintile was associated with a
2.6% decrease in plasma tHcy in non-smokers (P for trend <0.01) and a 4.1% decrease in
smokers (P for trend <0.001). In non-smokers the mean plasma tHcy concentration decreased
with 1.6 µmol/L from the first to the fifth quintile, whereas in smokers it decreased 2.8 µmol/L.
In women we observed that the relation between folate intake and the plasma tHcy
concentration was also somewhat stronger in smokers than in non-smokers, though a
statistically significant interaction was absent.
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Figure 1 Mean plasma total homocysteine (tHcy) concentration in men and women by deciles of folate intake
Explanation of symbols: Means were adjusted for intake of riboflavin, vitamin B6 and B12, methionine, age, smoking (no/yes) and
consumption [drinkers (£2 and >2 alcoholic drinks/d) vs. non-drinkers]. Folate intake was standardized to average energy intake in
our population (i.e. 9391 KJ/d). Asterisks indicate significantly different from the lowest decile of folate intake, P<0.05. Bars
represent 95% confidence intervals.
Figure 2 Mean plasma total homocysteine (tHcy) concentration by quintiles of folate intake in men, stratified for
smoking
Explanation of symbols: Means were adjusted for intake of riboflavin, vitamin B6 and B12, methionine, age and alcohol consumption
[drinkers (£2 and >2 alcoholic drinks/d) vs. non-drinkers].  Asterisks indicate significantly different from the lowest quintile of folate
intake, P<0.05. Bars represent 95% confidence intervals.
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Figure 3 Mean plasma total homocysteine (tHcy) concentration by quintiles of folate intake in males, stratified for
alcohol consumption
Explanations of symbols: Means are adjusted for intake of riboflavin, vitamin B6 and B12, methionine, age and smoking (no/yes).
Asterisks indicate significantly different from the lowest quintile of folate intake, P<0.05. Bars represent 95% confidence intervals.
In men we observed that alcohol consumption also modified the relation between folate
intake and the plasma tHcy concentration (figure 3). An increase of one quintile in folate intake
was associated with a decrease in the plasma tHcy of 5.4% (P for trend <0.001) in non-
drinkers, 2.8 % (P for trend <0.01) in drinkers of £2 drinks alcohol/d, and 1.5% (P for
trend=0.2) in drinkers of >2 drinks alcohol/d. The highest plasma tHcy concentration was
observed in non-drinkers with a low folate intake (first quintile: 16.5 µmol/L). In women,
alcohol did not modify the relation between folate intake and the plasma tHcy concentration.
Discussion
This was the first study in which the association between dietary intake of the B-vitamins
involved in homocysteine metabolism and the non-fasting plasma tHcy concentration was
investigated for a large population-based sample aged 20-65 years. Our results indicate that
after adjustment for confounders, folate was the only B-vitamin independently inversely
associated with the plasma tHcy concentration. Furthermore, we showed that in men this
relation was stronger in smokers and weaker in alcohol drinkers.
In an earlier study we showed that our measurement of the plasma tHcy concentrations is
precise and valid, and thus suitable for use when studying associations (23). Habitual dietary
intake data were collected with a semi-quantitative food-frequency questionnaire. A validation
study indicated that the reproducibility and relative validity of food groups predominantly
contributing to the intake of the B-vitamins (i.e. milk and milk products, meat, potatoes, bread
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and vegetables) for this questionnaire were acceptable and comparable with those of other
food-frequency questionnaires (24).
Our finding that folate is an important dietary correlate of the plasma tHcy concentration
confirms the findings of observational studies in middle-aged (17) and elderly (18,19) subjects.
In contrast with those studies, however, we observed no association between plasma tHcy and
riboflavin (17), vitamin B6 (17-19) and B12 (17), probably because of the more detailed
statistical adjustment that we applied. For example, using the same model as used in the
Framingham study (18), we found an association between vitamin B6 and the plasma tHcy
concentration in men only but not in our complete model. Alcohol consumption emerged as the
strongest confounder in this association; methionine intake was the next strongest confounder.
Moreover, the other 2 studies (17,19) did not correct the intake of one B-vitamin for the intake
of the others. We suspect that if this had been done, there would have been no associations
between the plasma tHcy concentration and riboflavin, vitamin B6, and B12. This suspicion is
suggested by the weakening of these associations after correction for breakfast cereals, many
of which are fortified with vitamins in the United States (17).
Because different B-vitamins are frequently present in the same foods, the intake of one
vitamin can be a marker for the intake of another vitamin. Our results showed that the
univariate associations between the plasma tHcy concentration and riboflavin, vitamin B6 and
B12 existed mainly because of confounding by folate intake. The importance of folate can be
explained by its role in homocysteine metabolism. Folate, in the 5-methyltetrahydrofolate form,
is the substrate donor in the remethylation of homocysteine to methionine (9). In contrast, the
other B-vitamins are cofactors of enzymes and are not used up during homocysteine
degradation; thus, they are not often a limiting factor.
The cross-sectional design of our study limited our identification of causal relations; however,
recent intervention trials showed that increases in the dietary folate intake resulted in decreases
in plasma tHcy concentrations in apparently healthy subjects (36,37). Thus, the relation
between folate and the plasma tHcy concentration is likely to be causal. Assuming causality 3
important conclusions can be drawn from the dose-response relation between folate intake and
the plasma tHcy concentration. First, it describes a curve with a slope that is somewhat steeper
at its beginning but that gradually becomes flatter at higher folate intakes, similar to what was
shown in other observational studies (18,20). This finding implies that an increase in folate
intake [e.g. achieved by consuming an additional bowl of salad and a glass of orange juice each
day (providing >50 µg folate)], has the largest effect on the plasma tHcy concentration when
folate intakes are low (<200 µg/d). Second, plasma tHcy concentrations decrease at folate
intakes >200 µg/d, which is the recommended dietary intake level in the Netherlands (38) and
many other countries (39); thus, this intake is not sufficient to maintain an optimal low plasma
tHcy concentration, as also suggested by other researchers (40-42). Finally, the curve did not
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reach its nadir within this range of folate intakes; thus, the recommended intake should be
>300 µg/d.
In men, we observed a stronger inverse relation between folate intake and plasma tHcy in
smokers. Although it might appear that the interaction is drawn by the high mean plasma tHcy
concentration at the lowest folate intake quintile in smokers, the interaction is also highly
significant (P=0.002) when folate intake is analyzed on a continuos scale. In women we
observed a comparable pattern in plasma tHcy concentration after stratification for smoking,
but there was no statistical interaction. The interaction was not explained by a lower plasma
folate concentration in smokers (32,33,43) because in our study population the plasma folate
concentration in smokers was similar to that of non-smokers after correction for folate intake.
The much higher plasma tHcy concentration in smokers with a similar low folate intake to that
of non-smokers possibly points to the induction of a local folate deficiency in cells exposed to
cigarette smoke (33). A high folate intake in smokers might secure enough folate for the
remethylation of homocysteine within cells, preventing the export of excess in homocysteine to
plasma.
In men the relation between folate intake and the plasma tHcy concentration was also
modified by alcohol consumption. This relation was strongest in non-drinkers and absent in
drinkers of  >2 drinks/d. We observed no interaction in women, likely because of the small
range of alcohol intake: only 42% of the women regularly drank alcohol and only 7% drank >2
drinks/d.
A priori, we expected that, in subjects with a low folate intake, alcohol drinkers would have
higher plasma tHcy concentrations than would non-drinkers because of the adverse effect of
alcohol on the B-vitamin status (34,35). Quite the opposite was true (figure 3). This contrast
with the cited studies (in which a high amount of alcohol was studied) may have been due to
the moderate alcohol consumption in our study (10% of the male drinkers in the present study
consumed >5 alcoholic drinks/d). These findings add to the evidence for a potential beneficial
health effect of moderate alcohol consumption on the cardiovascular system (44).
We evaluated whether the interaction was due to the type of alcohol consumed. For men in
the highest alcohol category, beer was an important contributor to total folate intake. Men in
the lowest folate intake quintile were more frequently wine drinkers: they drank twice as much
wine (~1 drink/d) as did men in the other quintiles. Wine contains betaine (45), which serves
as a methyl donor for the less common remethylation of homocysteine by betaine-
homocysteine methyltransferase (restricted to liver, kidney and adrenal gland tissues) (9). This
process might, at least partly, explain why these male drinkers had a low plasma tHcy
concentration despite their low folate intake. We were not able to adjust for betaine intake due
to the lack of dietary data for this nutrient.
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We conclude that, of the B-vitamins involved in homocysteine metabolism, folate is the most
important dietary determinant of the plasma tHcy concentration. In the general Dutch
population studied, the Dutch folate recommendation was not met by 31% of the men and
61% of the women. It is important to note that even if all of the subjects had met the
recommendation of 200 µg/d, this amount would not lead to an optimal low plasma tHcy
concentration. Our study showed that a high dietary intake of folate can make a substantial
contribution to a reduction in plasma tHcy concentration in the general population, which is
important because each 1-µmol/L decrease in tHcy concentration may be associated with a
10% reduction in risk of cardiovascular diseases (3). These results provide an additional
scientific foundation for current public health educational programs targeted at increasing the
consumption of plant foods, which are particularly rich in folate, to reduce chronic diseases.
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The effect of the MTHFR 677 C>T polymorphism on the
relation between folate intake, plasma folate and plasma
homocysteine in the general Dutch adult population
Context: The common MTHFR 677 C>T polymorphism decreases the enzyme activity and hence the formation of
the circulating form of folate. It has been speculated that TT subjects have higher folate requirements.
Objective: To assess the effect of this polymorphism on the relations: folate intake ® plasma folate
concentration ® total homocysteine concentration (tHcy).
Design, Setting and Participants: Cross-sectional analyses of the above relations in a random sample
(n=2051) of a population-based Dutch cohort (20-65 years).
Results: An increasing folate intake was associated with an increasing plasma folate concentration in all
genotypes (CC, CT and TT). The steepest positive relation was seen in CT subjects: at a low folate intake (155 µg/d)
the plasma folate resembled that of TT subjects (CT: 5.8, TT: 5.7 nmol/L), but at a high folate intake (267 µg/d)
plasma folate resembled that of CC subjects (CT: 8.4, CC: 8.7 nmol/L). In TT subjects, plasma folate remained low
(7.1 nmol/L) despite a high folate intake. The relation between plasma concentrations of folate and tHcy was inverse
in all genotypes and most pronounced in TT subjects: at a low plasma folate concentration (4.0 nmol/L) the tHcy
concentration was much higher for TT subjects than for the other genotypes (TT: 20.9, CT: 15.4, CC: 14.3 µmol/L),
while at high concentrations (13.7 nmol/L) the difference in tHcy concentration was negligible. The relation between
folate intake and the tHcy level also inverse and most pronounced in TT subjects.
Conclusions: Extrapolating our results shows that TT subjects need at least 10% more dietary folate than CT
and CC subjects to achieve a comparable high plasma folate level and a comparable low tHcy level.
Submitted as: A. de Bree, W.M.M. Verschuren, A.L. Bjørke-Monsen, N.M.J. van der Put, S.G. Heil, F.J.M. Trijbels and
H.J. Blom. The MTHFR 677 C>T genotype modifies the relation between folate intake, plasma folate and plasma
homocysteine.
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Introduction
The enzyme methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-
methylene-tetrahydrofolate (THF) to 5-methyl-THF. 5,10-Methylene-THF is an important
compound for DNA and RNA syntheses and 5-methyl-THF is the methyl donor for the
remethylation of homocysteine to methionine (1,2). A common variant of MTHFR (3),
characterized by a C to T missense mutation at nucleotide 677 (4), decreases the enzyme
activity. The prevalence of this mutation is relatively high in the general population, e.g. the
prevalence of homozygosity (TT) is 5-15% in several Caucasian populations (5), therefore it is
called a polymorphism.
A lower MTHFR activity is associated with a higher plasma total homocysteine (tHcy)
concentration (4,6), which is most pronounced in TT subjects with a marginal folate status (7).
The polymorphism also has an effect on the distribution of folates between cells and plasma
(8). Van der Put et al was the first to show that in TT subjects the plasma folate concentration
was lower and the erythrocyte folate concentration was higher as compared with CC subjects
(9). These metabolic changes are postulated to modify the risk of chronic diseases including
cardiovascular diseases (10,11), cancer (12) and dementia (13-15) and neural tube defects
(9,16).
Several researchers have postulated that the folate requirements of TT subjects might be
higher than that of CT and CC subjects (7,17,18), nevertheless, to our knowledge no study
quantified this increased need. In this study, we present data describing the effect of the 677
C>T polymorphism on the relation between folate intake and plasma folate concentration and
on the subsequent relation between plasma folate and tHcy concentration. Furthermore, the
effect of the polymorphism on the relation between folate intake and the tHcy concentration
was investigated (figure 1).
Figure 1 Graphical presentation of the relations investigated in the present study
Explanation of symbols: 1=Relation between dietary folate intake and plasma folate concentration; 2=Relation between plasma
folate concentration and plasma tHcy concentration; 3=Relation between dietary folate intake and plasma tHcy concentration: Solid
arrows indicate relations, discontinuous arrows indicate effect modification.
folate intake plasma folate tHcy
MTHFR 677 C>T
1 2
3
MTHFR 677 C>T Polymorphism and Homocysteine
65
Subjects and Methods
Subjects
We drew an age and sex-stratified random sample of 3025 subjects out of the MORGEN
population examined from 1993 until 1996 (n=19,066) (19). The MORGEN study is a cross-
sectional study of probability samples of men and women living in 3 Dutch towns (Amsterdam,
Maastricht and Doetinchem) located in different regions in the Netherlands. The municipal
population registers were used as sampling frames. The external Medical-Ethical Committee of
the TNO Toxicology and Nutrition Institute, who follows the guidelines of the Helsinki
Declaration, has approved the MORGEN study.
Data collection
Respondents completed two self-administered questionnaires: a general and a semi-
quantitative food-frequency questionnaire. Subsequently, trained research assistants performed
a physical examination at the Municipal Health Service.
From the general questionnaire we extracted information on sex, age and smoking. A semi-
quantitative food-frequency questionnaire (20,21) provided information on dietary habits, from
which we calculated the intake of folate and alcoholic beverages. Besides the intake of folate,
we also assessed the intake of other nutrients (vitamin B2, B6, B12 and methionine) closely
interrelated with folate (1,22,23). The food-frequency questionnaire did not collect information
on the doses and contents of vitamin supplements. Hence, from all analyses we excluded
subjects who used supplements that might have contained B-vitamins (217 men and 371
women), to reduce misclassification of B-vitamin intake.
Blood sampling and biochemical determinations
During the physical examination, non-fasting venous blood samples were obtained. The
samples were collected in vacutainers containing 7.5% K3-EDTA (Safety-MonovetteÒ tubes,
Sarstedt, Tilburg, the Netherlands) and centrifuged within 1 h (10 minutes at 3000 x g). After
centrifugation the plasma and red and white blood cells were separated and stored at -20°C or -
80°C.
The tHcy concentration, including the protein-bound and non-protein-bound fractions of
homocysteine, was measured using high performance liquid chromatography with fluorescence
detection, as described by Fiskerstrand (24), with some modifications (25). The within- and
between-run coefficients of variation (CV) were 3.2% and 8.6%, respectively.
Plasma folate concentration was determined by a Lactobacillus casei microbiological assay
(26) and plasma vitamin B12 concentration was assessed by a Lactobacillus Leichmannii assay
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(27). Both the folate and the vitamin B12 assay were adapted to a microtiter plate format and
were carried out by a robotic workstation (Microlab AT plus; Hamilton Bonaduz). The within-
and between- run CV’s for folate were 4.3 and 10.4%, respectively, and for vitamin B12 1.1 and
1.7%, respectively.
DNA was extracted from frozen peripheral blood lymphocytes with a salting out procedure.
The presence of the 677 C>T mutation was assessed by polymerase chain reaction (PCR)
followed by restriction enzyme analysis with HinFI (4). For 182 men and 204 women the DNA
extraction or genotyping was unsuccessful. The genotype distribution was in Hardy-Weinberg
equilibrium.
Statistical analysis
Due to the exclusion of B-vitamin supplement users (n=588) and subjects with a missing
MTHFR genotype (n=386), all analyses are based on data of 2051 men and women.
The distributions of the plasma concentrations of tHcy, folate and vitamin B12 and the intake
of all nutrients were skewed with a long tail towards higher values; therefore, natural
logarithmic transformations were applied to normalize these distributions. Inverse
transformations were performed to provide geometric means and their 95% confidence
intervals. After logistic transformation, the intakes of the nutrients (B-vitamins and methionine)
were energy-adjusted according to the method of Willett et al (28,29).
Mean values of B-vitamin and methionine intake and of plasma concentrations of folate, B12
and tHcy were calculated by 677 C>T genotype (CC, CT and TT) and P values for trends were
calculated with univariate linear regression analyses with genotype as the independent variable.
The role of the 677 C>T polymorphism in the relations between 1) folate intake and plasma
folate concentration, 2) plasma folate and tHcy concentration and 3) folate intake and tHcy
concentration (figure 1) was described for men and women together, as effect modification by
sex was not observed for these relations. Effect modification by the polymorphism in the above
relations was evaluated in linear regression models with the inclusion of the appropriate
interaction terms e.g. folate intake ´ genotype. A P value <0.05 for the interaction term was
considered to indicate a statistically significant interaction.
Genotype-stratified relations were adjusted for age and sex, in multiple regression models we
also adjusted for alcohol consumption (drinks/d) and smoking (no/yes). Furthermore, we
adjusted for vitamin B12 intake in the relations with folate intake as explanatory variable, and
for plasma B12 in the relation with plasma folate as explanatory variable. As we did not have
plasma levels of vitamin B2, B6 and methionine we could only adjust the associations for
intakes of these nutrients.
The mean adjusted plasma folate or tHcy levels (and 95% confidence intervals) for tertiles or
quintiles (based on the total population, i.e. not genotype specific) of folate intake or plasma
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folate levels were calculated by analyses of covariance, as implemented in SAS “PROC GLM”.
Differences in mean levels compared with a referent category were tested using Bonferroni’s
adjustment for multiple comparisons.
Findings were considered statistically significant if the two-sided P-value was <0.05. Data
were analyzed with SAS statistical software (version 8.1) (SAS institute Inc., Cary, North
Carolina, USA).
Results
Dietary and blood indices by MTHFR 677 C>T genotype
The study population consisted of 1094 men and 957 women with a mean age of 41 years
(range 20-65 years). Dietary folate, vitamin B2, B6, B12 and methionine intakes were similar for
all genotypes (table 1). The plasma folate concentration was inversely associated with the
presence of a T allele. Compared with CC subjects, the average plasma folate concentration
was 1.7 nmol/L lower in TT subjects and 0.8 nmol/L lower in CT subjects. The prevalence of a
low plasma folate concentration (defined as <4.5 nmol/L) increased with the presence of the
mutation: 8% in CC subjects, 11% in CT subjects and 23% in TT subjects. There was no
association between the 677 C>T polymorphism and the plasma vitamin B12 concentration.
We observed a strong positive trend (P<0.0001) between the presence of the T allel and the
tHcy level (table 1). On average, the presence of one T allele resulted in a 0.7 µmol/L higher
tHcy concentration and two T alleles resulted in a 4.2 µmol/L higher tHcy level compared with
subjects with no T alleles. The prevalence of hyperhomocysteinemia, (defined as tHcy >17.4
µmol/L), increased dramatically with the presence of the mutation: 8% in CC subjects, 12% in
CT subjects and 38% in TT subjects.
The effect of the 677 C>T MTHFR genotype on the relations between intake of
folate, plasma folate and tHcy levels
The 677 C>T polymorphism statistically significantly modified the relation between 1) folate
intake and plasma folate concentration (table 2a), 2) plasma folate and tHcy concentration
(table 2b), and 3) folate intake and tHcy concentration (table 2c).
Table 2a presents the age and sex-adjusted relation between folate intake and plasma folate
concentration by genotype, both in tertiles and continuously. The mean plasma folate
concentration increased with an increasing folate intake for all genotypes, however, more
strongly in subjects with a T allele. The difference in plasma folate level between the 1st tertile
(T1) and the 3rd tertile (T3) was 2.0 nmol/L for CT subjects and 1.7 nmol/L for TT subjects,
compared with 1.5 nmol/L in CC subjects. On a continuous scale, in the age and sex-adjusted
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models, the relation between folate intake and plasma folate level was also stronger in subjects
with one or two T alleles than in subjects with no T allele (see b-coefficients in table 2a).
Table 1 Mean levels and range (1st - 99th percentile) of dietary and blood indices by MTHFR 677 C>T genotype for
men and women aged 20-65 years
all
(n=2051)a
CC
(n=983)b
CT
(n=907)c
TT
(n=206)d
P for
trend
Folate intake (µg/d) 204
124-330
205
124-358
203
125-316
201
111-309
0.09
Vitamin B2 intake (mg/d) 1.53
0.88-2.93
1.53
0.86-2.92
1.52
0.88-2.93
1.53
0.90-2.82
0.8
Vitamin B6 intake (mg/d) 1.77
1.14-2.58
1.78
1.14-2.60
1.76
1.11-2.48
1.75
1.19-2.59
0.09
Vitamin B12 intake (µg/d) 4.53
1.86-12.1
4.58
1.93-12.1
4.47
1.82-11.5
4.58
2.08-12.0
0.4
Methionine intake (mg/d) 1.81
1.14-2.63
1.81
1.13-2.64
1.80
1.16-2.57
1.83
1.20-2.53
0.9
Plasma folate (nmol/L) 7.4
2.4-22.4
8.0
3.4-22.2
7.2
2.5-20.9
6.3
2.6-26.6
<0.001
Plasma vitamin B12 (pmol/L) 284
102-638
288
105-735
283
105-649
274
101-683
0.1
Plasma tHcy (µmol/L) 13.6
7.8-39.5
12.9
7.5-22.5
13.6
8.1-33.4
17.1
8.1-67.1
<0.001
Explanations of symbols: a=The minimal number of valid observations subjects was 2037; b=The minimal number of valid
observations for CC subjects was 928; c=The minimal number of valid observations for CT subjects was 904; d=The minimal
number of valid observations for TT subjects was 205.
The multiple adjusted (age, sex, alcohol consumption, smoking, intake of vitamin B2, B6, B12
and methionine) b-coefficients show that the relation between folate intake and plasma folate
level was most strong in CT subjects. The adjusted relations are visualized in figure 2a. At a low
folate intake level (1st quintile, i.e. mean intake of 155 µg/d) the plasma folate level of CT
subjects was almost equal to that of TT subjects: mean plasma folate level was 5.7 nmol/L in
TT and 5.8 nmol/L in CT subjects. However, at high folate intake (5th quintile, i.e. mean intake
of 267 µg/d) the plasma folate level of CT subjects was almost identical to that of CC subjects:
mean plasma folate level was 8.4 nmol/L in CT versus 8.7 nmol/L in CC subjects.
Table 2b shows the age and sex-adjusted relation between plasma concentrations of folate
and tHcy, by genotype. The mean tHcy concentration decreased with increasing plasma folate
concentration for all genotypes. This reduction was larger in CT subjects than in CC subjects
(2.9 vs. 2.0 µmol/L), and largest in TT subjects (7.6 µmol/L). The age and sex-adjusted b-
coefficient confirmed the strong inverse relation between the plasma folate and tHcy
concentration for TT subjects on a continuous scale.
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Table 2a Mean (and 95% confidence interval (CI)) plasma folate concentration per tertile (T) of folate intake,
stratified by genotype
Mean folate
intake per
tertile
T1
166 µg/d
T2
205 µg/d
T3
250 µg/d
ba of folate included
continuously in
simpleb model (95%
CI)
ba of folate
included
continuously in
multiplec model
(95% CI)
CC, n=938d 7.1
(6.8;7.4)
8.2
(7.8;8.6)
8.6
(8.2;9.0)
0.47
(0.34;0.60)
0.41
(0.24;0.58)
CT, n=907e 6.2
(5.9;6.5)
7.3
(7.0;7.6)
8.2
(7.8;8.6)
0.68
 (0.54;0.82)
0.76
(0.58;0.94)
TT, n=206f 5.5
(4.9;6.2)
6.4
(5.6;7.4)
7.2
(6.4;8.2)
0.77
(0.40;1.14)
0.63
(0.16;1.10)
Table 2b Mean (and 95% confidence interval (CI)) tHcy concentration per tertile (T) of plasma folate concentration,
stratified by genotype
Mean plasma
folate per
tertile
T1
4.6 nmol/L
T2
7.5 nmol/L
T3
11.9 nmol/L
ba of folate included
continuously in
simpleb model
(95% CI)
ba of folate
included
continuously in
multiplec model
(95% CI)
CC, n=938d 14.1
(13.7;14.5)
12.9 (12.6;13.2) 12.1 (11.8;12.4) -0.17
(-0.20; -0.13)
-0.15
(-0.18; -0.11)
CT, n=907e 15.1
(14.8;15.5)
13.2 (12.8;13.5) 12.2 (11.9;12.6) -0.25
(-0.29; -0.22)
-0.22
(-0.25; -0.18)
TT, n=206f 20.6
(19.1;22.3)
14.9 (13.3;16.6) 13.0 (11.6;14.6) -0.48
(-0.57; -0.39)
-0.38
(-0.47; -0.28)
Table 2c Mean (and 95% confidence interval (CI)) tHcy concentration per tertile (T) of folate intake, stratified by
genotype
Mean folate
intake per
tertile
T1
166 µg/d
T2
205 µg/d
T3
250 µg/d
ba of folate included
continuously in
simpleb model (95%
CI)
ba of folate
included
continuously in
multiplec model
(95% CI)
CC, n=938d 13.7
(13.4;14.1) 12.6 (12.3;12.9) 12.4 (12.1;12.7)
-0.24
(-0.31; -0.16)
-0.20
(-0.30; -0.10)
CT, n=907 e 14.6
(14.2;15.0) 13.4 (13.0;13.7) 12.8 (12.4;13.2)
-0.36
(-0.44; -0.28)
-0.30
(-0.41; -0.19)
TT, n=206 f 19.6
(17.8;21.6)
16.3 (14.6;18.2) 15.2 (13.7;16.9) -0.78
(-1.08; -0.49)
-0.53
(-0.90; -0.15)
Explanation of symbols: a=b ’s of linear regression models, they express the change in respectively log plasma folate or log tHcy
associated with 1 unit change in log folate intake or log plasma folate; b=adjustments for age and sex; c=adjustments for age, sex,
intake of vitamin B2, B6, and methionine, smoking (no/yes) and alcohol consumption (drinks/d). The models in table 2a and 2c
were adjusted for vitamin B12 intake, and the model in table 2b for plasma vitamin B12; d,e,f=minimal number of observations
d=925; e=901; f=205.
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Figure 2a Mean adjusteda plasma folate concentration by quintiles of folate intake in Dutch men and women aged
20-65 years, stratified for genotype
Explanation of symbols: a=Means are adjusted for age, sex, smoking (no/yes) alcohol consumption (drinks/d), intake of vitamin B2,
B6 and B12, methionine; Asterisks indicate significantly different plasma folate concentration compared with the first quintile of the
respective genotype: * P<0.05, ** P<0.01, *** P<0.001.
After multiple adjustment the negative b-coefficient for the relation between the plasma
folate (continuously) and the tHcy concentration for all genotypes did not appreciably change
(table 2b). These relations are visualized in figure 2b. The effect of the MTHFR 677 C>T
polymorphism was most obvious at a low plasma folate level (1st quintile, i.e. mean plasma
folate of 4.0 nmol/L): TT subjects had a mean tHcy level of 20.9 µmol/L compared with 15.4
µmol/L in CT subjects and 14.3 µmol/L in CC subjects. At high plasma folate levels (5th quintile,
i.e. mean plasma folate of 13.7 nmol/L) the tHcy concentration in all genotypes were similar
(CC=12.0 µmol/L, CT=11.8 µmol/L, TT=12.6 µmol/L).
4.0
5.0
6.0
7.0
8.0
9.0
10.0
140 160 180 200 220 240 260 280
Folate intake (µg/d)
P
la
sm
a 
fo
la
te
 (
n
m
o
l/L
)
CC CT TT
* ***
***
***
***
**
***
MTHFR 677 C>T Polymorphism and Homocysteine
71
Figure 2b Mean adjusteda tHcy concentration by quintiles of plasma folate concentration in Dutch men and women
aged 20-65 years, stratified for genotype
Explanation of symbols: a=Means are adjusted for age, sex, smoking (no/yes) alcohol consumption (drinks/d), intake of vitamin B2,
B6 and methionine, and plasma vitamin B12; Asterisks indicate significantly different plasma folate concentration compared with the
first quintile of the respective genotype: * P<0.05, ** P<0.01, *** P<0.001.
Finally, table 2c shows the age and sex-adjusted relation between folate intake and the tHcy
concentration, by genotype. In general, these relations were comparable to those between the
plasma folate and the tHcy concentration described above. The age and sex-adjusted b-
coefficient of the relation between the concentration of plasma folate and of tHcy on a
continuous scale, was strongest for TT subjects. The same is true for the multiple adjusted
relation.
The b-coefficients for the relation between folate intake and the tHcy concentration were
larger than those for the relation between plasma folate and tHcy concentration. This is due to
the fact that extreme low or high values are more likely to occur in intake than in plasma levels.
The b-coefficients of continuous relations are sensitive to these extremes. When summarizing
the data in tertiles we saw that the effect of extremes disappears: the difference in tHcy
concentration over the tertiles is higher for plasma folate level than for folate intake.
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Figure 2c Mean adjusteda tHcy concentration by quintiles of folate intake in Dutch men and women aged 20-65
years, stratified for genotype
Explanation of symbols: a=Means are adjusted for age, sex, smoking (no/yes) alcohol consumption (drinks/d), intake of vitamin B2,
B6, B12 and methionine; Asterisks indicate significantly different plasma folate concentration compared with the first quintile of the
respective genotype: * P<0.05, ** P<0.01, *** P<0.001.
Figure 2c visualizes the multiple adjusted relation between folate intake and the tHcy level. At
a low folate intake (1st quintile, i.e. mean intake of 155 µg/d) the tHcy concentration of TT
subjects is statistically significantly higher than of CT and TT subjects. At a high folate intake
(5th quintile, i.e. mean intake of 267 µg/d) the tHcy concentration of TT subjects was similar to
that of CT subjects, but statistically significantly higher than the concentration of CC subjects
(TT=15.7 µmol/L, CT=13.1 µmol/L, CC=12.4 µmol/L).
Discussion
This is the first population-based study that extensively studied the effect of the MTHFR 677
C>T polymorphism on the relation between folate intake, plasma folate and tHcy concentration.
TT subjects had a lower plasma folate concentration despite the fact that their folate intake was
equal to that of CT and CC subjects. CT subjects experienced an unfavorable effect of their T
allele only when they had a low folate intake. The effect of the T allele in the relation between
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plasma folate and tHcy level was most pronounced in TT subjects with a low plasma folate
concentration. The same is true for the relation between folate intake and the tHcy level.
In the present study, 10% of the subjects were identified homozygous for the 677 C>T
mutation; heterozygotes accounted for 44% of the subjects. These values are similar to those
reported in other Caucasian populations (5). The fact that we had a complete data-set for a
sub-sample of the original random sample (n=3025) did not substantially affect the
representativity of our study sample: the distribution of age, lifestyle factors, biological
cardiovascular disease risk factors (i.e. blood pressure, total and HDL cholesterol level) was
equal for subjects who were (n=2051) and were not (n=974) included.
The intake of folate and other relevant nutrients was assessed with a food-frequency
questionnaire validated for the intake of food groups predominantly contributing to the intake of
the studied nutrients (i.e. vegetables, bread, milk and milk products, meat and potatoes) (21).
Furthermore, folate intake correlated with plasma folate level in the same magnitude
(Spearman correlation 0.27) as in other Dutch studies (30,31). Plasma folate levels were
somewhat lower compared with levels measured in other Dutch populations (9,30,32,33). This
difference may be attributable to different methods used to measure the folate concentration
(34,35); in addition, we excluded all B-vitamin supplement users (see subjects and methods)
and they had higher plasma folate concentrations (data not shown).
The product of MTHFR, 5-methyl-THF, is the predominant circulating form of folate, whereas
the enzyme substrate 5,10-methylene-THF is found mainly intracellularly (8,36). As the 677
C>T mutation results in a reduced specific enzymatic activity of MTHFR (~34% residual activity
in TT, ~71% residual activity in CT relative to CC) (37), the expected result of the presence of a
T allele is a lower plasma folate concentration. After Van der Put et al (9) many investigators
have reported a lower plasma folate concentration in TT subjects compared with CC subjects
(17,38-44). We were able to investigate whether differences in folate intake could explain this
observation. This was not the case: for each folate intake quintile (where folate intake was
equal for all genotypes) TT subjects always had lower plasma folate concentrations compared
with CT and CC subjects (figure 2a). A comparable finding was briefly mentioned in another
study, but the results were not shown (17).
Extrapolating figure 2a, indicates that TT subjects would reach the average mean plasma
folate level of CC subjects in the highest quintile (i.e. 8.7 nmol/L) at an average folate intake of
about 375 µg/d (i.e. at an intake level 40% higher than the current mean of the 5th quintile in
TT individuals). Note, however, that despite the substantial differences in mean plasma folate
concentration between TT and CC subjects, these differences did not always reach statistical
significance due to the relatively small number of TT subjects. Statistical power was not a
problem in the larger group of CT subjects. We observed that carrying one T allele only shows a
disadvantage, i.e. a low plasma folate concentration, in subjects with a folate intake in the
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lowest quintile. Yet, a folate intake at or above the mean level of the 2nd quintile (i.e. >186
µg/d) resulted in similar plasma folate concentrations in CT subjects as for CC subjects. Our
observation that the CT genotype can lead to low plasma folate levels when folate intake is low,
may add another explanation (11) for the inconsistent results that are found when the risk of
cardiovascular diseases is quantified in TT subjects versus CT and CC subjects together.
The effect of the MTHFR 677 C>T polymorphism on the relation between plasma folate and
tHcy concentration (figure 2b), was most pronounced in TT subjects: in the lowest plasma
folate quintile (mean plasma folate concentration: 4.0 nmol/L) TT subjects had a very high tHcy
concentration compared to CT and CC subjects. On the other hand, in the highest plasma folate
quintile (mean plasma folate concentration: 13.7 nmol/L) the tHcy concentration of TT subjects
was equally low as that of CT and CC subjects. A statistically significant difference in mean tHcy
concentration between the genotypes was no longer present at an average plasma folate
concentration of 7.5 nmol/L (3rd plasma folate quintile). From figure 2a we can deduce that TT
subjects would reach this average plasma folate concentration at a daily folate intake of ~300
µg/d, a level 10% higher than the current mean of the 5th quintile in TT individuals. Note that
this is probably an optimistically low estimation as only in the highest plasma folate quintile the
tHcy concentrations of the genotypes were similar (figure 2b). From figure 2c it can be deduced
that when TT subjects would have a mean intake level of 300 µg/d, this would lead to a lower
tHcy concentration, approaching the level of CC subjects. Yet, to achieve a similarly low tHcy
concentration, a folate intake of more than 300 µg/d is probably necessary.
The effect of the polymorphism on the relation between the plasma folate and tHcy
concentration agrees with other studies (7,11,45). So far, one other study has reported the
modifying effect of the polymorphism on the relation between folate intake and the tHcy level
(17). Similar as in the present study, they found that at a low folate intake TT subjects had
much higher tHcy levels compared with CT and CC subjects. Alternatively, at high folate intakes
the tHcy level of TT subjects was more comparable to that of CT and CC subjects. These results
in general population samples agree with the results found in folic acid intervention studies.
These trials showed a steeper decrease in tHcy concentration as a response to an increased
folate intake in TT subjects compared with CT and CC subjects (39,46).
The mechanism behind the observation that a high folate intake protects against high tHcy
concentrations and low plasma folate levels in subjects with a T allele is nicely illustrated by
recent findings of Guenther et al (23). In a system with bacteria they showed that a mutation
homologous to the human MTHFR 677 C>T mutation was associated with an enhanced
dissociation of flavin adenine dinucleotide (FAD, i.e. cofactor form of vitamin B2). An optimal
folate supply prevented the loss of FAD and suppressed the inactivation of the enzyme (23).
In conclusion, this study describes an important gene-environment interaction in the general
population. Our findings indicate that subjects with the 677 C>T mutation, especially those with
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the mutation in homozygous form, have a higher dietary folate requirement to obtain a plasma
folate concentration comparably high as that of CT and CC subjects. Once they have reached a
high plasma folate concentration, their tHcy concentration is not different from that of CT or CC
subjects. Currently, the recommended dietary intake of folate for adults is 200–300 µg/d in The
Netherlands (47) and other European countries (48). This recommendation is estimated to be
sufficient to cover the needs of the majority (97.5%) of the healthy population. This study
demonstrated that 10% of the population, with the TT genotype of the MTHFR 677 C>T
polymorphism, requires more folate than 300 µg/d to optimize their plasma folate and tHcy
concentration. In light of our results, a reconsideration of the Dutch recommendations according to
the recent new dietary reference intakes in the United States (i.e. 400 µg of folate/d) (49) may be
appropriate.
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Lifestyle factors and plasma homocysteine in the general
Dutch adult population
The authors cross-sectionally investigated the extent to which coffee, tea, and alcohol consumption, physical
activity, and smoking were associated with the non-fasting total plasma homocysteine (tHcy) concentrations in a
random sample of 3025 Dutch adults aged 20-65 years from a population-based cohort examined in 1993-1996
(n=19,066).
The lifestyle factors most strongly associated with the tHcy concentration were smoking (positive), alcohol
drinking (negative), and coffee consumption (positive). The smoking effect was most prominent in women, and the
alcohol effect was most pronounced in men. Data indicated that independently of other lifestyle factors, age, and
intake of folate and B-vitamin supplements, a change in lifestyle could result in a 0.1 to 1.7 µmol/L change in the
tHcy concentration. The authors conclude that lifestyle changes could result in a public health relevant change in the
tHcy concentration.
Published as: A. de Bree, W.W.M. Verschuren, H.J. Blom and D. Kromhout. Lifestyle factors and plasma
homocysteine concentrations in a general population sample. Am J Epi 2001;154:150-154.
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Introduction
From a public health viewpoint it is important to identify modifiable factors that influence the
plasma total homocysteine (tHcy) level, because elevated concentrations are associated with an
increased risk of cardiovascular diseases (1,2). Folate intake is identified as the most important
dietary determinant of the tHcy concentration (3,4). Besides diet, other lifestyle factors such as
smoking (5), physical activity (6), and consumption of alcohol (7-9), coffee (5,10-13), and tea
(10) may have an effect on tHcy levels in the general population. Inconclusive results for
alcohol and coffee consumption and a lack of representative populations with a broad age
range creates the need for further investigation. In addition, only two studies have corrected for
the confounding effect of folate intake (7,11). Using a representative sample of the general
Dutch population aged 20-65 years, we studied the association of these lifestyle factors with
tHcy concentrations, taking folate intake into account.
Materials and methods
The subjects and methods of this study have been described extensively elsewhere (14).
Briefly, we drew an age- and sex- stratified random sample (n=3025) of subjects in a
population-based cohort that was examined during 1993-1996 (n=19,066) (15).
Data were collected with self-administered questionnaires and a physical examination. On the
basis of responses to questions about smoking, we categorized subjects as either non-smokers
or light (<10 cigarettes/d), moderate (³10 - <20 cigarettes/d) or heavy (³20 cigarettes/d)
smokers. Physical activity was reported as the average amount of time (minutes/week) spent in
various activities during leisure time, work time, household activity, and commuting (e.g.,
cycling to work) over the previous year. For the statistical analyses, we defined 4 levels of
weekly activity: “sedentary”: <0.5 h; “moderately active”: ³0.5 - <3.5 h; “active”: ³3.5 h of
which £2 h heavy activity; and “very active”: ³3.5 h of which >2 h heavy activity (16).
Information from subjects participating in 1993 (n=408) was not included, since the questions
on activity in 1993 were different from those posed in 1994-1996.
A semi quantitative food-frequency questionnaire (17,18) provided information on the
consumption of alcohol, coffee, and tea, which was recoded into units per day. Energy-adjusted
folate intake was estimated as described elsewhere (4).
The tHcy concentrations from non-fasting venous blood samples were determined as
described by Fiskerstrand et al (19), with some modifications (20).
We used the SAS software (version 6.12) for all statistical analyses (SAS Institute, Inc., Cary,
North Carolina). Comparisons between men and women were conducted using Wilcoxon’s 2-
sample tests for continuous variables and chi-squared tests for proportions. The tHcy
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distribution was normalized by logarithmic transformation. Thus, geometric means are
presented unless stated otherwise. Each lifestyle-tHcy association was evaluated by univariate
and multivariate linear regression. Differences in adjusted mean tHcy concentrations as
compared with a reference category were tested using analyses of covariance. In the
multivariate models, we adjusted for age (years), folate intake (µg/d), intake of B-vitamin
supplements (no/yes), and the other studied lifestyle factors. When considered as confounders,
the lifestyle factors were included continuously, except for smoking, which was included as 3
indicator variables (light, moderate, and heavy smoking) with non-smokers used as the
reference group.
Results
Age and the prevalences of inactivity and smoking were equal for men and women (table 1).
Women had a lower tHcy concentration, folate intake, alcohol and coffee consumption than
men but a higher tea consumption than men.
Table 1 Selected characteristics of Dutch men and women aged 20-65 years examined in 1993-1996
Characteristics Men (n=1493)a Women (n=1532)a
Mean SD Mean SD
Age (years) 40.5 12.1 41.0 12.5
tHcy (µmol/L)b 14.6 6.1 13.1* 4.6
Folate intake (µg/d) b 240 75 194* 53
Coffee (cups/d) 4.9 3.2 4.1* 2.8
Tea (cups/d) 1.5 1.9 2.1* 2.4
Alcohol (glasses/d) 1.9 2.3 0.7* 1.1
Less than 30 min of moderate or heavy physical
activity/week (%)
21.7 20.9
Current smokers (%) 35.4 37.3
Explanation of symbols: a=The minimal number of valid observations for men was 1488 and for women 1529, except for physical
activity: where the percentages were based on 1297 men and 1319 women; b=Arithmetic value; SD=standard deviation; Asterisks
indicate a statistically significant difference from males P<0.001.
Univariate linear regression (table 2), in which the beta coefficients express a proportional
change in tHcy level because of the logarithmic transformation, showed that in both men and
women coffee consumption was positively associated, tea consumption was negatively
associated, and physical activity was not associated with the tHcy concentration. Alcohol
consumption showed a negative association with the tHcy concentration in men only, and
smoking showed a positive association, in women only.
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Table 2 Proportional change and 95% confidence interval (CI) in the tHcy concentration associated with a one-unit
change in various lifestyle factors among Dutch men and women aged 20-65 years examined in 1993-1996
Men Women
Univariate
n=1493a
Adjustedb
n=1287a
Univariate
n=1532a
Adjustedb
n=1314a
% 95% CI % 95% CI % 95% CI % 95% CI
Coffee (cups/d)  0.77   0.32,  1.22 0.48 -0.02,  0.99 1.67 1.20,  2.14 1.03 0.46, 1.60
Tea (cups/d) -1.03 -1.77, -0.29 -0.43 -1.25,  0.38 -1.00 -1.56, -0.44 -0.18 -0.80, 0.44
Alcohol (glass/d)
Low folate intake
High folate intake
-1.15 -1.77, -0.54 -1.06
-1.52
-0.79
-1.71, -0.41
-2.73, -0.31
-1.52, -0.06
-0.16 -1.40,  1.08 -0.47 -1.77, 0.82
Physical activityc 0.39 -1.08, 1.86 1.05 -0.44,  2.54 0.34 -1.16, 1.84 1.71 0.25, 3.16
Non-smoking vs.
smoking 1.79 -1.19, 4.77 0.84 -2.38,  4.07 6.21 3.45, 8.97 3.56 0.52, 6.59
Explanation of symbols: a=The minimal number of valid observations for men was 1488 and for women 1529, except for physical
activity: the data were based on 1297 men and 1319 women. Multivariate results were based on a minimum of 1287 men and 1314
women; b=Adjustments were made for age, folate and B-vitamin supplement intake and the other lifestyle factors mentioned in this
table; in the analyses where smoking was considered as confounder we adjusted with indicator variables with non-smokers as
reference; c=Refer to materials for definition of categories.
The multivariate results showed essentially the same associations, except that the inverse
relation with tea disappeared and activity level became positively associated in women. In table
2, results for alcohol consumption in men are also presented stratified for folate intake (below
and above the median intake level of 204 µg/d), because of the interaction between alcohol
and folate intake (4). Smoking also showed an interaction with folate intake in men (4),
demonstrating a significant positive association among men with folate intakes below the first
quintile (i.e., <176 µg/d). We did not stratify the results for folate intake, since this would only
have affected the power of the analyses, whereas the direction of the association between
smoking and tHcy remained positive.
The adjusted results for coffee, alcohol, and smoking are displayed in figures 1-3
respectively. Drinking >6 cups of coffee/d was associated with a 1.4 µmol/L higher tHcy
concentration in men and a 1.1 µmol/L higher concentration in women, as compared with
coffee abstainers (figure 1). Drinking >2 glasses of alcoholic beverages/d was associated with a
1.7 µmol/L lower tHcy level in men with a low folate intake (£204 µg/d) and a 0.8 µmol/L lower
level in men with a high folate intake (>204 µg/d), as compared with alcohol abstainers (figure
2). Women who smoked heavily had a 0.8 µmol/L higher tHcy concentration than women who
did not smoke (figure 3).
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Figure 1-3 Mean adjusted plasma total homocysteine (tHcy) concentration according to lifestyle among Dutch men
(u) and women (n) aged 20-65 years examined in 1993-1996
Figure 1 Coffee consumption
Figure 2 Alcohol consumption
Figure 3 Smoking
Explanations of symbols: The error bars indicate 95% confidence intervals. For alcohol consumption, the results for men are
stratified to folate intake. The means are adjusted for age, tea consumption, physical activity, folate and B-vitamin supplement
intake and the other lifestyle factors in this figure; in the analyses where smoking was considered as confounder we adjusted with
indicator variables with non-smokers as reference. Asterisks indicate statistically significant different tHcy concentration in
comparison with the first category: * P<0.05, ** P<0.01, *** P<0.001.
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Discussion
In this study, smoking and coffee and alcohol consumption were associated with tHcy
concentrations, independently of other lifestyle factors, age, use of B-vitamin supplements, and
folate intake, the latter being the major dietary determinant of the tHcy concentration. The
effect of smoking was most pronounced in women, and the alcohol effect was most pronounced
in men.
The positive dose-response relation that we found between coffee consumption and the tHcy
concentration is consistent with most (10-12) but not all (13) observational studies.
Reservations about the effect of coffee on the tHcy level have been refuted by recent
intervention studies (21,22). The randomized crossover designs of the latter studies increased
the likelihood of there being a causal relation between coffee consumption and the tHcy
concentration.
The intervention studies showed similar effects for filtered coffee (1.5 µmol/L) (21) and
unfiltered coffee (1.2 µmol/L) (22), indicating that the tHcy-raising factor is not removed by the
use of paper filters. Caffeine is a proposed factor (10,22) as it might obstruct the conversion
from homocysteine to cysteine by acting as a vitamin B6 antagonist (22). Therefore, the null
finding for tea in the present study was not unexpected, since the amount of caffeine in tea is
small (23). Intervention studies with assessment of both decaffeinated coffee and regular
coffee would provide more insight on this topic.
High levels of alcohol consumption increase the tHcy concentration (24,25); however, we
studied moderate alcohol consumption (16% of our male drinkers consumed ³4 glasses/d). An
inverse relation between moderate alcohol consumption and the tHcy concentration has been
observed previously in men from Caerphilly (7) and in Norwegian men and women (8).
However, as in the present study, no statistically significant association was found among US
women in another study (9); this could be due to the small range of alcohol intakes in women.
The fact that we observed no association in women could indicate a dose effect of ethanol.
On the other hand, the type of alcoholic beverage consumed could be important (25). Beer was
the most frequently consumed alcoholic beverage among men. Beer contains vitamins that
serve as cofactors in homocysteine metabolism, i.e. folate, vitamin B2 and B6. Although residual
confounding cannot be excluded, beer consumption was significantly inversely associated with
the tHcy concentration independently of these vitamins. This might point to ethanol or another
substance in beer (other than B-vitamins) being the tHcy-lowering factor. Betaine, which is
present in wine (26), could also have contributed to the overall inverse relation between alcohol
and the tHcy level. Betaine is used in a metabolic route independent of folate to methylate
homocysteine to methionine (27). Because of the lack of dietary data on betaine we were
unable to adjust for it.
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In the multivariate analyses, we observed a weak positive relation between physical activity
and the tHcy concentration in women. This contrasts with the protective effect observed in the
Hordaland Homocysteine Study (6). Since activity is generally associated with a healthier
lifestyle (28), our finding is the opposite of what would be expected. Intervention studies might
be able to elucidate the effect of activity on the tHcy concentration.
In accordance with other population-based studies (6,9) smoking was positively associated
with the tHcy level, the effect being clearest in women. The mechanism behind the increase is
unidentified. Smokers often have a lower plasma folate status than non-smokers (29-31);
however, in the present study, this was explained by a lower folate intake. Thus, smoking does
not seem to reduce the availability of folate for the remethylation of homocysteine to
methionine. This suggests that smoking either induces local effects in cells exposed to cigarette
smoke (30), or changes in the plasma thiol redox status (homocysteine is an aminothiol) (32)
by a higher formation of reactive oxygen species (33,34), or inhibits the action of enzymes such
as methionine synthase (35).
Subjects participating in surveys like ours might be more health conscious than non-
participants. All subjects invited to participate in the MORGEN study (15) received a response
card; approximately 70 percent returned the response card, while approximately 50 percent
completed the full assessment. A non-response study indicated that non-responders were more
likely to be men, smokers, non-drinkers of alcohol, and physically inactive. However, a
comparison of the distributions of date on sex, lifestyle, and demographic factors in our random
sample with nationwide data (36) showed similar percentages (14). Therefore, our results may
be applicable to a wider population of Dutch men and women.
In summary, smoking, and alcohol and coffee consumption were major lifestyle correlates of
the tHcy concentration. It is important to increase the public’s awareness that feasible changes
in lifestyle may favorably alter the tHcy concentration, which in turn may reduce the risk of
cardiovascular diseases.
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Type of alcoholic beverage and plasma homocysteine in
the general Dutch adult population
Published as: A. de Bree, W.M.M. Verschuren, H.J. Blom, and D. Kromhout. Alcohol consumption and plasma
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Letter to the editor
Several recent publications (1,2) have reported on a potential beneficial health effect of
moderate alcohol consumption on the cardiovascular system. We would like to complement
these reports with data on the relation between alcohol consumption and the plasma total
homocysteine (tHcy) concentration. A high tHcy concentration is associated with an increased
risk of cardiovascular diseases, therefore, it is important to know how lifestyle factors might
influence the tHcy concentration.
Observational studies indicate that alcohol consumption might be related to the tHcy
concentration in a J-shaped fashion (3): alcoholics have a very high tHcy concentration (4) and
moderate alcohol consumers (£4 glasses/d) have a lower tHcy concentration compared with
non-drinkers (3,5). In our study population, a random sample (n=3025) of a population-based
cohort of Dutch men and women (20-65 years) (6), we cross-sectionally observed lower tHcy
concentrations at higher levels of alcohol consumption (assessed with a food-frequency
questionnaire). This trend was statistically significant in men (P<0.001); non-drinkers (n=132)
had a (geometric) mean tHcy concentration of 14.2 µmol/L, compared with 13.9 µmol/L in
drinkers of £2 glasses/d (n=838), 12.5 µmol/L in drinkers of >2-<4 glasses/d (n=306) and 13.1
µmol/L in drinkers of ³4 glasses/d (n=214). An overall statistically significant inverse trend
(P<0.05) remained after correction for age, smoking, physical activity, coffee and tea
consumption, dietary folate intake and use of B-vitamin supplements.
An intriguing question is whether the inverse relation can be ascribed to ethanol intake or
that the type of alcoholic beverages consumed is important, as the recent intervention trial of
Van der Gaag et al (7) suggests. They showed, in a 3 week randomized cross-over trial, that
despite the equally administered amount of ethanol (4 glasses/d=40 g/d) beer does not affect
the tHcy concentration, whereas wine and spirits induce an increase. Motivated by these results
(7) we studied whether different types of alcoholic beverages were differently related to the
tHcy concentration in males (table 1). We found that higher beer consumption was inversely
associated to the tHcy concentration, whereas wine (red and white) and spirits showed no
relation with the tHcy concentration. Thus, like Van der Gaag et al (7), we showed that beer
drinking does not have an adverse effect on the tHcy concentration. In fact, we observed a
favorable effect, which may seem inconsistent. However, as the relation between alcohol
consumption and the tHcy concentration might be J-shaped (3) and our study contained few
heavy drinkers (16% of the male drinker drank >4 glasses/d) we were probably measuring an
effect in the descending part of the J-curve. The intervention trial provided relatively high
alcohol doses (7) and might have measured an effect at or beyond the nadir of the curve.
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Table 1 Meana plasma homocysteine (tHcy) concentration in male alcohol drinkers by tertiles of beer, wine and
spirits
Tertile Beer
(n=1179)
Wine
(n=1179)
Spirits
(n=1179)
N Intake
(g/d)
Glasses/
db
tHcyc N Intake
(g/d)
Glasses/
db
tHcyd N Intake
(g/d)
Glasses/
db
tHcye
1 423 20 0.1 14.3 398 0 0 13.6 579 0 0 13.8
2 387 177 0.9 13.8 385 6 0.06 13.8 208 1 0.02 13.7
3 369 747 3.7 13.0 396 87 0.9 13.7 392 33 0.7 13.6
Beta (95% CI)f:-0.007 (-0.011,-0.003)% -0.003 (-0.022, 0.016)% 0.026 (-0.021,0.074)%
Explanation of symbols: a=Geometric means: anti-log of the logarithmically transformed tHcy values, to normalize the distribution;
b=Each glass contains about 10 g of ethanol; c,d,e=tHcy adjusted for age, coffee and tea consumption, smoking, physical activity,
dietary folate intake and B-vitamin supplement, other alcoholic drinks, alcohol free beer and: c=dietary vitamin B6 and B2 intake,
wine and spirits, d=beer and spirits, e=beer and wine. Due to missing values in covariables, the multivariate analyses (analyses of
covariance) were based on data of 1174 male alcohol drinkers; f=The beta’s of the regression analysis express a proportional
change in tHcy, due to the logarithmic transformation (95% CI=95% confidence interval). For example, an increase of 200 grams
of beer (1 normal glass) is associated with a decrease in tHcy of 1.4%.
The beneficial effect of beer drinking on the tHcy concentration could be due to its folate,
riboflavin and vitamin B6 content, all important for the enzymatic homocysteine conversion.
Nevertheless, the inverse relation with beer was independent of these nutrients (table 1), which
might indicate a dose effect of ethanol. This is further suggested by the absence of a significant
association with alcohol consumption in female drinkers, who on average drink less then men,
and the fact that the amount of ethanol consumed in the third tertile (T3) of beer consumption
exceeds that of T3 in the wine and spirit drinkers by far. Intervention studies with moderate
amounts of ethanol (<40 grams/d), or observational studies in populations where beer is not
the predominant alcoholic drink, may elucidate whether our result is due to residual
confounding of B-vitamins in beer, or that ethanol is responsible for the beneficial effect of
moderate ethanol consumption on the tHcy concentration. Acknowledgements
This work was financially supported by a grant of the Netherlands Heart Foundation (grant
no. 96.147). H.J. Blom is established investigator of the Netherlands Heart Foundation (grant
no. D97.021).
References
1. Hoffmeister H, Schelp FP, Mensink GB, Dietz E, Bohning D. The relationship between alcohol consumption, health indicators
and mortality in the German population. Int J Epidemiol 1999;28:1066-1072.
2. Nanchahal K, Ashton WD, Wood DA. Alcohol consumption, metabolic cardiovascular risk factors and hypertension in women.
Int J Epidemiol 2000;29:57-64.
3. Vollset, S. E., Nygard, O., Kvale, G., Ueland, P. M., and Refsum, H. The Hordaland Homocysteine Study: Lifestyle and total
plasma homocysteine in Western Norway. In: Graham, I., Refsum, H., Rosenberg, I. H., and Ueland, P. M.
Homocysteine Metabolism: From Basic Science to Clinical Medicine. Massachusetts: Kluwer Academic Publishers
1997:177-182.
4. Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, Cardoso JN, Leitao CN, Mira FC.
Hyperhomocysteinemia in chronic alcoholism: Correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin
Nutr 1996;63:220-224.
Chapter 7
92
5. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJH. Homocysteine and ischaemic heart disease in the Caerphilly
cohort. Atherosclerosis 1998;140:349-356.
6. de Bree A, Verschuren WMM, Blom HJ, De Graaf-Hess A, Trijbels FJM, Kromhout D. The homocysteine distribution:
(mis)judging the burden. J Clin Epidemiol 2001;54:462-469.
7. Gaag MS, Ubbink JB, Sillanaukee P, Nikkari S, Hendriks H. Effects of consumption of red wine, spirits, and beer on serum
homocysteine. Lancet 2000;355:1522.
8
Biological cardiovascular risk factors and plasma
homocysteine in the general Dutch adult population
Published as: A. de Bree, W.M.M. Verschuren, H.J. Blom and D. Kromhout. Biological cardiovascular risk factors and
plasma homocysteine levels in the general Dutch population. Atherosclerosis 2001;154:513-154.
Chapter 8
94
Letter to the editor
A raised plasma total homocysteine (tHcy) concentration is considered to be a risk factor for
cardiovascular diseases (CVD) (1). However, evidence provided by prospective studies is
weaker than that offered by case-control and cross-sectional studies (2). In addition, a genetic
defect resulting in elevated tHcy concentrations is not consistently associated with the risk of
CVD (3). This has raised the question whether the observed association between the tHcy
concentration and CVD can be attributed to confounding by biological CVD risk factors (2,3). In
this study we describe the association between cholesterol (total and HDL), blood pressure
(diastolic and systolic) and waist circumference and the tHcy concentration.
 We performed a sub-study on 1493 men and 1533 women within a population-based cross-
sectional study of 19,066 subjects aged 20-65 years randomly selected from three Dutch towns.
Data were collected with self-administered questionnaires and a physical examination, which
included the drawing of blood. Standard validated techniques were used for biochemical
analyses and physical measurements.
As the distribution of the non-fasting tHcy concentration was positively skewed, we log-
transformed the values and present geometric means. Mean tHcy concentration was higher in
men (13.9 µmol/L) than in women (12.6 µmol/L). Linear regression analyses only showed a
weak inverse relation between HDL cholesterol and the tHcy concentration in men (P=0.09). In
women, all risk factors were unfavorably associated with tHcy concentrations (P for all beta’s
<0.2). Multivariate linear regression analyses only revealed associations in women: each
mmol/L increase in total cholesterol was associated with a 1.9% (P=0.008) increase in tHcy
concentration and each mmol/L decrease in HDL cholesterol was associated with a 3.9%
(P=0.04) higher tHcy concentration. Adjustments were made for age (years), coffee (cups/d)
and alcohol (glasses/d) consumption, smoking (no/yes), folate intake (µg/d), B-vitamin
supplement use (no/yes) and the other studied biological risk factors (for blood pressure we
used systolic blood pressure). The multivariate relations are shown in figure 1.
Logistic regression was used to calculate multivariately adjusted odds ratio’s (OR) for
hyperhomocysteinemia (defined as tHcy >17.4 µmol/L). The OR for subjects with hypertension
(diastolic ³95 mmHg and/or systolic ³160 mmHg) was 1.21 (95% confidence interval
(CI)=0.69-2.12) in men and 1.92 (95% CI=0.96-3.84) in women, for subjects with a high
total/HDL cholesterol ratio (>5) 0.83 (95% CI=0.58-1.17) in men and 1.78 (95% CI=1.10-2.89)
in women, and for subjects with a high waist circumference (men: ³94 cm, women: ³80 cm)
1.27 (95% CI=0.89-1.81) in men and 0.85 (95% CI=0.56-1.29) in women.
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Figure 1 Mean adjusteda tHcy concentration according to quartilesb of biological CVD risk factors.
Explanation of symbols: Error bars indicate the 95% confidence intervals; a=Means are estimated with analysis of covariance:
“PROC GLM” in SAS (version 6.12). Adjustments were made for age (years), coffee (cups/d) and alcohol (glass/d) consumption,
smoking (no/yes), folate intake (µg/d), B-vitamin supplement use and the risk factors in this figure; b=The quartiles were based on
the distribution of the whole population; Asterisks indicate a tHcy concentration that is significantly different from the concentration
in the first quartile: * P<0.05, ** P<0.01.
In this population-based study, biological risk factors for CVD were not related with the tHcy
concentration in men. However, in women, an adverse cholesterol profile was significantly
associated with a 78% increased risk of hyperhomocysteinemia, and hypertension tended to be
associated with a comparable increase in risk (92%). Another population-based study has
observed associations with cholesterol level and blood pressure in men as well as in women,
which could be due to overall larger power of that study and the large proportion of subjects
between 65-67 years (4).
It is unlikely that the associations observed in this study are the result of the insulin
resistance syndrome (5), as we found no relation with waist circumference. In addition, most
pronounced relations were seen in women, which might point to an effect of estrogens.
Alternatively, lifestyle could also be an explanation. Briefly, the few observed associations with
biological CVD risk factors are in the direction of an increased risk of CVD. Therefore, inaccurate
control for biological risk factors could falsely increase the risk estimate in studies that quantify
the relation between the tHcy concentration and CVD. Nevertheless, confounding of biological
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CVD risk factors can probably not fully explain the frequently observed relation between tHcy
concentrations and CVD.
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Plasma homocysteine, B-vitamins and the risk of coronary
heart disease mortality in the general Dutch adult
population
Background: Elevated plasma total homocysteine (tHcy) levels and B-vitamin status are associated with the risk
of coronary heart disease (CHD). So far, results from prospective studies have been inconclusive.
Objective: To determine the relations between plasma concentrations of tHcy, folate, vitamin B6 (PLP) and B12
and CHD mortality.
Design: Prospective case-cohort study.
Setting: A population-based cohort of ~36,000 Dutch adults aged 20-59 years at baseline.
Participants: A random sample from the cohort (n=630) complemented with all subjects who died of CHD
(n=102) during a mean follow-up of 10.3 years.
Measurements: Plasma tHcy, folate, PLP and vitamin B12 concentrations were determined. CHD mortality was
identified through linkage with the national mortality register of Statistics Netherlands.
Results: Men with a tHcy level in the highest tertile (T3) compared with men in the lowest tertile (T1) had a
relative risk (RR) of CHD of 1.14 (95% confidence interval (CI)=0.50-2.61) after adjusting for age, study center,
hypertension, HDL and total cholesterol, smoking and creatinine. For women this RR was 2.04 (95% CI=0.48-8.62).
In women only, high folate levels were associated with a statistically significant protection of fatal CHD (T3 vs. T1:
RR: 0.22, 95% CI=0.06-0.87). Plasma PLP and vitamin B12 concentrations were not associated with CHD risk.
Conclusions: Elevated tHcy levels are not a major risk factor for CHD mortality in this population sample of
relatively young Dutch subjects. Of the plasma B-vitamins only folate concentrations in women were associated with
a lower risk of CHD mortality.
Submitted as: A. de Bree, W.M.M. Verschuren, H.J. Blom, M.R. Nadeau, F.J.M. Trijbels and D. Kromhout. Coronary
heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study.
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Introduction
About 30 years ago McCully and Wilson (1) postulated that moderately elevated plasma total
homocysteine (tHcy) concentrations were causally related to the development of coronary heart
disease (CHD). Although initially numerous case-control and cross-sectional studies supported
this hypothesis (2), nowadays several issues have led to a more cautious approach of elevated
tHcy concentrations being a causal risk factor for CHD. The first concern is that the exact
mechanism that underlies this association is not understood (3). Furthermore, a genetic defect
in the gene encoding for MTHFR (a key enzyme in homocysteine metabolism), resulting in
elevated tHcy concentrations is not consistently associated with the risk of CHD (4). Finally,
prospective epidemiological studies, which compared with case-control and cross-sectional
studies have a stronger methodological design to identify causal relationships, show less
convincing evidence for the hypothesis (5). Thus, pending intervention trials in which the tHcy
concentration is lowered with folic acid, and other B-vitamins (6), proof of a causal relation
between the tHcy concentration and CHD is not available.
Of the prospective studies that have been performed in populations not selected on the basis
of their risk of CHD, a small majority showed an independent statistically significant association
between elevated tHcy levels and the development of CHD (7-15). Others found associations
that were compatible with an increased risk, but lacked statistical significance (16-18) and a
minority found no association (19-23). These inconsistencies could partly derive from different
lengths of follow-up and from differences in the study populations.
We prospectively studied the relation between the tHcy concentration and the risk of CHD
mortality after 10.3 years of follow-up, in Dutch adult (20-59 years) men and women free of
baseline cardiovascular diseases. In addition, we also investigated plasma concentrations of
folate, vitamin B6 (PLP) and B12 in relation to CHD mortality. These B-vitamins, which are
important in homocysteine metabolism, may be inversely associated with CHD (16,24-27).
Methods
Study population
From 1987 through 1991 the Monitoring Project on Cardiovascular Disease Risk Factors
collected information on more than 36,000 men and women aged 20-59 years from 3 Dutch
towns (Amsterdam, Doetinchem and Maastricht). All participants were physically examined and
filled out a self-administered questionnaire (28).
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Baseline measurements
During the physical examination the systolic and diastolic blood pressure was measured twice
on the left arm using a random zero sphygmomanometer, while the subject was seated. We
used the mean of the two measurements in our analyses. Weight and height were measured to
calculate the body mass index (BMI; kg/m2), an index of relative weight.
The self-administered questionnaire provided information on demographic variables (e.g.
education), history of cardiovascular diseases, history of diabetes, medication and several
lifestyle and dietary habits. Educational level, measured with a standardized questionnaire, was
classified into three categories: low (intermediate secondary education or less), medium
(intermediate vocational or higher secondary education) and high (higher vocational or
university education). A history of cardiovascular diseases was defined as a positive answer on
the questions: 1) “Are you medically treated by a physician or specialist for heart problems?” 2)
“Did you ever experience a myocardial infarction?” 3) “Did you undergo heart surgery?” and 4)
“Did you ever experience a cerebrovascular accident?” The question: “Do you have diabetes?”
was used to define a history of diabetes. Hypertension was defined as systolic blood pressure
³140 mm Hg or diastolic blood pressure ³90 mm Hg or the use of anti-hypertensive medication.
Smoking habits were dichotomized into non-smoking and smoking (³ 1 cigarette/d). The
amount and type of alcoholic beverage was recoded into total alcohol consumption in glasses/d.
Coffee consumption was recorded in cups/d. Vitamin supplement use was requested in
categories, e.g. vitamin C, multivitamins, B-vitamins complex, etc. The questionnaire did not ask
for the vitamin dose or for the exact frequency with which supplements were taken. From these
categories we created a variable which indicated whether a subject used supplements
containing B-vitamins or not (note that folic acid was not commonly present in supplements at
the time of baseline measurements). Participants scored physical activity separately for activity
during work and leisure time. Of these scores we created one physical activity variable with
three levels: 1) inactive, i.e. little or no exercise during leisure time and/or work time, 2)
regularly active, i.e. regular exercise during leisure time (~4 h/week), no physical activity during
work, and 3) regular strenuously active, i.e. regular (strenuous) exercise during leisure time,
and/or frequent or continuously physically strenuous work. This categorization correlated
positively with HDL cholesterol levels.
Mortality follow-up
The mortality follow-up lasted until January 1, 2000 (minimum of 8 years and maximum 13
years). Information about the vital status was obtained from the municipal population registry
in the town of residence. If a person had moved with unknown destination, the date on which
the person’s name was removed from the municipal population register was used as a censor
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date. For our population, 0.02% was lost to follow-up. Causes of death were identified through
linkage with Statistics Netherlands.
Causes of death were coded according to the ninth revision of the International Classification
of Diseases (ICD-9) for deaths that occurred before January 1, 1996 (~50% of all deaths) and
according to the tenth revision (ICD-10) for deaths that occurred from January 1, 1996
onwards. CHD was defined as ICD-9 codes 410-414 or ICD-10 codes I20-I25.
Definition of the cohort
We used a case-cohort design for the present study. This means that the plasma tHcy, B-
vitamins and creatinine concentrations were determined for all subjects (cases) that died of
CHD during January 1987 and January 2000 (n=170) and a random sample (n=749), also
called the reference- or sub-cohort, of the total Monitoring Project population. No stratification
or matching was performed for the random sample that served as the source of information
about the full cohort.
Laboratory measurements
During the physical examination, non-fasting venous blood samples were collected in EDTA
tubes. To obtain plasma, the samples were centrifuged after a maximum storage period at
room temperature of 3 hr. Non-fasting plasma total- and HDL cholesterol were enzymatically
determined using a Boehringer test kit, within three weeks after collection. HDL cholesterol was
determined after precipitation of the apo-B-containing lipoproteins with
magnesiumphosphotungstate (28). The cholesterol levels were determined at the Central
Clinical Chemistry Laboratory of the University Hospital Dijkzigt in Rotterdam, a reference
laboratory that participated in the standardization program of the World Health Organization.
For the present study, additional laboratory analyses were carried out in plasma samples that
were stored at -20°C for 10-14 years. The laboratory technicians were unaware of the case-
status of the samples. The tHcy concentration, including the protein-bound and non-protein-
bound fractions of homocysteine, was measured using high performance liquid chromatography
with fluorescence detection, as described by Fiskerstrand (29) with some modifications (30).
The within- and between-run coefficients of variation (CV) were 2.9% and 6.1%, respectively.
Plasma folate and vitamin B12 was determined with a commercial radio assay (Quantaphase
II, B12/Folate radioassay, Bio-Rad Diagnostics Group) in the laboratory of Dr. Jacob Selhub of
the Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. For folate
the within- and between- run CV’s were 11.4 and 13.1%, respectively and for vitamin B12 5.1
and 7.6%, respectively. Plasma vitamin B6 (measured as pyridoxal 5’ phosphate, i.e. PLP) was
measured with a semi-automated fluorometric method by high-performance liquid
chromatography, with a within- and between-run CV of respectively 5.7% and 9.7%. Plasma
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creatinine was determined with a modified Jaffe method, with a within- and between- run CV of
respectively 1.1% and 1.5%.
Data analyses
All statistical analyses were done with SAS statistical software (version 8.1) (SAS Institute
Inc., Cary, North Carolina, USA). We only used subjects with complete information on plasma
concentrations of tHcy, B-vitamins and creatinine, blood pressure, cholesterol level, smoking,
history of cardiovascular diseases and diabetes: i.e. 154 CHD cases and 669 subjects from the
reference cohort (n=821 in total, as 2 CHD cases belonged also to the reference cohort).
Additionally, 89 subjects were excluded because they reported prevalent cardiovascular
diseases at baseline. Thus, all analyses in this report are based on 732 subjects: 103 incident
CHD cases and 630 reference subjects, as 1 CHD case belonged also to the reference cohort.
To determine the relation of the tHcy level with other variables, the reference cohort was
divided into equal thirds (tertiles) according to the tHcy distribution. Analyses of covariance
implemented in the SAS “PROC GLM” procedure were used to compute age, sex and study-
center adjusted mean levels, or percentages, of variables by tertiles of the tHcy concentration.
Trends over the tertiles were computed with linear regression analyses, modeling the tertiles as
a continuous variable. For the concentrations of tHcy, B-vitamins and creatinine we present
geometric means, as these variables were skewed towards higher values and we used
logarithmic transformations to normalize their distributions.
To determine the relation between several variables and case-status, we computed mean, or
percentage, values with analyses of covariance for cases versus the reference cohort, and
tested the difference with “PROC GLM”.
Cox’s proportional-hazard analysis was used to estimate the relative risks (RRs) of CHD
mortality in relation to tertiles of tHcy and plasma B-vitamin levels. Additional analyses with the
independent variables as continuous variables were also performed. To calculate valid 95%
confidence intervals (CIs) around the RRs in this case-cohort design (31,32) we used a SAS
macro available at http://lib.stat.cmu.edu.general/robphreg. Interaction terms between our
independent variables of interest (plasma levels of tHcy and B-vitamins) and age, sex, smoking,
hypertension and cholesterol level, were evaluated. As we found a significant interaction
between plasma folate and sex, we stratified our analyses for sex.
Variables that were included as possible confounders in multivariate models were age, study
center (indicator variables for Maastricht and Doetinchem with Amsterdam as reference center),
creatinine level, hypertension, smoking (no/yes), HDL cholesterol, total cholesterol, BMI,
physical activity (indicator variables for regularly active and regularly strenuously active, with
inactive subjects as reference), education (indicator variables for high and medium education,
with low education as reference), and alcohol consumption (indicator variables, in men: >0 - £2
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glasses/d and >2 glasses/d with abstainers as reference, in women: >0 - £1 glasses/d and >1
glasses/d, with abstainers as reference). As there were only 7 subjects (4 CHD cases) who had
a history of diabetes after exclusion of subjects with cardiovascular diseases at baseline, we did
not adjust for this variable.
Results
Characteristics of the cohort
Table 1 shows the age, sex and study-center adjusted mean levels or percentages of
variables in the reference cohort according to the tertile distribution of the tHcy concentration.
Variables that were inversely associated with the tHcy concentration were plasma levels of B-
vitamins and B-vitamin supplement use. Variables that were positively associated with the tHcy
concentration were creatinine level, diastolic blood pressure and prevalence of hypertension
(borderline). Other lifestyle and CHD risk factors were not associated with the tHcy
concentration.
Table 1 Age-, sex- and study center-adjusted mean levels of study variables according to tertiles (T) of the tHcy
concentration in the reference cohort
Tertiles of tHcy
Variable T1 (n=207) T2 (n=206) T3 (n=217) P for trend
tHcy (µmol/L)
Range
11.0
6.4-12.6
13.8
12.7-15.3
19.2
15.4-53.9
Plasma folate (nmol/L 7.5 6.3 5.1 0.0001
Plasma PLP (nmol/L) 44.7 40.9 36.6 0.0001
Plasma vitamin B12 (pmol/L) 328.5 298.2 276.7 0.0001
Plasma creatinine (µmol/L) 102.0 104.7 109.3 0.0001
Systolic blood pressure (mm Hg) 119.3 120.4 121.4 0.13
Diastolic blood pressure (mm Hg) 74.9 75.6 76.9 0.04
Total cholesterol (mmol/L) 5.6 5.5 5.5 0.7
HDL cholesterol (mmol/L) 1.3 1.3 1.3 0.3
BMI (kg/m2) 24.6 24.5 24.7 0.9
Alcohol (glasses/d) 1.2 1.4 1.0 0.2
Coffee (cups/d) 4.6 5.0 4.7 0.6
Smokers (%) 37 34 42 0.3
B-vitamin supplement users (%) 24 22 15 0.02
Hypertension (%) 13.5 17.9 19.9 0.07
Diabetes (%) 0.9 0.5 0.04 0.2
Inactive (%) 24 25 27 0.4
Low education (%) 68 57 64 0.3
Mean differences between CHD cases and non-cases
Table 2 shows the variables that were associated with case-status. Cases were older, were
more likely to be male, and had higher tHcy and lower plasma folate and PLP concentrations.
Furthermore, their CHD risk profile was unfavorable compared with non-cases. For example,
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they had a higher blood pressure (systolic and diastolic) and total cholesterol level.
Furthermore, their HDL cholesterol level was lower, and they were more likely to be smokers.
Relative risk of CHD
During a mean follow-up of 10.3 years, 78 men and 25 women died of CHD. Table 3 shows
that there was a statistically non-significant positive association between the tHcy concentration
and the incidence of CHD mortality in men as well as in women, after correction for age and
study center. The relative risk (RR) of CHD mortality for those in the highest tertile (T3) of tHcy
levels versus the lowest tertile (T1) was 1.32 (95% confidence interval (CI)=0.68-2.55) in men
and 2.30 (95% CI=0.72-7.34) in women. After additional adjustment for CHD risk factors (HDL
cholesterol, total cholesterol, hypertension, creatinine and smoking) the RR attenuated. As
there was no statistically significant interaction between sex and the tHcy concentration on the
RR of fatal CHD, we calculated the RR for each 5 µmol/L increase in tHcy concentration for men
and women together. After adjustment for the variables of model 2 (table 3) and for sex, we
found a RR of 1.03 (95% CI=0.83-1.29).
Table 2 Age-, sex- and study center-adjusted mean levels of study variables in CHD cases versus non-cases
Variables
Non-cases
(n=630)
Fatal CHD cases (n=103) P for
difference
Age (years) (not adjusted for age) 41.5 51.6 0.0001
Males (%) (not adjusted for sex) 48 75 0.0001
tHcy (µmol/L) 14.4 15.4 0.04
Plasma folate (nmol/L) 6.3 5.7 0.03
Plasma PLP (nmol/L) 41.1 34.6 0.008
Plasma B12 (pmol/L) 302.5 283.7 0.1
Plasma creatinine (µmol/L) 106.1 106.8 0.6
Systolic blood pressure (mm Hg) 121.1 130.4 0.0001
Diastolic blood pressure (mm Hg) 76.4 82.1 0.0001
Total cholesterol (mmol/L) 5.6 6.0 0.0003
HDL cholesterol (mmol/L) 1.3 1.1 0.0001
Coffee (cups/d) 4.8 5.1 0.4
Alcohol (glasses/d) 1.3 1.4 0.4
BMI (kg/m2) 24.7 26.7 0.0001
Smokers (%) 37 72 0.0001
B-vitamin supplement users (%) 20 23 0.5
Hypertension (%) 19 40 0.0001
History of diabetes (%) 0.5 4 0.003
Inactive (%) 25 24 0.8
Low education (%) 64 75 0.03
The plasma folate concentration was inversely associated with the risk of CHD mortality in
women (P for trend 0.03) after correction for age and study center. There was no association in
men. Additional correction for CHD risk factors did not materially change the protection of a
high folate level for fatal CHD in women. The RR of CHD mortality for women in T3 of plasma
folate versus T1 was 0.22 (95% CI=0.06-0.87). To check whether this effect was independent
of the level of other B-vitamins and tHcy we also adjusted for plasma concentrations of tHcy,
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PLP and vitamin B12, and vitamin B supplement use. This resulted in a RR for T2 versus T1 of
0.45 (95% CI=0.11-1.92) and a RR for T3 versus T1 of 0.22 (95% CI=0.04-1.32). Thus, the RR
estimates did not change, however the confidence intervals widened. The adjusted (model 2,
table 3) RR for each 5 nmol/L increase in plasma folate concentration was 0.16 (95% CI=0.03-
0.78) in women.
Table 3 Relative risks (RR) and 95% confidence intervals (CI) of tertiles of the concentration of tHcy, and B-vitamins
in relation to CHD mortality
Men (n=379) Women (n=353)
T1 T2 T3 P for
trend
T1 T2 T3 P for
trend
Meana plasma
tHcy (µmol/L)
11.4 14.5 20.1 10.6 13.3 18.4
No. cases
%
25 6.6% 19
5.0%
34
9.0%
5
1.4%
7
2.0%
13
3.7%
RR model 1b
95% CI
1 0.63
0.31-1.31
1.32
0.68-2.55
0.4 1 1.48
0.42-5.23
2.30
0.72-7.34
0.2
RR model 2c
95% CI
1 0.78
0.31-1.93
1.14
0.50-2.61
0.7 1 1.31
0.28-6.05
2.04
0.48-8.62
0.3
Meana plasma
folate
(nmol/L)
4.2 6.1 9.5 4.0 6.1 9.6
No. cases
% 25 6.6%
21
5.5%
32
8.4%
12
3.4%
8
2.3%
5
1.4%
RR model 1b
95% CI
1 0.87
0.43-1.77
1.31
0.68-2.52
0.4 1 0.40
0.14-1.13
0.26
0.08-0.85
0.03
RR model 2c
95% CI
1 1.15
0.50-2.62
2.00
0.82-4.87
0.1 1 0.45
0.14-1.45
0.22
0.06-0.87
0.03
Meana plasma
PLP (nmol/L)
28.8 46.3 75.4 19.4 33.5 64.2
No. cases
%
45
11.9%
11
2.9%
22
5.8%
12
3.4%
5
1.4%
8
2.3%
RR model 1b
95% CI
1 0.39
0.18-0.85
0.73
0.38-1.40
0.2 1 0.44
0.14-1.35
0.50
0.18-1.36
0.2
RR model 2c
95% CI
1 0.95
0.37-2.44
1.27
0.52-3.11
0.6 1 0.48
0.14-1.63
0.77
0.22-2.63
0.6
Meana plasma
vitamin B12
(pmol/L)
223.1 307.9 423.7 197.6 289.0 438.7
No. cases
% 30 7.9%
26
6.9%
22
5.8%
7
2.0%
11
3.1%
7
2.0%
RR model 1b
95% CI
1 0.76
0.39-1.49
0.58
0.29-1.15
0.1 1 1.15
0.41-3.20
0.70
0.22-2.24
0.5
RR model 2
c
95% CI
1 0.72
0.30-1.69
0.95
0.40-2.29
0.8 1 1.30
0.40-4.18
0.99
0.26-3.74
0.9
Explanation of abbreviations: a=Geometric mean; b=Adjusted for age and study center; c=Adjusted for age, study center, HDL
cholesterol, total cholesterol, hypertension, creatinine and smoking.
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We observed a statistically non-significant positive association between higher plasma folate
levels and higher risk of CHD mortality in men, after multiple adjustment. As this was
unexpected, we compared the characteristics of male cases in T3 with those in T1 and T2.
Cases in T3 had a lower concentration of tHcy and total cholesterol, were less often smokers
and had higher HDL cholesterol levels. Only their systolic and diastolic blood pressures were
somewhat higher compared with men in T1. Thus, in general they were healthy cases, which
may explain the higher RR after correction for CHD risk factors. The adjusted RR for each 5
nmol/L increase in folate concentration in men was 1.41 (95% CI=0.76-2.63).
We observed no statistically significant associations between plasma PLP and plasma vitamin
B12 and incidence of CHD mortality in men as well as women. The adjusted RR for each 10
nmol/L increase in plasma PLP concentration in men and women was 1.03 (95% CI=0.99-1.07),
and for each 50 pmol/L increase in vitamin B12 concentration the adjusted RR was 0.99 (95%
CI=0.85-1.16).
Adjusting our multivariate models also for education, physical activity, alcohol consumption
and body mass index did not lead to other conclusions. Additional exclusion of subjects who
reported diabetes at baseline also did not materially change our results, but only affected the
power of our analyses. For example, in women the RR for each 5 nmol/L increase in plasma
folate concentration changed to 0.21 (95% CI=0.04-1.00) from 0.16 (95% CI=0.03-0.78).
Discussion
In this prospective study we found no statistically significant association between the plasma
tHcy concentration and the incidence of CHD mortality. We found a significant protective effect
of a higher plasma folate concentration for the risk of CHD mortality in women only. Plasma PLP
and vitamin B12 concentrations were not associated with the incidence of CHD.
There are several methodological factors that might have contributed to an underestimation
of any true effects. Firstly, due to the fact that the present study was not designed to measure
the tHcy concentration, whole blood was not cooled nor centrifuged within 1 hr after drawing.
This could have led to an increase in the tHcy concentration in the blood samples, which is ~0.6
µmol/L per hour, independently of baseline tHcy concentration (33). Secondly, our plasma
samples were stored at -20°C for a maximum period of 14 years. For the plasma concentration
of tHcy (34-36) and vitamin B12 and PLP (37) this was probably not a substantial problem.
However, folate levels decline in a systematic manner (37). Nevertheless, our data on tHcy and
folate concentrations were probably suitable to study associations, since the Spearman
correlation and the regression coefficient for the relations between concentrations of plasma
folate and tHcy, and between concentrations of plasma B12 and tHcy in the present study were
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similar to those in our large cross-sectional study (33). In the latter study all plasma samples
were centrifuged within 1 hr after drawing and were predominantly stored at –80°C for ~6
years (33). Finally, in the present study biochemical parameters were measured only once. Due
to measurement errors and within-person fluctuations in blood parameters, a single
measurement may underestimate the magnitude of the RR (38), referred to as regression
dilution bias.
The number of fatal CHD cases was relatively small after exclusion of subjects who reported
a history of cardiovascular diseases. Judging from the RRs of CHD mortality calculated in table 3
(T3 vs. T1 in men: 1.14, 95% CI=0.50-2.61; in women: 2.04, 95% CI=0.48-8.62) it might
seem that we lacked statistical power to identify significant risk estimates. Yet, the RR
calculated for each 5 µmol/L increment in tHcy concentration for men and women together
(1.03, 95% CI=0.83-1.29) indicates that in this population the relation between the tHcy
concentration and CHD mortality is weak.
One of the strengths of our study is that we adjusted for plasma creatinine, a marker for
renal function. A high creatinine level indicates a decreased renal function, which leads to a
decreased homocysteine clearance (39). Furthermore, a decreased renal function is associated
with a higher risk of CHD (40). Therefore, omitting the correction for creatinine might lead to a
higher risk estimate; without creatinine in our multivariate model the additive risk for each 5
µmol/L increase in tHcy concentration (for men and women together) doubled from 1.03 to
1.06 (95% CI=0.86-1.31). Another strength of our study is that we included men as well as
women, which warrants the generalizability of our results to the whole adult population.
It seems unlikely that the previously described methodological factors are mainly responsible
for the weak association between the tHcy concentration and CHD in the present study. The
explanation for a weak association could lay in the proposed mechanism of action of an
elevated tHcy level; it might be a short-term risk marker, which in the presence of other CHD
risk factors promotes CHD (3). Evidence that an elevated tHcy level is a short-term marker is
provided by data of the Physicians’ Health Study. After 5 years of follow-up a significant
increased risk of CHD was found in men with elevated tHcy levels (11), however, extending the
follow-up to 7.5 years yielded a non-significant RR (27). Furthermore, in the same study
population no significant association was observed between the tHcy concentration and the risk
of angina pectoris after 9 years of follow-up (41). Two other studies also observed a stronger
relation between the tHcy concentration and the risk of CHD mortality (23) and between the
tHcy concentration and total cardiovascular disease mortality (14) during the first few years of
follow-up.
Evidence that elevated tHcy levels may in particular promote CHD under conditions
predisposing to CHD, comes from prospective studies which consistently show that an increased
tHcy level is a risk factor for cardiovascular events (among which CHD) and total mortality in
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subjects with an increased CHD risk (10,19,40,42-49). Furthermore, of the five prospective
studies with elderly populations (average age >60 years) (7,10,13,14,23), only one (23) did not
show a clear significant association between the tHcy concentration and CHD. As in elderly the
chance of silent, pre-clinical, CHD is larger, this finding is in line with the hypothesis that an
elevated tHcy concentration triggers an acute event in high-risk populations. Nevertheless,
these results could also indicate that an elevated tHcy concentration is a marker of pre-clinical
CHD.
A short-term harmful effect of an elevated tHcy concentration was not observed in our study
population when we looked at the risk of CHD mortality in the first 5 years of follow-up (data
not shown). Yet our data supported the suggestion that raised tHcy levels might trigger an
event in high-risk subjects, as the RR of CHD mortality per 5 µmol/L increment in tHcy
concentration in subjects with cardiovascular diseases at baseline was 1.58 (95% CI=0.81-
3.09).
In summary, the fact that we studied relatively young subjects, free of baseline CHD could be
an explanation for the observed weak association between the tHcy concentration and CHD.
This result, although weak, is generally in line with other prospective studies with subjects not
selected for their risk of CHD (7-23). Based on most of these studies (7-9,11-18,21-23) Ueland
et al (50) recently calculated a pooled odds ratio for each 5 µmol/L increase in tHcy
concentration of 1.20 (95% CI=1.14-1.25). Our estimate (1.03, 95% CI=0.83-1.29) revealed a
much lower RR for each 5 µmol/L increase in tHcy concentration, but the confidence intervals of
both estimates overlap.
We found that high folate concentrations were associated with a significant decrease in RR of
CHD mortality in women only, which is in line with the results of Morrison et al (24). Other
studies that investigated plasma folate concentration in relation to CHD observed inverse
relations in men as well as women (25), or in men only (26). Two studies did not find
significant associations (16,27), although the risk estimate was compatible with the hypothesis
that high folate levels might contribute to the protection of CHD. In addition, other prospective
studies that investigated the relation between folate status and all cardiovascular diseases as
endpoint, showed a beneficial effect of higher folate levels (51-53). Thus, it is not unlikely that
folate might have a protective role in the development of CHD. In our study, this protective
effect in women was (at least partly), independent of the tHcy concentration.
The concentration of the other two B-vitamins that were investigated in this study, plasma
PLP and vitamin B12 did not show a relation with CHD. Evidence from previous prospective
studies is not entirely consistent but suggests that the PLP concentration may be inversely
associated with CHD (16), although not always statistically significant (27). In the present
study, the simple adjusted models suggested a protective effect of higher PLP levels on CHD
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risk. However, this disappeared after correction for traditional CHD risk factors. The null finding
with the plasma vitamin B12 concentration agrees with that found in the ARIC study (16).
In conclusion, we found that elevated tHcy levels are not a major risk factor for CHD in a
population sample of Dutch subjects below the age of 60 years and free of cardiovascular
diseases at baseline. On the other hand, high plasma folate concentrations were associated
with a lower CHD risk, in women only. Randomized trials are needed to clarify the complex
relations between plasma concentrations of tHcy and B-vitamins, and CHD (6).
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Introduction
The main objectives of this thesis were to investigate possible determinants of plasma total
homocysteine (tHcy) concentrations, and to quantify the association between tHcy
concentrations and the risk of coronary heart disease (CHD) mortality. Both the determinants
and the association with CHD were explored in general Dutch adult populations.
This general discussion starts with an evaluation of the utilized study populations. Thereafter,
the measurement of main variables and methodological issues accompanying the measurement
of these variables are discussed. Then our main findings with respect to tHcy-determinants are
summarized and evaluated in the context of other studies and recent findings. Subsequently,
the association between the tHcy concentration and CHD is discussed in light of the mechanism
by which elevated tHcy concentrations might increase the risk of CHD, taking the ongoing
discussion on whether or not the tHcy concentration is causally related to CHD into
consideration. Consequently, some directions for future research are given, finishing with
implications of our results for prevention and treatment.
Evaluation of the study populations
The results described in this thesis are mainly based on data of two large monitoring studies.
The Monitoring Project on Risk Factors and Health in the Netherlands (MORGEN study) (1) was
used for studying the tHcy-determinants cross-sectionally. The data from the Monitoring Project
on Cardiovascular Disease Risk Factors (2) were the basis for our prospective study in which we
quantified the relation between the tHcy concentration and the risk of CHD mortality.
Selective participation and loss to follow up
Full participation in the monitoring studies required completing extensive self-administered
questionnaires and being physically examined at one of the study centers. This considerable
effort might have contributed to the relatively low overall response rate (i.e. ~50%). However,
about 10% of the non-response could be ascribed to errors in the municipal population
registration and to the fact that people had moved since the address data were obtained (2).
Generally, participants (respondents) of extensive health surveys are more health conscious
than non-respondents are. Non-response surveys of both monitoring studies indicated that non-
respondents were more likely to be male, and to be smokers (2). This selective response did
probably not affect the results of the cross-sectional study (discussed in chapter 3). With regard
to the prospective study, the number of fatal CHD cases was somewhat lower than expected
based on the number of persons examined (~36,000), the age and sex distribution of the
respondents and the mean follow-up; 170 vs. 180 CHD deaths. It seems unlikely that this lower
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number was due to relatively healthier participants in our study compared with the general
Dutch population. A more plausible explanation is that medical treatment has improved over the
years, which leads to longer survival of CHD patients. Loss to follow-up was not a major
concern since this was only 0.02% (chapter 9).
Study size and study design aspects
The cross-sectional study population was a large (n=3025) age and sex stratified random
sample of the MORGEN study. This enabled us to study the effect of various tHcy-determinants
in a balanced manner for both men and women in different age categories. However, further
stratification (e.g. with respect to MTHFR 677 C>T genotype), reduced statistical power.
A case-cohort design was used for the prospective study. This is a design developed to (cost-
)efficiently use the data of a full cohort, comparable to a nested case-control design.
Participants of the Monitoring Project on Cardiovascular Disease Risk Factors were the source
population for our case-cohort study. Of all these subjects data were collected during 1987-
1991 (baseline). A random sample was drawn from the full cohort after an average follow-up of
10.3 years. This random sample is called the sub-cohort. The sub-cohort was not stratified and
included also a few CHD cases. The remaining majority of CHD cases that were not part of the
sub-cohort were added to the sub-cohort. In other words, the case-cohort population consists
of all cases that occurred during follow-up in the full cohort and the non-cases included in the
sub-cohort.
The major advantage of the case-cohort design above the nested case-control design is that
the sub-cohort can provide information on the full cohort (3). Thus, due to information on
person-years at risk of exposed and non-exposed subjects, the same epidemiological incidence
measures can be calculated as in a full cohort study. To achieve precise measures, the size of
the sub-cohort should be about four-fold or more of the number of cases (4). Our sample was
about six-fold larger than the number of cases.
The specific features of a case-cohort study compared with a full cohort and a nested case-
control study are summarized in box 1.
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Box 1 The case-cohort design
A case-cohort study efficiently uses information of a full cohort study. For the full cohort information of all subjects is collected at
baseline. After follow-up, a random sample from the full cohort is drawn (sub-cohort), including non-cases and cases. All
remaining cases that were not part of this random sample are added (3).
Schematically the data used in a full cohort study, a nested case-control study, and a case-cohort study can be presented as
follows (adapted with permission from (3)):
Exposure CHD deaths Non-CHD deaths Total number Person years
Full cohort design
exposed A B A+B PY1
non-exposed C D C+D PY0
total A+C B+D N PY
Nested case-control design
exposed A b ? ?
non-exposed C d ? ?
total A+C b+d ? ?
Case-cohort design
random sample from cohort
exposed A b’ a’ + b’ py1
non-exposed C d’ c’ + d’ py0
total A+C n py
Capitals: numbers in the full cohort, small print: samples from the cohort
a’, b’, c’ and d’: these subjects are the random sample of the full cohort. In the statistical analysis these subjects are the source of
information on person-years of (non-) exposure of the full cohort.
The RELATIVE RISK (RR) can be estimated both with the nested case-control design and with the case-cohort design:
In the full cohort study, this is a ratio of the ABSOLUTE RISK in exposed and non-exposed: [A/A+C]/ [B/B+D];
In the nested case-control study, this is the exposure ODDS RATIO: [Ad/bC]. Note that this ratio estimates the disease odds ratio of
the cohort, and provided that A and C are small (rare disease assumption), it approaches the RR in the cohort;
In the case-cohort study this is estimated by the case-cohort ODDS RATIO: [A/(a’+b’)]/[C/(c’+d’)], which is an estimate of the RR in
the cohort, whether the outcome is rare or not.
In contrast to the nested case-control design, a case-cohort design has information on the person-years exposed or non-exposed.
Therefore, several additional measures can be calculated which reflect those in the full cohort:
INCIDENCE DENSITY or incidence rate, which is the number of CHD cases during a given period of time as a proportion of the total
person time at risk in the population:
among exposed=a’/py1
among non-exposed=c’/py0
INCIDENCE DENSITY RATIO , which is a more valid measure of the RR in studies with a long follow-up or in the presence of competing
mortality: [a’/py1]/[c’/py0] (4).
If the sample fraction, i.e. f=n/N, is known, the corresponding numbers or person-years in the cohort can be estimated, for
example the estimate of A+B equals: (a’+b’)/f. With these calculations absolute cumulative incidence and absolute incidence
densities can be calculated (4)
The sub-cohort can be used as a reference sample for different outcomes (5), which is also an advantage above the nested case-
cohort design. A draw back of the case-cohort design lies in the fact that the standard error of the RR estimates in multivariate
analyses is invalid due to dependency in the data, existing between the case-group and the referent group. However, recently a
Cox’s proportional-hazard method that calculates valid standard errors for this type of study design is available for SAS-software
as a macro available from the internet http://lib.stat.cmu.edu.general/robphreg.
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Measurement of main variables
Errors in the measurement of variables lead to misclassification that may affect the validity of
study results. The result of measurement error can be differential (dependent on the values of
other variables) or non-differential (independent of the values of other variables). Non-
differential random misclassification may weaken the effect estimates. Non-differential
systematic misclassification will not change the effect estimates. The specific effect of
differential misclassification on the results is difficult to determine; hence this type of error is of
greater concern because it can give spurious associations. In the following section several
issues that might have contributed to measurement errors in this thesis will be evaluated.
Conditions prior to the measurement of plasma tHcy and B-vitamins
concentrations
Table 1 summarizes the recommendations regarding collecting, handling and storing blood
samples for the measurements of tHcy and B-vitamin levels. Furthermore, it shows to what
extent we fulfilled these recommendations and what the effect might have been on our results.
Generally it is recommended to collect fasting blood samples for the measurement of the
tHcy concentration (6). However, for the monitoring surveys that were used in this thesis, it
was not feasible to obtain fasting blood samples. For the cross-sectional study we had
information on the time of the last taken meal or drink. The tHcy concentration of fasting
samples was on average 0.7 µmol/L higher than in non-fasting samples (see chapter 3). Yet,
the number of fasted subjects was very low (3%), thus, substantial bias of our effect estimates
is unlikely.
The tHcy concentration of blood collected in sitting position is lower (maximally 30%), than
that of blood collected after a supine (horizontal) rest (7). As blood collection in our studies was
standardized to sitting, this should be taken into account when horizontally collected samples
(e.g. of bedridden patients) are compared with our values.
The tHcy concentration increases in whole blood when left at room temperature (8,9). This is
probably due to a continuous synthesis and export of homocysteine from blood cells (9,10). To
overcome this increase in tHcy concentration, one should centrifuge or cool blood immediately
after drawing. The samples of the cross-sectional study were centrifuged within 1 h, but the
samples of the prospective study were stored at room temperature for a maximum of 3 h.
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Table 1 Recommendations regarding collecting, handling and storing blood samples for the measurements of tHcy
and B-vitamin concentrations
Recommendation Recommendation fulfilled in: Effect on the tHcy
concentration if not
handled according to
the
recommendations
Effect on B-vitamin
concentrations if not
handled according to
the
recommendations
Type of
measurement
error
Cross-sectional
study?
Prospective
study?
Collecting blood:
subjects should be
fasting to reduce
effect of last eaten
meal
no:
samples were non-
fasting, but
information was
collected on time
of last taken meal
no:
samples were
non-fasting, no
information was
collected on
time of last
taken meal
tHcy concentration
of fasting samples
were 0.7 µmol/L
higher compared
with non-fasting
samples
(chapter 3)
no effect of fasting
(data not presented)
non- differential
Handling blood:
only for tHcy
concentration;
centrifugation within
1 hr or direct
cooling of whole
blood
yes:
random sample
selected from
subjects of which
blood was
centrifuged within
1 h
no:
maximum
storage at room
temperature for
3 h
0.6 µmol/L increase
in tHcy/h,
independent of
baseline value
(chapter 3)
not relevant for B-
vitamins
non- differential
Storing plasma:
at or below -80°C
yes, partly:
storage at –20°C
for maximum of
17 months
-80°C for
maximum 51
months
no:
storage at -20°C
for 14 years
probably negligible
as the tHcy
concentration
remains stable at
room temperature
for 2 weeks (11),
and stable at -20°C
for at least 2 years
(8,11,12)
B12 and B6 remain
stable for at least 4
years, folate
declines
systematically
independent of
baseline value (13)
non- differential
In chapter 3 we showed that the increase in tHcy concentration is independent of baseline
tHcy levels. Thus, when all whole blood samples are left at room temperature for the same
amount of time, the increase in tHcy concentration is similar for all samples, thereby leaving the
ranking of subjects according to their tHcy level intact. However, the duration of storage at
room temperature of the samples from the prospective study varied; some might have been
centrifuged within 1 h, whereas others will have been centrifuged after 3 h. This will have
introduced some random error. To evaluate this error we compared the age- and sex-specific
mean tHcy concentrations of the prospective study with those of the cross-sectional study (in
which all samples were centrifuged within 1 h). This showed that on average the values of the
prospective study were 1 µmol/L higher. The maximal standard deviation (SD) of this increase
is estimated to be no larger than 1 µmol/L. This SD is small compared with the SD of the tHcy
concentrations of the case-cohort population, i.e.: 5.6 µmol/L (n=732). Therefore, the
extraneous variation introduced by the increase will only have had a small diluting effect on the
association between the tHcy concentration and CHD mortality.
Misclassification due to altered concentrations as a result of prolonged storage of the plasma
samples, again is mostly restricted to the prospective study. Storage at relatively high
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temperatures (i.e. -20°C) is especially deleterious for the concentration of folate, that declines
in a systematic manner (13), possibly because some of the folates are destroyed through
oxidation (14). This could explain why the plasma folate concentrations were on average
somewhat lower in the prospective study compared with the cross-sectional study (6.7 vs. 7.4
nmol/L). Yet, the storage conditions did not affect the ranking of subjects, as the Spearman
correlation between the plasma folate and tHcy concentration in the prospective study was
equal to that in the cross-sectional study (i.e. r=-0.4). Thus, the absolute levels of the plasma
folate concentration need to be interpreted with caution, yet the data were suitable to study
associations because the ranking of subjects remained intact.
Absence of a gold standard
For the determination of tHcy or B-vitamin concentrations in plasma no ultimate reference
method is available. Of all methods to determine the tHcy concentration, i.e. capillary
electrophoresis, immunoassays, gas-liquid chromatography and various methods of high
performance liquid chromatography (HPLC) (15), the gas chromatography mass spectrometry
assay is sometimes used to establish the relative validity of another method because it is
sensitive and specific (16). For the measurements of the concentration of B-vitamins the
number of available methods is also substantial.
Appreciating that each laboratory has its own adaptations for these methods, the variation in
methods is large. This is reflected in the considerable differences in measured concentrations of
e.g. tHcy (i.e. 6-15%) (17-20) and folate (i.e. 27.6%) (21) in one sample determined in several
laboratories. In some cases the between-laboratory differences exceeds the between-method
variation (20).
Due to the inter-laboratory differences, concentrations measured in one laboratory cannot be
reliably compared with those determined in another laboratory without evaluation of inter-
laboratory differences (see also chapter 3). This severely complicates the establishment of
normal levels, and as a consequence of this, also of deficient (in case of vitamins) and elevated
(in case of tHcy) levels. Certified reference material is urgently needed to improve inter-method
and inter-laboratory agreement (16). An external quality control program, analogous to the
cholesterol standardization program of the World Health Organization (WHO), is needed to
supervise and to maintain standardization.
In the absence of a gold standard, absolute validity can not be assessed. However, the
incorporation of reference plasma samples in an analytical run allows the calculation of the
precision, i.e. the reproducibility of a measurement. For the cross-sectional and the prospective
study we used the most common method to measure the tHcy concentration: high performance
liquid chromatography (HPLC) with fluorometric detection. The within (<3.2%) and between
(<8.6%) run coefficients of variation (CV) of this method indicate that there is close agreement
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between successive measurements of the same sample and the results obtained with the same
method under different conditions. In the cross-sectional study the folate and vitamin B12
concentrations were determined microbiologically, whereas for the prospective study a radio
assay was applied. The coefficients of variation with the radioassay were higher compared with
those of the microbiological assay, but they were acceptable (CV-within <11%, CV-between
<13%). The plasma vitamin B6 concentration (measured as pyridoxal 5’ phosphate, i.e. PLP)
was measured with a HPLC method with satisfying within- and between-run CVs (5.7% and
9.7%, respectively).
Data on habitual dietary intake was only used in the cross-sectional study. For this purpose
we used a semi-quantitative food-frequency questionnaire. The relative validity was assessed in
63 men and 58 women by calculating the Spearman correlation between the food-frequency
questionnaires and the average of 12 24-h dietary recalls (22). Of the main contributors to the
B-vitamin intake, the relative validity was somewhat low for vegetables (r=0.38 in men and
r=0.31 in women), and for meat, but only in men (r=0.47). In women the relative validity of
reported meat consumption was high (r=0.70). The relative validity of other foods groups
mainly contributing to the B-vitamin intake (bread, potatoes, milk and milk products) and of
alcoholic and non-alcoholic drinks, ranged between 0.58 and 0.87. Overall, the relative validity
of this questionnaire was generally sufficient. The low relative validity for vegetables was also
observed for other questionnaires (reviewed in (22)).
Once an estimate of habitual intake is acquired, this needs to be translated into nutrients. For
this translation, food composition tables are necessary. The use of such tables introduces
measurement errors at various levels. Errors may result from the assumption that the nutrient
content of a specific food is constant, which in reality may vary considerably depending on e.g.
sunlight, soil, and type of breed. Furthermore, when the foods sampled for the analytical
determination do not represent those commonly eaten, this leads to errors. Finally, errors are
introduced due to inaccuracy of the analytical data, missing data, and incorrect use of data from
other food composition tables (23).
For the studies described in chapter 4 and 5, we used the most recent data available for
foods commonly eaten in the Netherlands. Dutch data for folate were not available at the time
our study started, but they were provided by Konings et al who measured folates in foods with
an improved HPLC method (24,25). The estimated folate intake with this advanced method was
about 30% lower compared with an estimate based on the British food composition table (26).
The British table was used for comparison due to its completeness and the fact that all food
samples were analyzed using the same method. Despite differences in absolute intake level, the
ranking of subjects according to their intake was similar for the two used food composition
tables; the Spearman correlation between folate intake calculated with the British table and
with the recent Dutch values was high (i.e. r=0.88).
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Intra-individual variation
Intra-individual variation in plasma parameters and dietary intake may also introduce
measurement errors. Concerning plasma parameters, this variation is due to errors in the
measurement, but also to real hour-to-hour or day-to-day biological fluctuations. Using an
average of repeated measurements will reduce this type of non-differential error, but in our
study we only had single measurements. From the literature it is known that the intra-individual
coefficient of variation in tHcy concentration is ~9% day-to-day (7), ~7-8% over a month
(27,28) and 9% over a year with little seasonal variation (29). This indicates that a single
measurement reasonably reflects a persons average tHcy level. Furthermore, this level of intra-
individual variation is comparable with that of total cholesterol and systolic blood pressure (30).
To our knowledge, data on the intra-individual variation in levels of B-vitamins are not available.
Intra-individual variation in dietary intake may result in an attenuation of an association when
the reported dietary intake does not represent the long-term habitual dietary intake. The
reproducibility of reported dietary intake with the food-frequency questionnaire used in the
cross-sectional study was evaluated in the previously described validation study (22). This was
done by calculating the Spearman correlation coefficient between food groups reported in 2
questionnaires completed 12 months apart. Of the food groups that predominantly contributed
to the intake of our main nutrients, the correlation for vegetables was 0.65 for women and 0.76
for men. For the other food groups (bread, potatoes, milk and milk products, meat, alcoholic
and non-alcoholic beverages) it ranged between 0.68 (for meat in men) and 0.92 (for alcoholic
beverages in women) (22). This indicates that the reported dietary intake did not change
considerably over 1 year.
Although a sufficient reproducibility excludes a large effect of random errors in the reporting
of food intake, it can not exclude conscious or unconscious under- or over-reporting of habitual
food intake. Alcohol consumption is an item that is frequently under-reported, whereas
vegetable and fruit intakes are often over-reported. When this happens systematically, the
ranking of subjects remains the same. Consequently this will not have an effect on measures of
association. However, when reporting depends on a persons’ risk profile (like body mass index-
dependent under-reporting (31)), this leads to differential misclassification of subjects.
Differential misclassification can either overestimate an association (when high-risk persons
exaggerate their unhealthy lifestyle) or underestimate an association (when high-risk persons
deny their unhealthy lifestyle). Energy adjustments, like we applied for all nutrients, may reduce
some measurement error due to reporting errors (32).
Multicollinearity between dietary variables
To assess an independent effect of intake of folate and vitamin B2, B6 and B12 on tHcy
concentrations, we corrected the associations for intake of the other three B-vitamins and
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methionine. Because these nutrients are frequently present in the same types of food, they are
highly inter-correlated. This raises the problem of multicollinearity in multivariate regression
models. For example, folate intake is highly correlated with vitamin B6 intake (Spearman
r=0.8). Suppose a model in which the tHcy concentration is predicted by folate intake with a
simultaneous correction for vitamin B6 intake. Due to the high correlation between folate and
vitamin B6 intake, the degree in which folate intake can vary, is largely reduced by the fact that
the level of vitamin B6 intake is statistically kept constant. Fortunately, energy adjustment
largely reduced the inter-correlation of the nutrients from between 0.44-0.82 to 0.12-0.67. With
the energy adjusted variables we evaluated whether we experienced a reduced variance in our
models. This was done by calculating the variance inflation factor (VIF). For none of our models
the VIF exceeded 2.4, whereas multicollinearity is to be concerned when the VIF is larger than
10.0 (33).
Remaining to the above-mentioned example, we may conclude that multicollinearity probably
did not hamper the adjustment for the intake of other B-vitamins in the relation between folate
intake and the tHcy concentration. This makes it less likely that the observed relation between
folate intake and the tHcy concentration is in fact an underlying relation between e.g. vitamin
B6 intake and the tHcy concentration. Moreover, the simultaneous correction for vitamin B2, B6,
B12 and methionine intake while studying the relation between folate intake and the tHcy
concentration will have reduced the chance of residual confounding. Residual confounding
occurs if one cannot properly account for factors that are associated with the outcome (in this
case the tHcy concentration) and the exposure (in this case folate intake).
Measurement of physical activity, smoking, biological CHD risk factors and
genetic background
Physical activity is difficult to quantify, as it comprises activity during leisure time, work,
study, household activities and commuting (e.g. cycling to work). Depending on the
questionnaires used in the studies we distinguished 4 levels of activity (cross-sectional study)
and 3 levels of activity (prospective study). Both classifications were positively associated with
HDL cholesterol (34). As this is a recognized response to increased exercise levels (35,36),
physical activity was probably ranked in a reasonably valid manner. Furthermore, the
reproducibility and relative validity of a simplified version of the physical activity questionnaire
used in the cross-sectional study was suitable for ranking subjects according to their level of
physical activity (37).
In several chapters we used information on smoking habits, either to evaluate whether it
interacted with other variables (chapter 4), to study the independent effect on tHcy
concentrations (chapter 6), or to adjust for it as a confounder (chapter 5, 7-9). When classifying
subjects into never, ex, light, moderate and heavy smokers, misclassification can occur at the
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level of the number of cigarettes smoked per day. This classification was only used in chapter 6.
For the other chapters we used a dichotomous variable indication whether a subject is a current
smoker or not. The chance of recall bias for this crude variable is likely to be smaller. On the
other hand, for those associations in which smoking is a strong confounder, residual
confounding due to the lack of detailed smoking habits may be a problem. Fortunately, in none
of our analyses smoking was strongly associated with our explanatory variables.
Total and HDL cholesterol levels were measured in fresh blood samples in a standardized
reference laboratory, which largely decreases the chance of measurement errors. Yet, as we
only had a measurement at one point in time, a dilution of effects can occur due to intra-
individual variation (see previous section). Measuring blood pressure twice and using the
average in the analyses reduced short-term intra-individual variation in systolic and diastolic
blood pressure. For the other measurements, like waist circumference, weight and height, no
special procedures other than standardized protocols were applied to reduce measurement
errors that were likely to be small.
The outcome of genetic mutation analyses is, compared with the determination of e.g. an
exact concentration, relatively simple since only three readings are possible (i.e. homozygous
mutant, heterozygous, and homozygous normal). As a computerized reading, which is not
influenced by personal interpretation, was not available for this genotype we designed a
protocol to reduce reading and coding errors. Since our genotype distribution was in Hardy-
Weinberg equilibrium and was similar to those reported in other Western-European studies
(38,39), misclassification did not seriously affect the prevalence of the genotypes.
Measuring CHD mortality
To survey which subjects of our cohort had died between the start of the study (1987) and
the censoring date (01-01-2000) we linked the unique personal identification numbers of our
participants with data of municipal registries. Data on the date of death from these registries
are known to be valid. When subjects could not be linked, the reason was investigated,
resulting in a very low loss-to-follow-up (i.e. 0.02%). Subsequently, the cause of death was
obtained from Statistics Netherlands. Coding of the causes of death could have involved some
measurement error, which may have weakened any true associations. Nevertheless, the
mortality of all types of cardiovascular diseases in this project was the same as in earlier
monitoring cohorts in the Netherlands (40).
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Discussion of main findings: determinants of homocysteine
Table 2 summarizes the findings on tHcy-determinants described in this thesis. In short, men
and older subjects had higher tHcy levels. Folate intake was the only B-vitamin inversely
associated with the tHcy concentration, showing a stronger relation in male non-drinkers and
male smokers.
Table 2 Summary of main findings with respect to tHcy-determinants
Potential determinant Association? Effect on tHcy concentration Ch
sex yes 1.3 µmol/L higher tHcy in G vs. E 3
age yes, E only 1.3 µmol/L higher tHcy in E 60-65 vs. E 20-29 years old 3
folate intake yes 2.2 µmol/L higher tHcy in Q1 vs. Q5 in G;
1.3 µmol/L higher tHcy in Q1 vs. Q5 in E
4
vitamin B2 intake no 4
vitamin B6 intake no 4
vitamin B12 intake no 4
interaction
folate intake ´  alcohol
use
yes, G only 3.4 µmol/L higher tHcy in Q1 vs. Q5 in non-drinking G;
1.8 µmol/L higher tHcy in Q1 vs. Q5 in G drinking £2 glasses/d;
1.4 µmol/L higher tHcy in Q1 vs. Q5 in G drinking >2 glasses/d
4,6
interaction
folate intake ´
smoking
yes, G only 2.8 µmol/L higher tHcy in Q1 vs. Q5 in smoking G;
1.6 µmol/L higher tHcy in Q1 vs. Q5 in non-smoking G
4,6
MTHFR C677T
polymorphism
yes 4.2 µmol/L higher tHcy in TT vs. CC genotype 5
interaction
folate intake ´  MTHFR
C677T polymorphism
yes 1.4 µmol/L higher tHcy in Q1 vs. Q5 in CC and CT subjects;
4.1 µmol/L higher tHcy in Q1 vs. Q5 in TT subjects
5
interaction
plasma folate ´
MTHFR C677T
polymorphism
yes 2.3 µmol/L higher tHcy in Q1 vs. Q5 in CC subjects;
3.6 µmol/L higher tHcy in Q1 vs. Q5 in CT subjects;
8.3 µmol/L higher tHcy in Q1 vs. Q5 in TT subjects
5
coffee consumption yes 1.4 µmol/L lower tHcy in 0 vs. >6 cups of coffee/d in G;
1.1 µmol/L lower tHcy in 0 vs. >6 cups of coffee/d in E
6
tea consumption no 6
smoking yes, E only 0.8 µmol/L lower tHcy in non-smoking vs. E smoking ³20 cigarettes/d 6
physical activity yes, E only 0.6 µmol/L higher tHcy in heavily active vs. sedentary E 6
alcohol consumption yes, G only folate intake below median: 1.7 µmol/L higher tHcy in G drinking 0 vs. >2
glasses of alcohol/d;
folate intake above median: 0.8 µmol/L higher tHcy in G drinking 0 vs. >2
glasses of alcohol/d
6
beer yes, G only 1.3 µmol/L higher tHcy in G abstaining from beer vs. G in highest beer
tertile (average 3.7 glasses of beer/d)
7
wine no 7
spirits no 7
total cholesterol yes, E only 0.6 µmol/L lower tHcy in Q1 (£4.47 mmol/L) vs. Q4 (>5.86 mmol/L) of
total cholesterol in E
8
HDL cholesterol yes, E only 1.0 µmol/L higher tHcy in Q1 (£1.05 mmol/L) vs. Q4 (>1.52 mmol/L) in
HDL cholesterol in E
8
waist circumference no 8
diastolic blood
pressure
no 8
systolic blood pressure no 8
Explanation of abbreviations: Ch=Chapter in this thesis, G=men; E=women; Q1=first quartile or first quintile (depending of
whether it is compared with Q4 or Q5), Q4=highest quartile, Q5=highest quintile, T1=first tertile, T3=highest tertile.
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The 677 C>T polymorphism in the gene encoding for MTHFR was associated with higher tHcy
levels. In addition, the relations between folate intake ® plasma folate concentration, plasma
folate concentration ® tHcy concentration and folate intake ® tHcy concentration were
different for the three genotypes (i.e. CC=homozygous normal, CT=heterozygous,
TT=homozygous mutant). The relations between the plasma concentration of folate and tHcy,
and between folate intake and tHcy concentration were inversely for all genotypes and the
steepest inverse slope was observed in TT subjects. The relation between folate intake and
plasma folate was positive for all genotypes and strongest in CT subjects.
Of the lifestyle factors, coffee consumption was associated with higher tHcy levels in both
men and women. Furthermore, smoking and physical activity were positively associated with
the tHcy concentration in women, and alcohol consumption was inversely associated with the
tHcy concentration in men. This inverse association was probably due to beer consumption.
Of the biological CHD risk factors, we only found weak associations in women: inverse
between HDL cholesterol and the tHcy concentration, positive between total cholesterol and the
tHcy concentration.
Age and sex
Consistent with other studies we found that men had higher tHcy levels than women (chapter
3). Some researchers have postulated that this difference between men and women is due to
muscle mass (41). Creatinine is an indicator of muscle mass. The data of the prospective study
(sub-cohort) indeed showed that after creatinine-adjustment there was no longer a relevant
difference in the tHcy concentration between men and women (data not shown).
Age was positively associated with the tHcy concentration, which was only significant in
women. We could not ascribe this relation to the occurrence of the menopause. This finding is
in line with several other investigations (42,43), yet there is evidence that pre-menopausal
women handle a methionine load more efficiently than post-menopausal women (44-46).
B-vitamin intake
Four B-vitamins are involved in homocysteine metabolism: folate, vitamin B2, B6 and B12. In
our population, vitamin B2, B6 and B12 intake were not associated with tHcy levels after
correction for intake of methionine and the other B-vitamins (including folate). We, and recently
also others (47,48), showed that a higher dietary folate intake is associated with a lower tHcy
level in adults, independently of other dietary and lifestyle factors (chapter 4). These results
complement those found in observational studies on dietary folate intake and the tHcy
concentration in middle aged (49,50) and elderly subjects (50-53). The fact that folate is the
most important dietary determinant of tHcy levels, is in line with its metabolic role. Folate is
used as a substrate: it donates the methyl-group for the conversion of homocysteine to
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methionine (see figure 1, General Introduction). On the contrary, vitamin B2, B6 and B12 are
not utilized when homocysteine is metabolized; they function as co-factors of enzymes in
homocysteine metabolism.
Table 3 Folate intake: recommended, actual and desired intake with regard to tHcy levels in the Netherlands.
Comparison between available data in 1997 and in 2001
1997 2001
men women reference men women reference
Recommended folate intake Recommended folate intake
200-300
µg/d
200-300
µg/d
chapter 2         remained the same as in 1997
Actual folate intake (mean) calculated with the British
food composition table (26):
Actual folate intake (mean) calculated with the Dutch food
composition table (25):
DNFCS 293 µg/d 238 µg/d (55)
chapter 2
DNFCS 215 µg/d 173 µg/d (25)
MORGEN  study 239 µg/d 192 µg/d chapter 4
Desired folate intake Desired folate intake
>350 µg/d >350 µg/d chapter 2 MORGEN study,
all
>300 µg/d >300 µg/d chapter 4
MORGEN study,
MTHFR 677 TT
(10% of the
population)
>>300 µg/d >>300 µg/d chapter 5
Explanations of abbreviations: DNFCS=second Dutch National Food Consumption Survey, MTHFR 677 TT=homozygous mutant.
Table 3 summarizes the main results with regard to folate intake. Between 1997 and 2001
the Dutch health authorities have not changed the dietary recommendations for folate. The only
health authority that changed the dietary recommendation for folate from 200 to 400 µg/d,
using data on the tHcy concentration as a functional parameter of the folate status, was the
USA Food and Nutrition Board (54).
Due to the lack of Dutch data before 2001 (25), folate intake in the second Dutch National
Food Consumption Survey (DNFCS) performed in 1992, was calculated with data mainly from
the British food composition table (55). Recently, a validated HPLC method was developed with
which the folate content of a large set of commonly eaten Dutch foods was measured (24).
With the new data the folate intake in the second DNFCS was recalculated. The average folate
intake was ~27% lower than calculated with the British food table. For the calculation of the
folate intake in our cross-sectional study (chapter 4) we also used the new food composition
data (25), and the average intake was similar to the estimate in the DNFCS.
A desired folate intake level was defined as the folate intake level associated with an
optimally low tHcy concentration in light of the continuous relation between the tHcy
concentration and the risk of CHD. In chapter 4, we showed that the relation between folate
intake and the tHcy concentration decreased continuously across the measured folate intake
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range: 140-300 µg/d, i.e. the average levels in first and last decile of the folate intake
distribution. The tHcy concentration did not reach a low-plateau value within this range. Thus,
we concluded that a desired folate intake level lies above 300 µg/d.
In chapter 5 we investigated the effect of the MTHFR 677 C>T polymorphism on folate
requirements in the same population. The MTHFR enzyme produces 5-methyl-tetrahydrofolate,
which is the main circulating form of folate used for the conversion of homocysteine to
methionine. The homozygous mutant (TT) form of this polymorphism is especially associated
with a reduction in specific enzyme activity (<50%) (56). The reduced activity of the enzyme
was reflected in the higher folate intake requirements of TT subjects. At the highest folate
intake levels, CC and CT subjects had a comparably low tHcy level (CC: 12.4 µmol/L and CT:
13.1 µmol/L). However, at this high folate intake level, TT subjects still had a high tHcy
concentration (15.7 µmol/L). With these data we estimated that the desired folate intake of TT
subjects lies at least 10% above the level for CT and CC subjects.
In summary, the desired folate intake estimated with available data in 1997 (>350 µg/d) is
supported by our cross-sectional data. Using the improved food folate data resulted in a lower
estimated folate intake than previously assumed, enlarging the gap between actual and desired
folate intake.
Lifestyle factors
Along with findings of most (47,53,57-59), but not all (48,50,60), observational studies coffee
consumption was positively associated with the tHcy concentration in both men and women
(chapter 6). Recent intervention trials have shown that this effect of coffee is causal (61-63).
Caffeine might be the factor that elevates the tHcy concentration (47,57,63), as it may inhibit
the conversion of homocysteine to cysteine by acting as a vitamin B6 antagonist (63).
Additionally, recent evidence became available that chlorogenic acid, a polyphenol that is
present in coffee in the same amount as caffeine, may also partly be responsible for the
increase in the tHcy concentration (64). When polyphenols are metabolized, methyl-groups
from methionine are necessary, which results in a higher production of homocysteine (64). Both
caffeine and chlorogenic acid are also present in tea, although in smaller doses, which explains
the absence of an association with tea consumption.
In our population, smoking was positively associated with the tHcy concentration, which was
most pronounced in women (chapter 6). Others found similar results (47,48,53,65,66). The fact
that the smoking effect remained after correction for coffee consumption and folate intake
(chapter 6)(48,67) excludes important confounding. Smokers generally consume a less healthy
diet. Indeed, in one study the effect of smoking disappeared after correction for plasma folate
(50). Correction for plasma folate concentration in place of folate intake in our study, slightly
attenuated the relation between smoking and the tHcy concentration (data not shown). The
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exact mechanism behind the increase in the tHcy concentration is unidentified, yet smoking
may induce local effects in cells exposed to cigarette smoke (68), or may influence the tHcy
concentration by changing the plasma thiol redox status (69-71), or may inhibit enzymes such
as methionine synthase (72).
Alcohol consumption is probably associated with the tHcy concentration in a J-shaped fashion
(53,73). For moderate alcohol consumption, we found a lower tHcy concentration in drinkers
compared with non-drinkers. This inverse relation was only observed in men, probably due to
the small alcohol intake range in women (chapter 6). Our findings agree with other
observational studies in men (74) and men and women combined (75,76). However, two
American studies found weak positive associations (47,66). As extremely high alcohol
consumption is associated with elevations in the tHcy concentration (77,78), alcoholics might
have drawn the positive association between alcohol and the tHcy concentration (47,66). Since
we accounted for the most important lifestyle confounders (folate intake, smoking, coffee
drinking), and we observed similar results after exclusion of ex-drinkers, our results suggest
that moderate alcohol consumption is associated with a beneficial lower tHcy concentration
compared with non-drinking. J-shaped relations between alcohol consumption and biological
CHD risk factors (like HDL cholesterol) have been reported as well (79).
Considering the type of alcoholic beverage, we found that beer was probably responsible for
the inverse association between alcohol consumption and the tHcy concentration, because we
saw no association with wine and spirits. However, the intake range of wine and spirits was
very small compared with the range of beer consumption (chapter 7: average intake in the
highest tertile <0.9 glasses/d for wine and spirits, vs. 3.7 glasses/d for beer). Thus, the positive
relation between beer and the tHcy concentration might also have been an ethanol effect
(chapter 7). In two other population-based studies, beer consumption was associated either
with a decrease (76) or no effect on the tHcy concentration (47). The results from two
intervention trials with beer, wine and spirits were inconsistent: one 3-week randomized cross-
over trial showed no association with the tHcy concentration after intervention with 4 glasses of
beer/d, compared with an elevation of the tHcy concentration with 4 glasses/d of wine or spirits
(80). Another trial, with a marginal 6-week non-randomized design in which participants could
drink the alcoholic beverage of their own preference (81), showed elevations in the tHcy
concentration for all three alcoholic beverage groups after daily consumption of 3 glasses/d.
Hence, the results for types of alcoholic beverages are not clear. Intervention studies with lower
doses of alcoholic beverages or with ethanol-water solutions may provide more insight in this
issue.
Our finding with regard to a weak positive association between physical activity and the tHcy
concentration (though only in women in multivariate models, chapter 6) is not in agreement
with weak inverse (48,65), or no association in other observational studies (50,53). One
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intervention study showed that acute exercise does not affect the tHcy concentration (82). As
an active lifestyle in general is associated with a more healthy lifestyle, and a more healthy
lifestyle with a lower tHcy concentration, our result is a likely chance finding, as residual
confounding of e.g. smoking is expected to result in an inverse association.
Lifestyle-diet and gene-diet interactions
In chapter 4 the relation between folate intake and the tHcy concentration in males differed
by the level of alcohol consumption: the slope of the relation was stronger in non-drinkers
compared with drinkers. In other words, at a low folate intake level non-drinkers had a higher
tHcy concentration than drinkers, whereas at a high folate intake no difference in the tHcy
concentration was present between drinkers and non-drinkers (chapter 4). The observation that
alcohol drinking might protect against a high tHcy level in subjects with a low folate intake was
recently also described in the elderly (66-94 years) (53). These researchers observed the
interaction in men and women combined. Nevertheless, the effect might be due to males, as in
general the variation in alcohol consumption in men is larger than in women.
In chapter 4 we also observed effect modification of smoking on the relation between folate
intake and the tHcy concentration, in men. The relation between folate intake and the tHcy
concentration was much stronger in smokers: at a low folate intake smokers had a much higher
tHcy level compared with non-smokers with a low folate intake. However, at a high folate
intake, smokers had a comparably low tHcy concentration as non-smokers. To our knowledge,
no such interaction has been reported until now.
The first gene-diet interaction with an effect on the tHcy concentration was reported by
Jacques et al (83). At present, numerous studies have confirmed that the homozygous mutant
form of the MTHFR 677 C>T polymorphism, is associated with a higher tHcy concentration
especially in subjects with a sub-optimal plasma folate status (50,83-100) (chapter 5), or a sub-
optimal folate intake (100) (chapter 5). However, to the best of our information the effect of
the 677 C>T mutation on the relation folate intake ® plasma folate, has not been shown
before. This relation was positive for all genotypes, but the steepest slope was observed for CT
subjects. At a low folate intake CT subjects had a low plasma folate concentration, comparable
to that of TT subjects. At a high folate intake, however, their plasma folate was high,
resembling that of CC subjects. In contrast, at a high folate intake TT subjects still had a lower
plasma folate level than CT and CC subjects. This implies that subjects with two TT alleles need
much more dietary folate to optimize their plasma folate status. Apparently, from the relation
between plasma folate and the tHcy concentration, once they have achieved a high plasma
folate level, the tHcy concentration of TT subjects is equally low as that in CT and CC subjects.
The finding that high folate intakes counteract the disadvantage of having one or two T
alleles is explained by recent findings of Guenther et al (101). In a system with bacteria they
Chapter 10
128
showed that a mutation homologous to the human MTHFR 677 C>T mutation was associated
with an enhanced dissociation of flavin adenine dinucleotide (FAD, i.e. cofactor form of vitamin
B2). An optimal folate supply prevented the loss of FAD binding and suppresses the inactivation
of the enzyme (101).
Biological CHD risk factors
In general, and also in our study (chapter 8), the associations of total cholesterol, HDL
cholesterol, systolic and diastolic blood pressure and measures of body fat and the tHcy
concentration are not very strong (65,102). Nevertheless, as they are associated with the tHcy
concentration in the direction of an increased risk of CHD, adjustments for these factors while
studying the relation between the tHcy concentration and the risk of CHD, is necessary.
Conclusions for determinants of homocysteine
Figure 1 illustrates the (univariately) explained variance in the tHcy concentration by the
determinants investigated in this thesis. It is shown that folate intake is by far the most
important modifiable determinant of the tHcy concentration, explaining almost 6% of the
variation in the tHcy concentration. Causality can not be inferred from data of a cross-sectional
study, but intervention studies (103-105) have shown that increasing the folate intake will lower
tHcy concentrations.
Figure 1 Explained variance in tHcy levels (%) by various determinants investigated in this thesis (data of the cross-
sectional study)
0
1
2
3
4
5
6
7
8
Se
x
Ag
e, 
me
n
Ag
e, 
wo
me
n
Fo
late
 in
tak
e
Alc
oh
ol 
co
ns
um
ptio
n, 
me
n
Alc
oh
ol 
co
ns
um
pti
on
, w
om
en
Alc
oh
ol c
on
su
mp
tion
, m
en
 w
ith 
low
 fo
late
 int
ak
e Sm
ok
ing
, m
en
Sm
ok
ing
, w
om
en
Sm
ok
ing
, m
en
 w
ith
 lo
w 
fol
ate
 in
tak
e
Co
ffe
e c
on
su
mp
tion
 
Ph
ysi
ca
l a
ctiv
ity,
 m
en
Ph
ysi
ca
l a
ctiv
ity,
 w
om
en
MT
HF
R 
67
7 C
>T
 ge
no
typ
e
To
tal 
ch
ole
ste
rol
 
HD
L c
ho
les
ter
ol
Dia
sto
lic 
blo
od
 pr
es
su
re
Sy
sto
lic 
blo
od
 pr
es
su
re
W
ais
t ci
rcu
mf
ere
nc
e 
E
x
p
la
in
e
d
 v
a
ri
a
n
c
e
 i
n
 t
H
c
y
 c
o
n
c
e
n
tr
a
ti
o
n
 (
%
) 
General Discussion
129
Coffee consumption is another relatively important determinant of tHcy concentration in men
and women of which the causality is proven in intervention trials (61-63). Concerning the other
modifiable factors, the relations of alcohol consumption (80,81) and physical activity (82) with
the tHcy concentration are also investigated in intervention trials. Yet the results of these trials
do not agree with findings from observational studies. This questions whether the interventions
were comparable to real life situations. With regard to smoking, whether the positive relation
with the tHcy concentration is a real effect, or originates from residual confounding by other
lifestyle habits, remains to be elucidated. In short, more experimental information on lifestyle
factors in relation to the tHcy concentration is needed.
A non-modifiable important tHcy-determinant is the 677 C>T variant of the MTHFR gene.
Subjects with the TT genotype require more folate for an optimal the tHcy concentration and
plasma folate status than CT and CC subjects. This should be taken into account when TT
subjects are identified and treated for high tHcy levels.
Discussion of main findings: plasma homocysteine, plasma B-
vitamins, and the risk of CHD
Our main findings of the prospective study described in chapter 9 are summarized in table 4.
We did not find a significant association between the tHcy concentration and the risk of CHD
mortality. This finding agrees with findings of 8 other prospective studies, which investigated
CHD (fatal and non-fatal) as one of the endpoints of interest (74,106-112). On the other hand it
disagrees with the results of 9 other prospective studies in which the tHcy concentration was
found to be statistically significantly positively associated with the risk of CHD (113-121).
Explanations for the lack of a significant association between the tHcy concentration and CHD
will be extensively reviewed in the following section: the controversy on homocysteine and the
risk of CHD.
Table 4 Relative risksa (95% confidence interval) of CHD mortality by plasma tHcy and B-vitamin concentrations
Exposure Men: highest vs. lowest tertile Women: highest vs. lowest tertile Ch
tHcy 1.14 (0.50-2.61) 2.04 (0.48-8.62) 9
Folate 2.00 (0.82-4.87) 0.22 (0.06-0.87) 9
Vitamin B6 1.27 (0.52-3.11) 0.77 (0.22-2.63) 9
Vitamin B12 0.95 (0.40-2.29) 0.99 (0.26-3.74) 9
Explanation of symbols and abbreviations: a=adjusted for age, study center, HDL and total cholesterol level, hypertension,
creatinine and smoking. Ch=chapter in this thesis.
Our finding that higher plasma folate levels are associated with a lower risk of CHD in
women, agrees with other prospective studies (122-124). However, not all studies found
statistically significant inverse associations (108,125). One study found a stronger inverse
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relation between plasma folate and fatal CHD in women compared with men (122). In our study
the inverse relation between plasma folaat and CHD was not simply less strong in men, in fact,
it tended to be positive. Likely, this is a chance finding as the male cases in the highest tertile of
plasma folate were on average healthy cases, e.g. they smoked less, had a lower blood
pressure and a higher HDL cholesterol level (see chapter 9).
The tendency that high plasma folate levels in men are associated with a smaller (or no) risk
reduction in CHD mortality could also derive from the fact that women obtain their folate from
fruits and vegetables, and men obtain their folate from less healthy sources like meat. For
example, the Spearman correlation between the plasma folate concentration and the intake of
fibers (a proxy for fruit and vegetable intake) was stronger in women compared with men in
our prospective study (women r=0.10, P<0.05 vs. men r=0.02, P=0.7). In men the folate
concentration was more strongly associated with the intake of meat (women r=0.03, P=0.5 vs.
men r=0.11, P<0.05). Meat consumption is associated with the simultaneous intake of other
dietary compounds of animal origin (like saturated fatty acids) that are positively associated
with the risk of CHD.
Evidence that plasma PLP, the biologically active form of vitamin B6 and vitamin B12
concentrations are inversely associated with the risk of CHD, was not provided by our study.
Although some case-control and cross-sectional studies have shown inverse relations between
PLP and the risk of CHD (42,126,127) the evidence from prospective studies is inconsistent
(108,125). Vitamin B12 is probably not inversely associated with the risk of CHD (108).
The controversy on homocysteine and the risk of CHD
Inborn errors
The first and strongest evidence for elevated tHcy levels as a causal risk factor for
atherothrombotic disease came from patients with inborn errors of homocysteine metabolism.
When patients with a genetically determined deficiency of cystathionine b-synthase (CBS) are
untreated, about 50% will have a vascular event before the age of 30 (128). Patients with other
inherited defects of homocysteine metabolism, like MTHFR deficiency (129) and defects in
cobalamin (vitamin B12) metabolism (130), also suffer from vascular diseases at a very young
age. The common denominator in these different metabolic defects is an extremely high tHcy
concentration (i.e. >100 µmol/L). Treating patients with inherited CBS deficiency with tHcy-
lowering nutrients (e.g. folic acid, vitamin B12, B6 and betaine) prevents vascular events at
young age (131). Despite treatment, the tHcy levels of these patients are well above the normal
range (i.e. >30 µmol/L)(131). This could mean that the relative risk of these patients to develop
premature CHD (<60 years) is still higher compared with persons with normal tHcy levels.
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Retrospective, cross-sectional and prospective studies
Earlier retrospective and cross-sectional studies have consistently showed a stronger relation
with the tHcy concentration than the more recent prospective studies (132-135). The meta-
analysis of Boushey et al (132) in 1995 summarized 11 retrospective and cross-sectional
studies, which all showed a significant increased risk of CHD for each 5 µmol/L increase in the
tHcy concentration (odds ratios all ³1.5). Of the 2 prospective studies available at that time,
one found a positive association (116) and one did not find an association (106). In 1998, this
meta-analysis was updated by Refsum et al (102). Of the additional 16 retrospective and cross-
sectional studies, which evaluated CHD as one of the endpoints of interest, only 3 did not find a
positive association between the tHcy concentration and CHD risk. One additional population-
based prospective study (117) showed a significant positive relation between the tHcy
concentration and the risk of CHD.
In 1998 another meta-analysis was performed that calculated the relative risk (RR) for
prospective and retrospective studies separately (134). The summary RR of CHD from all
available retrospective studies with population-based controls was 1.6 (95% confidence interval
(CI)=1.4-1.7). For prospective studies this RR was lower: 1.3 (95% CI=1.1-1.5). In 2000 the
totality of evidence was evaluated qualitatively (133) and the results from prospective studies
were in general weaker (or absent) in comparison with those of retrospective and cross-
sectional studies. Nevertheless, the most recent meta-analysis based only on prospective
studies with subjects not selected for their increased risk of CHD (135), calculated that each 5
µmol/L increase in the tHcy concentration was associated with a 20% increase in risk of CHD
(odds ratio: 1.2, 95% CI=1.1-1.3). Table 5 gives an overview of all the prospective studies
included in this meta-analysis, and is updated with the most recent studies.
There are several reasons for the different results between cross-sectional and retrospective
studies on the one hand, and prospective studies on the other hand. These will be evaluated in
the following paragraphs. Furthermore, explanations for different results between prospective
studies will also be discussed.
First, the issue of the chronological sequence between collecting information on study
subjects (including blood drawing) and the occurrence of the disease. In retrospective studies
data collection takes place after the CHD event. This means that the event might have distorted
recall of certain lifestyle (such as smoking) and dietary habits. Furthermore, it implicates that
medical treatment, like lipid-lowering drugs, anti-hypertensive therapy, or smoking cessation,
may have altered the levels of traditional CHD risk factors. Moreover, the disease could have
influenced blood levels of tHcy, but also of risk factors like blood pressure and cholesterol level
(107). In cross-sectional studies, tHcy levels and extent of the disease are assessed at the same
moment in time. As cases are typically persons with early signs of vascular disease (e.g.
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angiographically confirmed stenosis), the effect of the disease on CHD risk factors like blood
pressure and cholesterol level cannot be excluded (133). Prospective studies have the major
advantage that blood is collected before the event, thus no influence of the disease on lifestyle
and dietary habits, and blood parameters is expected, if subjects with vascular diseases at
baseline are excluded.
Box 2 The influence of vascular disease on tHcy concentrations
Several studies have measured tHcy levels on the day of a CHD event and compared it with the levels measured on days after the
event (up to 180 days after the event) (136-138). Typically they observed lower tHcy concentrations on the day of the event
compared with the concentrations on the days after the event. As no study measured tHcy levels just before the event, it can not
be excluded that tHcy concentrations were lower during the event and over time return to the normal level from before the event.
In addition, a rise in tHcy concentration may be due to the fact that a patient is going from an active life to bedridden; i.e., the
tHcy concentration in blood collected in supine position is higher than that collected sitting (maximally 30% higher) (7).
A metabolic reason for an increase in the tHcy concentration after the event is provided by Dudman (139). He suggests that the
increase in the tHcy concentration is the result of tissue damage and repair. Tissue repair involves synthesis of DNA, RNA and
proteins that require methyl-groups. Most methyl-groups originate from methionine and when methionine donates its methyl-
group, homocysteine is generated (see figure 1, General Introduction). Dudman postulates that a higher tHcy concentration
attracts leukocytes to the vascular endothelium, where they play a role in tissue repair and remodeling (139). However, to our
knowledge no studies have been done to test whether induced vascular damage increases tHcy concentrations.
Another mechanism that could explain a higher tHcy level in subjects with CHD is proposed by Brattstrom and Wilcken (140). They
reviewed currently available evidence and propose that atherosclerosis caused by traditional cardiovascular risk factors (such as
high blood pressure and smoking) impairs the renal function. As the kidneys are quantitatively important for the catabolism of
homocysteine, this might lead to higher tHcy concentrations.
The fact that the risk estimates of retrospective and cross-sectional studies are generally
higher compared with prospective studies, could on the one hand be explained by higher tHcy
levels after a vascular event (136) (see box 2 for further discussion of this issue). On the other
hand, if the disease and/or medical treatment modify the levels of CHD risk factors, then
retrospective and cross-sectional studies might also show higher risk estimates. Because
adequate control of the confounding effect of these risk factors on the association between the
tHcy concentration and the risk of CHD is not possible due to the masking of “true” levels of
these risk factors (107).
Second the issue of the simultaneous presence of higher tHcy concentrations and CHD
irrespective of whether these higher levels are the cause or the consequence of CHD. Due to
this issue one can assume that prospective studies that included subjects with pre-existing CHD,
in theory, should show a more consistent statistically significant positive association between
the tHcy concentration and the risk of CHD. Of the studies that are summarized in table 5, 3
studies offer support for this assumption. Stehouwer et al (109) showed that the tHcy
concentration was more strongly associated with the recurrence of an event rather than a first
ever myocardial infarction. Vollset et al (120) observed that after stratification for high and low
baseline risk (high risk indicated a history of myocardial infarction, stroke, angina pectoris,
General Discussion
133
diabetes, or hypertension), only high-risk persons showed a significant association between the
tHcy concentration and cardiovascular mortality. Furthermore, besides the findings presented in
table 5, Knekt et al (112) reported separately on men with prevalent CHD at baseline. In these
men, a higher tHcy concentration was significantly associated with the risk of CHD mortality and
morbidity. In our study the RR of CHD mortality in men and women with a history of CHD or
cerebrovascular accidents was larger than the estimate for men and women free of baseline
cardiovascular diseases (1.58, 95% CI=0.81-3.09 vs. 1.03, 95% CI=0.83-1.29, for each 5
µmol/L increase in the tHcy concentration). However, the number of subjects with baseline
cardiovascular diseases was too small to show a significant RR (chapter 9). Finally, in elderly
the chance of silent, pre-clinical, CHD is larger. Of the five prospective studies with elderly
populations (average age >60 years) (109,114,118,120,121), only one (109) did not show a
significant association between the tHcy concentration and the risk of CHD.
Prospective studies performed in high-risk populations consistently show that the tHcy
concentration is a strong predictor of cardiovascular mortality and morbidity (including CHD) in
subjects with CHD (141), diabetes (142-144), renal insufficiency (145,146), peripheral artery
disease (147), and systemic lupus erythematosus (148).
The third issue is the aspect of the duration of follow-up. If the tHcy concentration is a risk
factor in high-risk subjects, follow-up studies may show a stronger relation between the tHcy
concentration and CHD during the first few years of follow-up, because subject with pre-clinical
disease will decease earlier than those without pre-clinical disease. This is confirmed by data of
the Physicians’ Health Study. After 5 years of follow-up a significant increased risk of CHD was
found in men with elevated tHcy levels (116), however, extending the follow-up to 7.5 years
yielded a non-significant RR (125). Furthermore, in the same study population no significant
association was observed between the tHcy concentration and the risk of angina pectoris after 9
years of follow-up (149). Two other studies also showed a stronger relation between the tHcy
concentration and CHD mortality (109) and total cardiovascular disease mortality (121) during
the first few years of follow-up. Finally, the studies in table 5 with a short follow-up period (<5
years) showed in general more often a significant association between the tHcy concentration
and the risk of CHD. These results indicate that the tHcy concentration might be a short–term
risk factor for CHD.
An additional feature of prospective studies with a long follow-up is that a reduction in the
risk estimate may also occur as a result of changes in diet, lifestyle, or medical treatment during
follow-up. These factors may alter the tHcy concentration in such a manner that the baseline
tHcy concentration, is no longer representative for the concentration at the time of the event.
In addition, due to a combined effect of measurement errors and intra-individual variation, the
“usual” level of tHcy that is related to the risk of CHD might be difficult to approach with a
single tHcy measurement. The result of this so-called regression dilution bias, is an attenuated
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association between the tHcy concentration and the risk of CHD. This bias can be estimated and
corrected for by taking more blood samples over the period of follow-up and using the data of
replicate tHcy measurements (150,151).
In conclusion, the differences in strength of the association between prospective studies and
retrospective and cross-sectional studies can be ascribed to the fact that in prospective studies
data is collected before the event. Prospective studies with subjects not selected for their risk of
CHD show in general a weak association between the tHcy concentration and the risk of CHD.
Yet, ordering prospective studies into studies with and without subjects with pre-existing CHD,
with younger and older subjects, and with a long and a short follow-up, shows that associations
are more consistently found in studies including subjects with CHD, with elderly and with a
short follow-up. Prospective studies in high-risk populations consistently show a strong relation
between the tHcy concentration and CHD (RRs >2). These results could either mean that the
tHcy concentration is a short-term risk factor in subjects with a high risk of CHD, as suggested
by some researchers (107,152), or it could mean that elevations in the tHcy concentration are
merely a marker of the degree of the underlying vascular disease.
Other studies that give insight into whether the tHcy concentration is a marker of disease, or
causally related to the development of CHD are evaluated in the next paragraphs.
Homocysteine and thrombosis
As will be mentioned more extensively in the section on mechanisms, elevated tHcy level
might interfere with normal coagulation and fibrinolysis. There is considerable epidemiological
evidence that the tHcy concentration is a risk factor for venous thrombosis (153,154). The 3
prospective studies on the relation between the tHcy concentration and venous thrombosis all
show a significant positive association in subjects healthy at baseline (155), subjects with
systemic lupus erythematosus (148) and in subjects with a history of venous thrombosis (156).
In addition, thrombotic disease is responsible for 50% of the vascular events in patients CBS
deficiency (128). If the tHcy concentration is more a thrombogenic factor than an atherogenic
factor, part of the weak association between the tHcy concentration and the risk of CHD could
theoretically be due to the fact that CHD comprises heart diseases with both a thrombogenic
and atherogenic origin.
A primary thrombogenic effect of the tHcy concentration might explain why it is consistently
associated with an increased risk of CHD in high-risk subjects. If these subjects already have a
certain degree of atherosclerosis, tHcy-induced thrombosis might be the crucial factor causing
vascular occlusion.
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Table 5 Prospective studies on plasma tHcy concentrations and risk of (non-) fatal CHD in populations not selected
on the basis of risk of CHDa, adapted from (135)
Reference Study
Follow
up
years
Age Sex Outcome
At baseline
exclusion of:
RR for each 5-µmol/L
increase in tHcya
Stampfer et al,
1992 (116)
Physician's Health
Study, USA 5 40-84 M
fatal and non-
fatal MI and
CHD
past history of MI,
stroke, or TIA 1.29 (1.01-1.64)
Alfthan et al, 1994
(106),
North Karelia
Project, Finland
9 40-64 M, F fatal and non-
fatal MI
past history of
CVD
1.03 (0.66-1.53)
Arnesen et al,
1995 (117)
Tromsø Health
Study, Norway
4 34-61 M, F fatal and non-
fatal CHD
past history of MI 1.41 (1.06-1.88)
Evans et al, 1997
(107) MRFIT, USA
b 11+ 35-57 M non-fatal MI,
fatal CHD
past history of
morbidity (not
explained)
0.98 (0.83-1.15)
A'Brook et al, 1998
(113)
Scotland 7.6 35-64 M, F
CHD, unclear
whether fatal or
non-fatal
? 1.50 (1.28-1.78)
Ubbink et al, 1998
(74)
Caerphilly, UK 5 50-64 M fatal and non-
fatal IHD
no, adjustments
for prevalent CHD
1.22 (0.88-1.64)
Folsom et al, 1998
(108)
ARIC, USA 3.3 45-64 M, F fatal and non-
fatal CHD
past history of
CHD, stroke, or
TIA
1.15 (0.68-1.92)
Wald et al, 1998
(115)
BUPA, UK 8.7 35-64 M fatal IHD past history of
CHD
1.41 (1.20-1.65)
Stehouwer et al,
1998 (109)
Zutphen, the
Netherlands
10 64-84 M fatal and non-
fatal CHD
no, adjustments
for prevalent CHD
1.05 (0.97-1.15)
Bostom et al, 1999
(114) Framingham, USA 10 59-91 M, F fatal CHD ? 1.42 (1.13-1.77)
Bots et al, 1999
(118)
Rotterdam, the
Netherlands
2.7 >55 M, F fatal and non-
fatal MI
no, adjustments
for prevalent CHD
1.28 (1.05-1.76)
Ridker et al, 1999
(119)
Women's Health
Study, USA
3 mean
59
F fatal and non-
fatal CHD
past history of
CVD
1.74 (1.13-2.64)
Whincup et al,
1999 (110)
BRHS, UK 12.8 40-59 M fatal and non-
fatal MI
no, adjustments
for prevalent CHD
1.13 (0.99-1.29)
Kark et al, 1999
(121)
Jerusalem Study,
Israel 9-11 >50 M, F fatal CHD
no, association
remained after
exclusion of
history of CVD
1.34 (1.05-1.62)
Voutilainen et al,
2000 (111)
KIHDRF Study,
Finland
8,9 42-60 M fatal and non-
fatal CHD
history of CHD
0.88 (0.44-1.76) in
highest tHcy quartile vs.
lowest quartiles
Vollset et al, 2001
(120)
Hordaland elderly,
Norway
4.1 65-67 M,F fatal CHD no, adjustments
for prevalent CHD
1.46 (1.14-1.87)
Knekt et al, 2001
(112)
MCHES, Finland 13 45-64 M fatal and non-
fatal CHD
history of CHD
0.90 (0.51-1.60) in
highest tHcy quintile vs.
lowest quintile
de Bree et al
2001 (chapter 9)
MPCDRF, the
Netherlands
10.3 20-59 M,F fatal CHD history of CVD 1.03 (0.83-1.29)
Explanation of symbols and abbreviations: a=unless indicated otherwise; b=these men were selected for a baseline moderate risk
of CHD, based on a combination of their total cholesterol level, diastolic blood pressure and smoking habits; TIA=Transient
Ischemic Attack, MI=Myocardial Infarction, CVD=Cardiovascular Diseases, IHD=Ischemic Heart Disease; ?=unclear if subjects with
cardiovascular diseases at baseline were excluded.
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MTHFR 677C>T genotype and CHD
A person’s genotype of the 677 C>T variant of the MTHFR gene is present from birth
onwards and will not change over the years. The TT variant of this genotype leads to an
approximately 25% higher tHcy concentration compared with CC subjects (157). Nevertheless,
this genotype has not consistently been associated with CHD (157,158). These inconsistencies
might be attributable to a power problem (159). The average difference in tHcy concentration
between TT and CC subjects »2.6 µmol/L (157). According to a pooled RR estimate based on
prospective studies, this difference in tHcy concentration might produce a RR of 1.10-1.15
(135). The calculated point estimate of a meta-analysis (1.12, 95% CI=0.92-1.37) performed
by Brattstrom et al (157), though not statistically significant, is in line with an effect of this
magnitude. To identify a statistically significant RR of this size with a statistical power of 80%,
one needs between 7800-16,300 cases and an equal number of controls (135). Currently the
largest meta-analysis with ~8000 cases and ~8000 controls is being performed and the
outcome will give a more definite answer to the question whether this genotype is related to an
increased risk of CHD (160).
Mechanism by which homocysteine increases the risk of CHD
Investigations of patients with homocystinuria, animals and in vitro studies identified several
means by which the tHcy concentration may cause atherosclerosis and thrombosis. These
include endothelial injury, platelet activation, smooth muscle cell proliferation, oxidation of
blood lipoproteins like LDL-cholesterol, and endothelial leukocyte interaction (161). The
diversity in effects may reflect a true variety, but may also be due to the difficulty to mimic
atherosclerotic processes in short term in vitro studies, or to account for in vivo interrelations
between aminothiols, like homocysteine and cysteine (102). In addition, many of the above
mechanisms were shown in in vitro studies with non-physiologically high tHcy concentrations.
Numerous experiments were done with tHcy concentrations of 1000 to 10,000 µmol/L, in
comparison, untreated patients with inborn errors can have tHcy levels up to 400 µmol/L. In
addition, a lot of studies used free reduced homocysteine. As only 1% of the tHcy concentration
in plasma is free reduced homocysteine, the experimental concentrations sometimes
approached levels that are 50,000 times higher than the level that can be found in humans
(161). Finally, it can be difficult to disentangle effects of homocysteine from other thiols like
cysteine (102,161).
Despite these critical remarks, to date one of the most plausible mechanisms by which
homocysteine may cause atherosclerosis and thrombosis may be by endothelial dysfunction
(161-163). Endothelial cells play a vital role in regulating and maintaining vascular health. In
addition, endothelial cells are essential to hemostatic processes of cell adhesion and migration,
coagulation and fibrinolysis (162). A key regulatory system of endothelial cells involves nitric
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oxide synthase, which synthesizes nitric oxide (NO) (163). Endothelial derived NO regulates
vessel tone, inhibits platelet activation, adhesion and aggregation, limits smooth muscle cell
proliferation and modulates endothelial-leukocyte interaction (161). At normal tHcy
concentrations homocysteine reacts with NO to form S-nitroso-homocysteine, which has some
properties of NO; it inhibits platelet aggregation, it is a vasodilator and it prevents the formation
of reactive oxygen species (ROS). However, when endothelial cells are continuously exposed to
higher tHcy concentrations the result is a downwards spiral in which endothelial cells are no
longer able to reduce the toxicity of homocysteine (164,165). Besides a possible direct effect of
homocysteine on endothelial cells, it may also reduce NO activity by the formation of ROS
(166,167) and by inhibition of glutathione peroxidase (168,169), which is an important enzyme
protecting the endothelial cell against oxidative stress.
As NO regulates the vessel tone, several studies have measured the endothelium-dependent
flow-mediated vasodilatation in response to homocysteine. Impaired endothelium-dependent,
flow mediated vasodilatation has been documented in subjects with high tHcy concentrations
(170,171), in healthy subjects after a methionine-load induced high tHcy level (172,173), and in
healthy subjects after a physiologically higher tHcy concentration, generated by a protein rich
meal (174).
Intervention trials
Because of the tHcy-lowering effect of folic acid, several studies investigated the effect of
folic acid supplementation on intermediate endpoints of vascular damage. Endothelial
dysfunction is such an intermediate endpoint. Brown and Hu recently reviewed trials that
considered the effect of folic acid supplementation on endothelial function (162). The general
picture that emerges from these studies is that folic acid (5 to 10 mg/d) improves or restores
endothelium-dependent vasodilatation and may decrease the chance of thrombosis by reducing
levels of coagulation factors in healthy subjects and in patients with high tHcy levels (162). The
observed benefit is probably largely explained by the lowering of tHcy concentrations. However,
in one study folic acid infusion improved endothelial function, without an effect on the tHcy
concentration (175). In the latter study folic acid infusion reduced oxidative stress (175).
Moreover, another study showed that folic acid might improve NO production through
stimulation of NO-synthase (176). Thus, folic acid may have a beneficial effect on endothelial
function independent of the tHcy concentration.
In light of these results, it is interesting to mention that Chambers et al (177) suggest that
the lack of a strong association between lower tHcy levels, in response to folic acid therapy, and
improved endothelial function is due to the measurement of total homocysteine as the only
index of the homocysteine status. Box 3 describes this more extensively.
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Currently there are 3 non-controlled trials of which 2 show that supplementation with folic
acid (5000 µg) and vitamin B6 (250 mg) reduces the risk of cardiovascular events (coronary,
peripheral and cerebral) in patients with high tHcy levels and existing cardiovascular diseases,
to the level of patients with existing cardiovascular diseases, but with normal tHcy levels
(180,181). The other trial investigated the effect of folic acid (2500 µg), vitamin B6 (25 mg) and
vitamin B12 (250 µg) on the regression of carotid plagues. Vitamin supplementation resulted in
a decreased rate of progression of the plague growth in 101 patients with vascular disease with
normal and elevated tHcy levels (182).
Box 3 Non-protein bound and reduced free homocysteine as an index of the biological activity of homocysteine
Chambers et al (177) showed in a randomized placebo controlled intervention study in 89 male CHD patients, that
endothelium-dependent flow mediated dilatation improved after 8 weeks of supplementation with folic acid and
vitamin B12. This improvement correlated significantly with a reduction in non-protein-bound homocysteine (~30%
of the tHcy concentration), but was independent of changes in protein-bound homocysteine and plasma folate and
vitamin B12. Furthermore, in another study of their group with 14 healthy volunteers (10 men, 4 women) (178),
they found that the reduction in flow-mediated dilatation maximally correlated with concentrations of free reduced
homocysteine (~1% of the tHcy concentration), but not with the other forms of homocysteine.
The correlation between the tHcy concentration and reduced free homocysteine is small (0.4, p<0.05) (69), which
excludes that the tHcy concentration can be used as a proxy for the free reduced homocysteine concentration.
Measuring free reduced homocysteine is a complicated procedure, requiring immediate blood sampling processing
due to rapid changes in redox status of free aminothiols ex vivo and stored plasma samples cannot be used (179).
It therefore seems unlikely that the hypothesis that free reduced homocysteine is responsible for atherothombosis
(178) can be confirmed in large scale prospective epidemiological studies.
The only available randomized, placebo controlled trial with intermediate endpoints was
performed with 158 healthy siblings (without prevalent venous thrombosis, clinical arterial
disease and renal impairment) of patients with sub-clinical cardiovascular diseases. They
received a daily supplement either with 5000 µg folate and 250 mg vitamin B6 (n=78), or
placebo tablets (n=80), for a period of 2 years (183). In the treatment group the tHcy
concentration decreased as expected. Treatment was associated with fewer abnormal exercise
electrocardiography tests, which is a measure (though with internal validity shortcomings
(184)), of coronary atherosclerosis. An effect of treatment on other surrogate outcome
measures (ankle-brachial pressure index and duplex-scanning of the carotis and peripheral
arteries) was not observed (183).
The results of the above mentioned intervention trials with intermediate endpoints are in
favor of the hypothesis that lower tHcy concentrations are causally associated with a decreased
risk of vascular disease in patients with cardiovascular diseases (180-182) and in healthy
subjects (183). Yet, in all intervention trials folic acid was used. As this vitamin may have a
favorable effect on e.g. endothelial function (175,176) independently of the tHcy concentration,
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it is not clear whether the observed effect is due to a direct folic acid effect or to a lower tHcy
concentration.
Ongoing intervention trials will answer the question whether a lower tHcy concentration
through vitamin supplementation (folic acid, vitamin B6 and B12) has an effect on “hard” end
points, like CHD mortality (185,186). The results of these trials will become available within 2-4
years. If these trials show a reduction in CHD (or other vascular endpoints), this does not
answer the question whether the tHcy concentration is a causal risk factor in healthy subjects,
as all trials included high-risk populations to increase the statistical power. Note, that it is
questionable whether the trials performed in the USA are able to show a reduction in CHD, as
they will likely suffer from a lack of power due to the mandatory folic acid fortification since
1998 (187).
A question that also will not be answered by the currently ongoing trials is whether a lower
tHcy concentration or a higher B-vitamin intake (or both) is the cause of less CHD. This answer
can only be provided in trials using other tHcy-lowering compounds, like betaine (188).
Conclusion about the causal relation between homocysteine
and CHD
Table 6 weighs the available evidence to the extent that it offers support for the tHcy
concentration as a causal risk factor for CHD. It is beyond reasonable doubt that the extremely
high tHcy levels of patients with inborn errors cause CHD. However, what is the relevance of
this causal relation for the relation between moderately elevated tHcy levels and CHD?
Moderately elevated tHcy levels are associated with CHD in high-risk subjects, like with
diabetes, or with a history of CHD. In these patients an increased tHcy concentration might
provoke the event, resulting in a short-term association with the risk of CHD. Nevertheless, the
tHcy concentration might just as well be a marker of the degree of vascular disease.
Current epidemiological evidence does not provide strong evidence that elevations in the tHcy
concentration are harmful in healthy subjects. Yet, lowering tHcy levels through administration
of folic acid and vitamin B6 favorably influenced the progress of atherosclerotic disease in
healthy subjects measured with an exercise electrocardiography tests (183). The results of
another primary intervention trial with healthy subjects and well-validated intermediate
endpoints (carotid wall thickness and stiffness) will be available in 2004 (189).
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Table 6 Evidence for homocysteine being causally involved in the etiology of CHD
Type of evidence Extent to which itoffers support Comment
Inborn errors ++++
Untreated, these patients suffer or even die of
vascular disease, treatment prevents or delays
vascular events
Retrospective and cross-sectional
studies +
Due to the fact that blood sampling occurs after the
event, the effect of CHD on tHcy levels can not be
excluded
Prospective studies with healthy
subjects +
Evidence is stronger in older subjects and in studies
with a short follow-up period
Prospective studies with high-risk
subjects
++
In these types of studies it can not be excluded that
the increased levels of tHcy are a marker of the
degree of vascular disease
Prospective studies with venous
thrombosis
+
These studies indicate that the tHcy concentration
may predominantly be a thrombogenic factor, yet
the number of prospective studies is small
MTHFR 677 C>T genotype + Lack of evidence that the TT genotype is associated
with CHD may be a power problem
Mechanism of action ++ Especially the relation with endothelial functionseems plausible
Intervention trials with intermediate
endpoints +++ Beneficial effect could also be the result of folic acid
Explanation of symbols: + indicates minor support, ++++ indicates strong support.
Thus, anticipating on the ‘Directions for future research’, the only study that can answer the
question whether the tHcy concentration is a causal risk factor for CHD in healthy subjects, is
an intervention trial with healthy subjects, hard end-points and tHcy-lowering nutrients other
than folic acid. This trial should be carried out in apparently healthy subjects (e.g. free of
cardiovascular diseases and diabetes) with elevated tHcy concentrations to avoid a power
problem. Betaine could be used as a tHcy-lowering nutrient (188). It is, however, more likely
that such a trial will be initiated after the results of the secondary intervention trials are
available. If these trials do not show a reduced incidence of CHD in treated high-risk subjects,
this may not justify an intervention study in healthy subjects.
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Directions for future research
Pending the results of the intervention trials, more epidemiological (prospective) studies on
the tHcy concentration and cardiovascular diseases are not desirable, as they cannot provide
the ultimate answer for the causality question.
Future research should focus on experiments that elucidate which form of homocysteine
(reduced, (non-) protein bound) might cause atherosclerosis and/or thrombosis and by which
etiologic pathway. A promising pathway involves endothelial dysfunction. So far, endothelial
function in response to high tHcy levels, or in response to folic acid administration, have only
been investigated in small groups of healthy subjects. Future studies should include larger
groups of healthy subjects. In addition, to disentangle whether the increase in folic acid or the
reduction in the tHcy concentration are beneficial for the endothelium, it would be interesting to
explore the effects of betaine, vitamin B6, B12 or B2 supplementation on endothelial function.
Irrespective of whether beneficial effects on the endothelial function are due to a lower tHcy
concentration, or due to a higher folate concentration, in both cases a higher folate intake will
improve endothelial function. Thus, research on the desired folate intake level to achieve
beneficial endothelial responses is necessary. For example, endothelium-dependent
vasodilatation and other responses associated with endothelial function (improved coagulation)
could be monitored in experiments in which participants are provided with folate rich meals
containing different doses of folate.
A research question that remains interesting to investigate in observational studies is to what
extent the tHcy-determinants described in this thesis are important in subjects with a high-risk
of vascular disease. For example, in the general population drinking 6 cups of coffee/d is
associated with an average increase in the tHcy concentration of 1.3 µmol/L. It is not known
how strong this relation is in subjects with cardiovascular diseases or in other high-risk subjects.
Finally, effort should be taken to standardize the measurement of the tHcy concentration. If it
turns out that the tHcy concentration causes vascular diseases, it will be of utmost importance
to precisely and validly measure the concentration. Otherwise, an accurate estimate of a
person’s risk can not be made.
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Implications for prevention and treatment
Although definitive proof for a causal role of the tHcy concentration in the etiology of CHD is
lacking, even a moderate effect of the tHcy concentration on the occurrence of CHD deserves
attention, particularly since simple, safe, and inexpensive treatments exist that can lower the
tHcy concentration. As folate is the most important modifiable factor of the tHcy concentration,
it seems attractive to use folate as a means to reduce the tHcy concentration. In the USA, folic
acid fortification has proven to effectively lower tHcy levels (190,191). However, folic acid
fortification has the negative side effect that it may mask a vitamin B12 deficiency by correcting
the hematological, but not the neurological, abnormalities of vitamin B12 deficiency. Based on
this masking effect of folic acid, the Health Council of the Netherlands decided that only
products specifically intended for women who want to become pregnant, may be fortified with
folic acid (192). It is possible that this recommendation will be reconsidered as soon as
evidence from the secondary trials described above becomes available. Note, however, that the
ongoing discussion of the masking of a vitamin B12 deficiency would become irrelevant when
fortification with folic acid would be accompanied by simultaneous fortification with vitamin B12.
The increased attention on the tHcy concentration has created a demand for guidelines by
general practitioners and specialists, like cardiologists. As a result of this, the Netherlands Heart
Foundation has published a report that contains temporary guiding principles, pending the
results of intervention trials. For the Dutch situation, a “screen and treat” scenario is suggested
(193). In addition to avoiding negative side effects of the “treat all” scenario by fortification, this
scenario is probably more cost-effective than a treat all scenario (194).
Persons that are eligible for screening, i.e. the measurement of their tHcy concentration, are
those with a high risk of CHD, e.g. patients with diagnosed cardiovascular occlusions,
thrombosis, diabetes, renal insufficiency, and an unfavorable history of CHD in the family.
Subjects with an elevated tHcy concentration can be treated with a daily supplement of 500
µg/d of folic acid as this was proven to be equally effective in lowering the tHcy concentration,
as supplements with higher doses (195). Depending on the laboratory the definition of elevated
tHcy concentrations may differ, but generally a level above >15 µmol/L (196) is considered
elevated. Patients that are treated with folic acid should be followed up regularly, to monitor
their vitamin B12 status and to see whether their tHcy concentration decreases. If the tHcy
concentration does not decrease, a higher dose of folic acid can be chosen, or additional ways
to lower the tHcy concentration may be used, like administration of vitamin B6 or betaine. The
tHcy-lowering treatment should never interfere with the established treatments to prevent CHD,
like cholesterol-lowering medication, anti-hypertensive treatment, and encouragement of a
healthy lifestyle (193).
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For subjects without a high risk of CHD, an optimal folate intake might be beneficial as well,
since a low folate concentration or intake is not only inversely associated with the risk of CHD,
but also with colon cancer (197,198), pregnancy complications (199) and dementia (200-202).
Therefore, it seems worthwhile to initiate and maintain public health educational programs
targeted at increasing the consumption of plant foods, like the currently ongoing campaigns of
the Fruit and Vegetable Information Bureau, and the Netherlands Nutrition Centre.
Furthermore, stimulating a healthy lifestyle with moderate coffee and alcohol consumption, and
no smoking, will contribute to a lower tHcy concentration. This will lead, also independently of
the tHcy concentration, to a lower incidence of CHD.
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SUMMARY
Cardiovascular diseases, and especially coronary heart disease, are the most important cause
of death in industrialized countries. Major risk factors of coronary heart disease are a high total
cholesterol level and/or low HDL cholesterol level, smoking and a high blood pressure. Recently
increased concentrations of plasma homocysteine also have been associated with an increase
risk of coronary heart disease.
Homocysteine is an amino acid that is not incorporated in proteins, nor is it present in foods
in significant quantities. It is formed intracellularly when the amino acid methionine is
metabolized. The intracellular concentration of homocysteine is precisely regulated and any
excess is transported into plasma. Increased concentrations of homocysteine in plasma may
stimulate atherosclerosis and/or thrombosis.
To date there is no definitive proof that the association between raised homocysteine
concentrations and coronary heart disease is causal. However, assuming that this relation is
causal, a lower homocysteine concentration will have a beneficial effect on the occurrence of
coronary heart disease. Therefore, it is important to know which factors determine the
homocysteine concentration.
This thesis describes cross-sectional studies that investigated to what extent dietary, lifestyle,
genetic, and biological coronary heart disease risk factors determine the homocysteine
concentration. Furthermore, the relation between elevated homocysteine concentrations and
the risk of coronary heart disease mortality was quantified in a prospective study. The cross-
sectional and the prospective study populations comprised adults (20-65 years) representative
for the general Dutch population.
The potential of folic acid, the synthetic form of folate present in supplements, to lower the
extremely high homocysteine concentrations of patients with inborn errors of homocysteine
metabolism was recognized already several decades ago. The question remained whether
higher intakes of folate (from the dietary and/or  supplements) would result in lower
homocysteine concentrations in the general population. The available literature on this topic at
the time of 1997 is summarized in CHAPTER 2. In this review we described the recommended,
actual and desired folate intake. The literature search was focused on European adult
populations. As there was no threshold homocysteine level above which the risk of coronary
heart disease increased and as the risk of coronary heart disease was assumed to decrease
continuously with a decreasing homocysteine concentration, we estimated the desirable folate
intake in light of an optimally low homocysteine concentration.
Summary
154
The most important conclusions of this review were that the mean dietary folate intakes in
Europe (men: 291 µg, women: 247 µg per day) were in line with the recommendations (170-
300 µg per day), but were lower than the desired dietary intake of more than 350 µg per day
necessary for optimally low homocysteine levels.
If homocysteine is a causal risk factor for coronary heart disease, then public health
authorities need information on the proportion of subjects that might be “at risk”. This
proportion can be derived from the homocysteine distribution curve when from a practical point
of view a cut-off point for elevated homocysteine levels is chosen. Due to the continuous
association between homocysteine and the risk of coronary heart disease every cut-off point is
arbitrary. In CHAPTER 3 we provided a homocysteine distribution curve for the Dutch
population. For this purpose we measured the non-fasting homocysteine concentration in a
random sample of 3025 men and women aged 20-65 years. The mean homocysteine
concentration for men was 14.6 (minimum 5.9 and maximum 94.6) µmol/L and for women 13.1
(minimum 6.1 and maximum 72.2) µmol/L.
A prominent laboratory in Bergen, Norway, uses 15 µmol/L as a cut-off point to indicate
elevated homocysteine concentrations. We could not simply use this value as the homocysteine
concentration of one sample measured in different laboratories can vary considerably. To
compare homocysteine values we performed a comparative study for which the homocysteine
concentration of 301 plasma samples were measured in our laboratory (in Nijmegen) and in
Bergen. The result was a systematically higher homocysteine concentration in Nijmegen of –2.4
µmol/L. Taking this systematic difference into account, the prevalence of high homocysteine
levels (>17.4 µmol/L) was 14.4% in men and 8.9% in women. In comparison with data of
other European studies, for which the homocysteine concentration was also measured in
Bergen, the Dutch values (after correction for the systematic difference) were in general higher.
As mentioned before, information on the relation between dietary folate intake and
homocysteine concentration in the general population was limited. Furthermore, information on
the relation between the other B-vitamins essential in homocysteine metabolism and
homocysteine levels was also insufficient. In CHAPTER 4 we described the association between
dietary intakes of folate, riboflavin (vitamin B2), vitamin B6 and B12 and the homocysteine
concentration. For this study we used a sub-group (n=2435) of the above mentioned random
sample. Higher intakes of all B-vitamins were associated with lower plasma homocysteine
concentrations. However, after correction for confounding variables (other B-vitamins,
methionine, age, smoking and alcohol consumption) only folate was inversely associated with
the homocysteine concentration. An average low folate intake (men: 161, women: 160 µg per
day) was associated with a high tHcy concentration, in men on average 15.4 µmol/L and in
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women on average 13.7 µmol/L. An average high folate intake (men: 254, women: 262 µg per
day) was associated with a low homocysteine concentration, in men on average 13.2 µmol/L
and in women on average 12.4 µmol/L. In men, the difference in the mean plasma
homocysteine concentration between low and high folate intakes was greater in smokers than
in non-smokers (2.8 vs. 1.6 µmol/L), and greater in non-drinkers than in drinkers of more than
2 alcoholic drinks per day (3.5 vs. 1.4 µmol/L). We concluded that in this Dutch population,
folate was the only B-vitamin independently inversely associated with the plasma homocysteine
concentration. A higher dietary folate intake may substantially influence the plasma
homocysteine concentration.
Besides B-vitamins, the activity of enzymes that are involved in homocysteine metabolism is
also important for the homocysteine concentration. The enzyme 5,10-methylene-
tetrahydrofolate reductase (MTHFR) produces the main circulating form of folate that is
necessary for the conversion of homocysteine to methionine. A mutation in the gene encoding
for MTHFR, the 677 C>T polymorphism, decreases the enzyme activity. The activity is normal in
subjects with the CC genotype, somewhat reduced in CT subjects and clearly limited in TT
subjects. In CHAPTER 5 we described the consequences of this genotype for folate intake,
plasma folate and homocysteine concentration. Again we cross-sectionally analyzed a sub-group
(n=2051) of the random sample. The relation between folate intake and plasma folate was
positive in all genotypes. The steepest relation was seen in CT subjects: at a low folate intake
(mean: 155 µg per day) the plasma folate concentration of CT subjects resembled that of TT
subjects (CT: 5.8, TT: 5.7 nmol/L), but at a higher folate intake (mean: 267 µg per day) the
plasma folate concentration resembled that of CC subjects (CT: 8.4, CC: 8.7 nmol/L). In TT
subjects, the plasma folate concentration was always lower than that of CT and CC subjects
despite equally high folate intakes. The relation between the concentration of plasma folate and
homocysteine was inverse in all genotypes and most pronounced in TT subjects: at a low
plasma folate concentration (mean: 4.0 nmol/L) the homocysteine concentration was much
higher for TT subjects than for the other genotypes (TT: 20.9, CT: 15.4, CC: 14.3 µmol/L),
while at high folate concentrations (mean: 13.7 nmol/L) the difference in homocysteine
concentration between the genotypes was negligible. The relation between folate intake and
homocysteine was also inverse, and most pronounced in TT subjects. Our results suggested
that TT subjects need at least 10% more dietary folate than CT and CC subjects to achieve a
comparable high plasma folate level and a comparable low homocysteine level.
In CHAPTER 6 we described the relation between coffee, tea and alcohol consumption,
physical activity and smoking and the homocysteine concentration. Cross-sectional information
provided by the random sample (n=2601) was used for this goal. The lifestyle factors most
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strongly associated with the homocysteine concentration were coffee consumption (positive
association), smoking (positive association), and alcohol consumption (inverse association). We
did not observe a statistically significant association between tea drinking and homocysteine.
Furthermore, physical activity was weakly positively associated with homocysteine in women
only. Independently of other lifestyle factors, age, folate and B-vitamin supplement intake
drinking of more than 6 cups of coffee per day was associated with a 1.4 µmol/L higher
homocysteine concentration in men and a 1.1 µmol/L higher homocysteine concentration in
women, compared with non-drinkers. The smoking effect was most prominent in women; in
non-smokers the homocysteine concentration was 0.8 µmol/L lower than in smokers of more
than 20 cigarettes per day. The alcohol effect was most pronounced in men. In men with a
folate intake below the median (204 µg per day), the homocysteine concentration in non-
drinkers was 1.7 µmol/L higher compared with drinkers of more than 2 glasses of alcohol per
day. In men with a folate intake above the median, this difference in homocysteine was 0.8
µmol/L. From these results we concluded that changes in lifestyle factors may influence the
homocysteine concentration.
The inverse relation between alcohol consumption and homocysteine in men was further
investigated in CHAPTER 7. We distinguished between three types of alcoholic beverages: beer,
wine and spirits. Independently of other lifestyle factors and B-vitamin intake, beer drinking was
associated with a lower homocysteine concentration. Men drinking no beer had a homocysteine
concentration of 14.3 µmol/L, whereas men drinking on average 3.7 glasses of beer per day,
had a homocysteine concentration of 13.0 µmol/L. Drinking wine or spirits did not have an
effect on the homocysteine concentration, possibly due to the small range of intake relative to
the range of beer consumption. The observed association between beer and homocysteine can
probably not be ascribed to folate, and other B-vitamins present in beer, as we adjusted for
these effects. This might indicate that ethanol intake is inversely associated with the
homocysteine concentration. We could not properly investigate this, as beer was the
predominant drink (i.e. ethanol provider) in this population.
In CHAPTER 8 we evaluated to what extent biological coronary heart disease risk factors are
associated with the homocysteine concentration. In this study we used data of the random
sample on total and HDL cholesterol levels, waist circumference and diastolic and systolic blood
pressure. Total and the HDL cholesterol levels were associated with the homocysteine
concentration in women only, independently of lifestyle factors, other biological coronary heart
disease risk factors and folate intake. The other biological coronary heart disease risk factors
were not associated with the homocysteine concentration. Women with a total cholesterol level
in the lowest quartile had a homocysteine concentration 0.6 µmol/L lower than that of women
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with a total cholesterol level in the highest quartile. The association between HDL cholesterol
and homocysteine was inverse: women with a HDL cholesterol level in the lowest quartile had a
homocysteine concentration 1 µmol/L higher than that of women in the highest HDL quartile.
Although not all biological coronary heart disease risk factors were statistically significantly
associated with the homocysteine concentration, it remains necessary to evaluate their
confounding effect when the relation between homocysteine and coronary heart disease is
investigated; because the relation between biological coronary heart disease risk factors and
homocysteine is in the direction of an increased risk of coronary heart disease.
Results of prospective studies that consider the relation between the homocysteine
concentration and the risk of coronary heart disease have been inconsistent. The same applies
to prospective studies that investigated the relation between plasma B-vitamins (inversely
associated with the homocysteine concentration) and coronary heart disease. To provide more
insight into this topic we determined the relation between plasma homocysteine, folate, vitamin
B6 (PLP) and B12 and coronary heart disease mortality in CHAPTER 9. This study was done
within a population-based cohort of ~36,000 Dutch adults aged 20-59 years at baseline, who
were followed for an average period of 10.3 years. The design was a case-cohort study, using a
randomly drawn reference cohort of 630 subjects to which all coronary heart disease (n=102)
cases, who were not part of the reference cohort, were added. All these subjects were free of
cardiovascular diseases at baseline.
After correction for age, sex, study center, hypertension, HDL and total cholesterol, smoking
and creatinine level we found that each 5 µmol/L increase in homocysteine was associated with
a statistically non-significant increased risk of 3% for coronary heart disease mortality (relative
risk (RR)=1.03, 95% confidence interval (CI)=0.83-1.29). In women only, high folate levels
were associated with a statistically significant protection of coronary heart disease mortality;
each 5 nmol/L increase in plasma folate concentration was associated with a RR of 0.16 (95%
CI=0.03-0.78). Plasma PLP and vitamin B12 concentrations were not associated with coronary
heart disease mortality. From these results we concluded that elevated homocysteine levels are
not a major risk factor for coronary heart disease in this population sample of relatively young
healthy Dutch subjects. In women, a higher plasma folate concentration might reduce the risk
of coronary heart disease.
In the last chapter of this thesis (CHAPTER 10) we evaluated the results described in this
thesis in light of other epidemiological studies. We focussed on methodological issues and we
evaluated to what extend there is proof that elevated tHcy concentrations are a causal risk
factor for coronary heart disease.
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For the most important homocysteine determinants, i.e., folate intake, coffee consumption,
and the 677 C>T polymorphism of the MTHFR gene, our results agree with those of other
epidemiological studies. Our results suggest an inverse association between alcohol
consumption and homocysteine; this needs further study as in other epidemiological studies
alcohol consumption was associated with higher homocysteine concentrations. The relation
between smoking and homocysteine needs to be studied in depth because other lifestyle factors
that are difficult to take into account may be responsible for the positive association between
smoking and a high homocysteine concentration.
Our result that an increased tHcy concentration is not an important risk factor for coronary
heart disease agrees with 8 of the 17 published prospective studies on this topic. The reason for
our lack of a statistically significant association could be due to methodological aspects: e.g. the
blood handling and storage conditions of this study were not optimal for the homocysteine
measurement and this might have diluted the association between homocysteine and coronary
heart disease mortality. However, a more likely explanation is provided by the mechanism by
which homocysteine might increase the risk of coronary heart disease. Some researchers have
hypothesized that homocysteine is a short-term risk marker that exacerbates the effects of
other coronary heart disease risk factors (like hypertension and hypercholesterolemia), and
thereby promotes an acute coronary heart disease event. If this is true, homocysteine is
probably not a major risk factor in a study with relatively young subjects free of baseline
cardiovascular diseases studied after a long follow-up. This hypothesis might also explain some
of the inconsistencies in the results of published prospective studies. Yet, the hypothesis is
mainly based on prospective studies with high-risk subjects (e.g. subjects with coronary heart
disease). This makes it difficult to exclude the possibility that the increased homocysteine levels
are the consequence of vascular damage present in these subjects.
The only studies that can provide definitive answers for the causality question, are
intervention studies. There are several ongoing secondary intervention trials, in which high-risk
subjects are supplemented with folic acid, vitamin B6 and B12. If these trials show that
homocysteine-lowering through vitamin supplementation, prevents coronary heart disease in
the treatment groups, this makes a strong case for the hypothesis that homocysteine is the
causative agent that leads to coronary heart disease in these high-risk subject. Note, however,
that if the incidence of coronary heart disease decreases in these trials, this could also be the
consequence of a higher intake of B-vitamins. Other intervention studies with different
homocysteine-lowering compounds (like betaine) may provide insight into whether a lower
homocysteine or a higher B-vitamin intake is responsible for the protection against coronary
heart disease. Primary intervention trials with apparently healthy subjects (e.g. no
cardiovascular diseases, no diabetes) with elevated homocysteine levels, are the only studies
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that can elucidate whether homocysteine is a causal risk factor for coronary heart disease in
healthy subjects.
In conclusion, elevated homocysteine levels are probably not a major risk factor for coronary
heart disease in healthy subjects. Yet, increased homocysteine concentrations are consistently
associated with an increased risk of coronary heart disease in high-risk subjects. Thus, with
regard to implications for prevention and treatment, we agree with the recent guidelines of the
Netherlands Heart Foundation that subjects at high risk of cardiovascular diseases may be
screened for elevated homocysteine levels. If elevations are observed, treatment with 500 µg of
folic acid per day can be applied under strict conditions. This will lower their homocysteine
concentration, and may have a beneficial effect on their risk of coronary heart disease. For
healthy subjects it remains important to follow the guidelines of health authorities to increase
the consumption of foods of plant origin. This will increase the intake of folate and
simultaneously the intake of other compounds which have a beneficial effect on health in
general.
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SAMENVATTING
Hart- en vaatziekten, en in het bijzonder coronaire hartziekten, vormen de belangrijkste
doodsoorzaak in geïndustrialiseerde landen. De belangrijkste risicofactoren voor het ontstaan
van coronaire hartziekten zijn: een hoog totaal cholesterolgehalte en/of een laag HDL-
cholesterolgehalte in het bloed, roken en een hoge bloeddruk. Verhoogde bloed homocysteïne
concentraties zijn recent ook in verband gebracht met een verhoogd risico op coronaire
hartziekten.
Homocysteïne is een aminozuur dat niet gebruikt wordt voor de opbouw van eiwitten en
nauwelijks voorkomt in de voeding. Het ontstaat intracellulair wanneer het aminozuur
methionine wordt gemetaboliseerd. De intracellulaire concentratie van homocysteïne wordt
exact gereguleerd. Een teveel aan homocysteïne in de cel wordt naar het bloedplasma
getransporteerd. Aldaar zouden verhoogde concentraties mogelijk atherosclerose en/of
trombose kunnen stimuleren.
Er is nog geen overtuigend bewijs dat het verband tussen een verhoging van het
homocysteïnegehalte en coronaire hartziekten causaal is. Indien deze relatie causaal is, dan zou
een verlaging van de homocysteïneconcentratie een daling van het aantal gevallen van
coronaire hartziekten tot gevolg hebben. Het is dan ook belangrijk om te weten welke factoren
het homocysteïnegehalte bepalen.
In dit proefschrift zijn onderzoeken beschreven die voedingsgewoonten, leefstijl, genetische
factoren en biologische risicofactoren voor coronaire hartziekten onderzocht hebben als
mogelijke determinanten van het homocysteïnegehalte. Deze studies werden gedaan in een
grootschalig dwarsdoorsnede-onderzoek. Daarnaast is een prospectief-onderzoek beschreven
waarin het risico gekwantificeerd is op het sterven aan coronaire hartziekten ten gevolge van
een verhoogde homocysteïne concentratie. De onderzoekspopulaties van het dwarsdoorsnede-
en het prospectief-onderzoek waren representatief voor de Nederlandse bevolking (20-65 jaar
oud).
Het is al enige decennia bekend dat bij patiënten met erfelijke afwijkingen in het
homocysteïnemetabolisme de extreem hoge homocysteïneconcentratie verlaagd kan worden
met foliumzuur. Foliumzuur is de synthetische vorm van folaat die in vitaminepreparaten
aanwezig is. Daarentegen was het de vraag of een hogere folaatinname (uit de voeding en/of
supplementen) de homocysteïneconcentratie in de algemene bevolking zou kunnen
beïnvloeden. De stand van zaken omtrent dit vraagstuk ten tijde van 1997 is samengevat in
HOOFDSTUK 2. In dit literatuuroverzicht beschreven we de daadwerkelijke, de aanbevolen en de
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wenselijke inname van folaat. Bij het zoeken naar literatuur beperkten wij ons vooral tot studies
die informatie gaven over Europese volwassenen. Aangezien niet bekend was vanaf welke
homocysteïneconcentratie een risico ontstaat op coronaire hartziekten en aangezien
aangenomen werd dat het risico continue daalt met het afnemen van het homocysteïne
gehalte, werd de wenselijke folaatinname geschat met het oog op een zo laag mogelijk
homocysteïnegehalte.
De belangrijkste conclusies van dit literatuuronderzoek waren dat de daadwerkelijke
folaatinname in Europa (mannen: 291, vrouwen: 247 µg per dag) overeenkwam met de
aanbevelingen (170-300 µg per dag). Echter de geconsumeerde en aanbevolen hoeveelheid
folaat was lager dan het wenselijke niveau van meer dan 350 µg per dag, dat nodig zou zijn om
een zo laag mogelijke homocysteïneconcentratie te bereiken.
Indien een verhoogd homocysteïnegehalte een causale risicofactor is voor het ontwikkelen
van coronaire hartziekten, dan is het voor instanties die zich richten op de volksgezondheid van
groot belang te beschikken over een goede schatting van het aantal mensen dat een verhoogd
homocysteïnegehalte heeft. Uit een homocysteïneverdelingscurve kan worden afgelezen
hoeveel procent van de populatie een homocysteïneconcentratie heeft boven een bepaalde
grenswaarde. De keuze van deze grenswaarde is relatief arbitrair waneer wordt aangenomen
dat het verband tussen het homocysteïnegehalte en coronaire hartziekten continue is. Echter
vanuit praktisch oogpunt is het nodig een grenswaarde te hanteren. Een
homocysteïneverdelingscurve voor Nederlandse volwassenen werd weergegeven in HOOFDSTUK
3. Hiervoor bepaalden we het niet-nuchtere homocysteïnegehalte in een aselecte steekproef
van 3025 mannen en vrouwen van 20-65 jaar. De gemiddelde homocysteïneconcentratie was
14,6 (minimum 5,9 en maximum 94,6) µmol/L voor mannen en 13,1 (minimum 6,1 en
maximum 72,2) µmol/L voor vrouwen.
Een vooraanstaand laboratorium in Bergen, Noorwegen hanteert 15 µmol/L als grenswaarde
voor een verhoogde homocysteïneconcentratie. Deze waarde konden wij niet eenvoudigweg
overnemen omdat er tussen laboratoria grote verschillen zijn in de gemeten
homocysteïneconcentratie van één plasmamonster. Om een vergelijking mogelijk te maken zijn
de homocysteïnewaarden van 301 plasmamonsters in ons laboratorium in Nijmegen en in
Bergen gemeten. Het resultaat gaf aan dat de waarden in Nijmegen systematisch 2,4 µmol/L
hoger lagen. Rekening houdend met dit verschil was het percentage met een verhoogde
homocysteïneconcentratie (>17,4 µmol/L) in Nederlandse mannen 14,4% en in vrouwen 8,9%.
In vergelijking met de gegevens van andere Europese landen waarvoor het
homocysteïnegehalte in Bergen werd gemeten, waren de Nederlandse waarden na correctie
voor het systematische verschil over het algemeen hoger.
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Zoals eerder vermeld, waren er weinig gegevens over de relatie tussen folaat uit de voeding
en het homocysteïnegehalte. Bovendien was weinig bekend over de relatie tussen het
homocysteïnegehalte en de inname van andere B-vitamines die essentieel zijn voor het
metabolisme van homocysteïne. Om die reden onderzochten wij (HOOFDSTUK 4) de relatie
tussen de inname van folaat, riboflavine (vitamine B2), vitamine B6 and B12 en de
homocysteïneconcentratie. Voor dit onderzoek maakten we gebruik van een subgroep (n=2435)
van de hierboven beschreven aselecte steekproef. Een hogere inname van B-vitamines ging
samen met een lagere homocysteïneconcentratie. Wanneer echter gecorrigeerd werd voor
mogelijk verstorende variabelen (inname van andere B-vitamines, inname van methionine,
leeftijd, roken en het drinken van alcohol) bleek dat alleen de folaatinname invers geassocieerd
was met de homocysteïneconcentratie. Een gemiddeld lage folaatinname (mannen: 161,
vrouwen 160 µg per dag) ging samen met een hoge homocysteïneconcentratie: bij mannen
gemiddeld 15,4 µmol/L en bij vrouwen gemiddeld 13,7 µmol/L. Een gemiddeld hoge
folaatinname (mannen: 254, vrouwen 262 µg per dag) ging samen met een lage
homocysteïnewaarde: bij mannen gemiddeld 13,2 µmol/L en bij vrouwen gemiddeld 12,4
µmol/L. Bij mannen was het verschil in homocysteïnegehalte tussen een lage en hoge
folaatinname groter bij rokers dan bij niet-rokers (2,8 vs. 1,6 µmol/L). Dit was ook het geval bij
mannen die geen alcohol dronken vergeleken met mannen die meer dan 2 alcoholische dranken
per dag gebruikten (3,5 vs. 1,4 µmol/L). Wij concludeerden dat in de Nederlandse bevolking
folaat als enige B-vitamine invers geassocieerd was met de homocysteïneconcentratie. Een
hogere folaatinname via de voeding zou dus een verlagend effect kunnen hebben op de
homocysteïneconcentratie.
Naast B-vitamines is ook de activiteit van enzymen die een rol spelen in het
homocysteïnemetabolisme van belang voor het homocysteïnegehalte. Het enzym 5,10-
methyleen-tetrahydrofolaatreductase (MTHFR) produceert de belangrijkste circulerende vorm
van folaat die nodig is voor de omzetting van homocysteïne naar methionine. Een mutatie in
het gen dat codeert voor MTHFR, het 677 C>T polymorfisme, vermindert de enzymactiviteit. De
enzymactiviteit is normaal bij personen met het CC-genotype, enigszins verminderd bij
personen met het CT-genotype en duidelijk verlaagd bij personen met het TT-genotype. In
HOOFDSTUK 5 beschreven we de consequenties van dit genotype voor de folaatinname, het
plasmafolaatgehalte en het homocysteïnegehalte. Opnieuw voerden we een dwarsdoorsnede-
onderzoek uit bij een subgroep (n=2051) van de aselecte steekproef. Het verband tussen
folaatinname en de plasmafolaatconcentratie was positief voor alle genotypen. De sterkste
positieve relatie was te zien bij personen met het CT-genotype: bij een lage folaatinname
(gemiddeld 155 µg per dag) was de plasmafolaatconcentratie van personen met het CT-
genotype vergelijkbaar met die van personen met het TT-genotype (CT: 5,8; TT: 5,7 nmol/L),
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echter bij een hogere folaatinname (gemiddeld 267 µg per dag) was de plasmafolaat
concentratie gelijk aan die van personen met het CC-genotype (CT: 8,4; CC: 8,7 nmol/L). Bij
personen met het TT-genotype bleek de plasmafolaatconcentratie altijd lager te zijn dan die van
personen met het CT- en CC-genotype ondanks gelijke folaatinname. De relatie tussen het
plasmafolaatgehalte en het homocysteïnegehalte was invers voor alle genotypen en het sterkst
bij personen met het TT-genotype: bij een lage plasmafolaatconcentratie (gemiddeld 4,0
nmol/L) was de homocysteïneconcentratie veel hoger dan voor de andere genotypen (TT: 20,9,
CT: 15,4; CC: 14,3 µmol/L), terwijl bij een hoge folaatconcentratie (13,7 nmol/L) het verschil in
homocysteïneconcentratie tussen de genotypen verwaarloosbaar was. De relatie tussen
folaatinname en het homocysteïnegehalte was eveneens invers en het duidelijkst bij personen
met het TT-genotype. Onze resultaten wezen erop dat personen met het TT-genotype op zijn
minst 10% meer folaat uit de voeding nodig hebben dan personen met het CT- en CC-genotype
om een vergelijkbaar hoog plasmafolaatniveau en een vergelijkbaar laag homocysteïneniveau te
verkrijgen.
In HOOFDSTUK 6 beschreven we de relatie tussen de leefstijlfactoren koffie-, thee- en
alcoholconsumptie, lichamelijke activiteit en roken en de homocysteïneconcentratie. We
gebruikten de cross-sectioneel verkregen informatie van 2601 personen uit de aselecte
steekproef. De leefstijlfactoren die het sterkst gerelateerd waren aan de
homocysteïneconcentratie waren koffieconsumptie (positief verband), roken (positief verband)
en alcoholconsumptie (invers verband). Er was geen statistisch significant verband tussen het
drinken van thee en de homocysteïneconcentratie. Het verband tussen lichamelijke activiteit en
het homocysteïnegehalte was alleen bij vrouwen zwak positief. Onafhankelijk van andere
leefstijlfactoren, leeftijd, folaatinname, en inname van B-vitamine supplementen was het
drinken van meer dan 6 kopjes koffie per dag geassocieerd met een 1,4 µmol/L hogere
homocysteïneconcentratie bij mannen en een 1,1 µmol/L hogere homocysteïneconcentratie bij
vrouwen, in vergelijking tot personen die geen koffie drinken. Het effect van roken was het
sterkst bij vrouwen. Bij de niet-rokende vrouwen was de homocysteïneconcentratie 0,8 µmol/L
lager dan bij vrouwen die meer dan 20 sigaretten per dag rookten. Het effect van
alcoholconsumptie was het duidelijkst bij mannen. Bij mannen met een folaatinname lager dan
de mediaan (204 µg per dag), was de homocysteïneconcentratie bij niet-drinkers 1,7 µmol/L
hoger dan bij mannen die meer dan 2 glazen alcohol per dag dronken. Bij mannen met een
folaatinname boven de mediaan was dit verschil in homocysteïneconcentratie 0,8 µmol/L. Op
basis van deze resultaten concludeerden wij dat een verandering in leefstijl het
homocysteïnegehalte kan beïnvloeden.
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Het inverse verband tussen alcoholconsumptie en het homocysteïnegehalte bij mannen werd
nader bestudeerd in HOOFDSTUK 7. Hier maakten we onderscheid tussen drie soorten
alcoholische dranken: bier, wijn en sterke drank. Onafhankelijk van andere leefstijlfactoren en
de inname van B-vitamines, was het drinken van bier geassocieerd met een lagere
homocysteïneconcentratie. Mannen die geen bier dronken hadden een
homocysteïneconcentratie van 14,3 µmol/L, terwijl mannen die gemiddeld 3,7 glazen bier per
dag dronken een homocysteïneconcentratie van 13,0 µmol/L hadden. Het drinken van wijn of
sterke drank had geen effect op de homocysteïneconcentratie. Dit komt mogelijk door de
beperkte consumptie van dit soort dranken in vergelijking met die van bier. Het feit dat bier
folaat en andere B-vitamines bevat, kan de gevonden relatie waarschijnlijk niet verklaren omdat
we voor deze effecten gecorrigeerd hadden. Dit zou er op kunnen wijzen dat de inname van
ethanol verantwoordelijk is voor het inverse verband met de homocysteïneconcentratie. Dit
konden wij niet nader onderzoeken, aangezien bier in onze onderzoekspopulatie de
belangrijkste bron van ethanol was.
In HOOFDSTUK 8 zijn we nagegaan in hoeverre biologische risicofactoren voor coronaire
hartziekten geassocieerd zijn met de homocysteïneconcentratie. Voor dit onderzoek maakten
we gebruik van de gegevens over het totaal- en HDL-cholesterolgehalte, de systolische en
diastolische bloeddruk en de buikomtrek van de aselecte steekproef. Alleen bij vrouwen bleek
het totaal en het HDL-cholesterolgehalte geassocieerd met de homocysteïneconcentratie, ook
ná correctie voor leefstijlfactoren, andere biologische risicofactoren voor coronaire hartziekten
en folaatinname. De andere biologische risicofactoren waren niet geassocieerd met de
homocysteïneconcentratie. Vrouwen met een totaal cholesterolgehalte in het laagste kwartiel
hadden een homocysteïneconcentratie die 0,6 µmol/L lager was dan die van vrouwen met een
totaal cholesterolgehalte in het hoogste kwartiel. De associatie tussen het HDL-
cholesterolgehalte en het homocysteïnegehalte was invers: vrouwen met een HDL-
cholesterolgehalte in het laagste kwartiel hadden een homocysteïneconcentratie die 1 µmol/L
hoger was dan bij vrouwen in het hoogste HDL-kwartiel. Ofschoon niet alle biologische
risicofactoren statistisch significant geassocieerd waren met de homocysteïneconcentratie, blijft
het van belang om het effect van deze factoren te evalueren. Immers, de resultaten wijzen op
een verband tussen biologische risicofactoren en het homocysteïnegehalte in de richting van
een verhoogd risico op coronaire hartziekten.
De resultaten van prospectieve studies omtrent de relatie tussen het homocysteïnegehalte en
de kans op coronaire hartziekten zijn niet consistent. Dit is ook het geval voor prospectieve
studies die gekeken hebben naar de associatie tussen de plasma concentraties van B-vitamines
(invers geassocieerd met de homocysteïneconcentratie) en de kans op coronaire hartziekten.
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Om meer inzicht in deze relaties te krijgen onderzochten wij het verband tussen enerzijds de
plasmaconcentraties van homocysteïne, folaat, vitamine B6 (PLP) en vitamine B12 en anderzijds
de sterfte aan coronaire hartziekten in HOOFDSTUK 9. Dit onderzoek werd uitgevoerd met
gegevens van een cohort van ruim 36.000 mannen en vrouwen (20-59 jaar) wat gevolgd werd
gedurende een periode van 10,3 jaar gemiddeld. Dit onderzoek had een zogenaamd “case-
cohort” opzet. Dit wil zeggen dat we van het totale cohort alleen gebruik maakten van de
gegevens van een aselecte steekproef van 630 deelnemers en van alle 102 sterfgevallen aan
coronaire hartziekten. Alle personen hadden bij aanvang van het onderzoek geen hart- en
vaatziekten.
Na correctie voor leeftijd, geslacht, onderzoekscentrum, hypertensie, HDL- en totaal
cholesterol, roken en de kreatinineconcentratie constateerden we dat elke 5 µmol/L stijging van
het homocysteïnegehalte geassocieerd was met een statistisch niet-significante stijging van 3%
in de kans op sterfte aan coronaire hartziekten (Relatief Risico (RR): 1,03; 95%
betrouwbaarheidsinterval (BI)=0,83-1,29). Verder vonden we dat uitsluitend voor vrouwen gold
dat een hogere plasmafolaatconcentratie geassocieerd was met een statistisch significante
bescherming tegen coronaire hartziekten: elke 5 nmol/L stijging van de
plasmafolaatconcentratie was geassocieerd met een RR van 0,16 (95% BI=0,03-0,78). De
plasmaconcentraties van PLP en vitamine B12 waren niet geassocieerd met het risico van
sterfte aan coronaire hartziekten. We concludeerden dat een verhoogde
homocysteïneconcentratie geen belangrijke risicofactor is voor sterfte aan coronaire hartziekten
in deze populatie van relatief jonge Nederlandse personen. Bij vrouwen zou een hogere
plasmafolaatconcentratie mogelijk het risico van coronaire hartziekten kunnen verlagen.
In HOOFDSTUK 10 zijn de resultaten van dit proefschrift besproken in het licht van andere
epidemiologische bevindingen. Hierbij kregen methodologische aspecten aandacht en verder
werd geëvalueerd in hoeverre er bewijs bestaat dat een verhoging van het
homocysteïnegehalte een oorzakelijke rol speelt in het ontstaan van coronaire hartziekten.
Van de onderzochte factoren waren de folaatinname, koffieconsumptie en het 677 C>T
polymorfisme in het MTHFR-gen de belangrijkste determinanten van het homocysteïnegehalte.
Dit komt overeen met de resultaten van andere epidemiologische onderzoeken. Meer onderzoek
is nodig naar de mogelijk inverse relatie tussen alcoholconsumptie en de
homocysteïneconcentratie aangezien er ook studies zijn die een positief verband rapporteren.
Ook de relatie tussen roken en de homocysteïneconcentratie zou nader bestudeerd moeten
worden, omdat andere leefstijlfactoren, waarvoor moeilijk te corrigeren is, mogelijk
verantwoordelijk zijn voor het gevonden positieve verband tussen roken en een hoge
homocysteïneconcentratie.
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Onze bevinding dat verhogingen in het homocysteïnegehalte geen belangrijke risicofactor zijn
voor het sterven aan coronaire hartziekten komt overeen met 8 van de 17 gepubliceerde
prospectieve studies over hetzelfde onderwerp. De reden dat wij geen statistisch significant
verband hebben gevonden kan liggen aan methodologische aspecten van ons onderzoek; de
condities van bloedafname en opslag waren niet optimaal voor de homocysteïnebepaling. Dit
kan hebben geleid tot een afzwakking van het verband tussen de homocysteïneconcentratie en
sterfte aan coronaire hartziekten. Het lijkt echter waarschijnlijker dat de verklaring ligt in het
mechanisme waarmee verhogingen in de homocysteïneconcentratie de kans op coronaire
hartziekten verhogen. Een aantal onderzoekers heeft namelijk geopperd dat een verhoogde
homocysteïneconcentratie een korte-termijn risicofactor is, die het effect van andere
risicofactoren voor coronaire hartziekten (zoals hypertensie en hypercholesterolemie) verergert,
en op deze manier een acuut coronair incident induceert. Wanneer deze hypothese klopt dan is
het logisch dat een verhoging van het homocysteïnegehalte geen belangrijke risicofactor is in
een langlopend prospectief onderzoek met relatief jonge personen zonder hart- en vaatziekten.
Het voorgestelde werkingsmechanisme lijkt ook een deel van de verschillen tussen uitkomsten
van alreeds gepubliceerde prospectieve studies te verklaren. De hypothese dat homocysteïne
een korte-termijn risicofactor is, is echter voornamelijk gebaseerd op prospectieve onderzoeken
met personen die geselecteerd waren op hun hoge risico voor het krijgen van hart- en
vaatziekten. Deze laten consistent een sterk verband zien tussen het homocysteïnegehalte en
de kans op coronaire hartziekten. De moeilijkheid bij dit soort onderzoeken is dat niet is uit te
sluiten dat het verhoogde homocysteïnegehalte een gevolg is van reeds aanwezige vaatschade
in deze personen.
De enige onderzoeken die een antwoord op het causaliteitsvraagstuk kunnen geven zijn
interventiestudies. Momenteel worden verschillende secundaire interventiestudies uitgevoerd
waarin personen met een hoog risico op hart- en vaatziekten supplementen met foliumzuur,
vitamine B6 and B12 toegediend krijgen. Indien deze interventiestudies aantonen dat een
homocysteïneverlaging door deze supplementen gepaard gaat met minder gevallen van
coronaire hartziekten, dan vormt dit een sterk bewijs voor de hypothese dat het
homocysteïnegehalte een factor is die coronaire hartziekten veroorzaakt bij hoog-risico
personen. Het is echter wel zo dat een daling in het aantal gevallen van coronaire hartziekten
ook (mede) het gevolg kan zijn van een hogere inname van B-vitamines. Interventiestudies met
andere homocysteïneverlagende stoffen (zoals betaïne) zouden de vraag kunnen beantwoorden
of bescherming tegen coronaire hartziekten een gevolg is van de verlaging van het
homocysteïnegehalte, of van de verhoging van de inname van B-vitamines. Interventiestudies
bij ogenschijnlijk gezonde personen (dat wil zeggen zonder hart- en vaatziekten, diabetes,
hypertensie, etc.) met een verhoogd homocysteïnegehalte, zijn de enige studies die kunnen
Samenvatting
168
aantonen of er een causale relatie bestaat tussen het homocysteïnegehalte en coronaire
hartziekten bij gezonde personen.
Concluderend kan gesteld worden dat een verhoogde homocysteïneconcentratie geen
belangrijke risicofactor zijn voor het krijgen van coronaire hartziekten bij gezonde personen.
Echter, bij hoog-risico personen zijn verhogingen in het homocysteïnegehalte wel consistent
geassocieerd met een verhoogd risico op coronaire hartziekten. Daarom sluiten we ons aan bij
de recente richtlijnen van de Nederlandse Hartstichting die adviseert om bij personen met een
hoog risico op hart- en vaatziekten het homocysteïnegehalte te bepalen. Als het
homocysteïnegehalte verhoogd is, kan onder strikte voorwaarden behandeling met 500 µg
foliumzuur per dag worden toegepast. Extra foliumzuur zal tot een daling van het
homocysteïnegehalte leiden en mogelijk tot een daling van de kans op het krijgen van coronaire
hartziekten. Voor gezonde personen blijft het belangrijk om tenminste de aanbevolen
hoeveelheid van twee ons groenten en twee stuks fruit per dag, op te volgen. Het gebruik van
meer plantaardige producten gaat gepaard met een hogere folaatinname en tegelijkertijd ook
met een hogere inname van andere plantaardige stoffen die een positief effect op de
gezondheid hebben.
DANKWOORD
Dan ben ik nu aangekomen aan het deel van het proefschrift dat de meeste mensen het
eerste lezen: het dankwoord. Een proefschrift schrijven doe je niet alleen en daarom wil ik even
stilstaan bij de vele mensen die hebben bijdragen aan het totstandkomen van dit (tot nu toe)
levenswerk.
Allereerst mijn co-promotor Monique Verschuren. Ondanks dat jouw hart misschien meer ligt
in het cholesterolonderzoek, heb je je niet afgesloten voor mogelijke andere risicofactoren voor
hart- en vaatziekten. Het onderzoek zoals beschreven in dit proefschrift is door jou bedacht, en
ik ben je dankbaar voor het vertrouwen dat je mij hebt gegeven om het onderzoek uit te
voeren en voor de vrijheid die je mij gaf om mijzelf te ontwikkelen gedurende dit promotie-
traject. Henk Blom, mijn tweede co-promotor, wil ik bedanken voor alle hersencel-prikkelende
inhoudelijke discussies die in de afrondende fase van dit boekje gewoon doorgingen terwijl je
op sabbatical leave in Californië was. Ik bewonder de vrolijkheid waarmee jij elk probleem
tegemoet gaat en de manier waarop jij met eigenwijze mensen zoals ik omgaat. Tot slot nog
een woordje tot jullie allebei: dank jullie wel voor de interesse die jullie altijd hebben gehad
voor de persoon ‘achter’ de AIO!
Daan Kromhout, mijn eerste promotor, jij bent vooral bij de laatste fase van het schrijven van
mijn proefschrift, ondanks (ook jouw) sabbatical leave, nauw betrokken geweest. Ik heb in een
korte tijd van je geleerd argumenten kwantitatief te onderbouwen en aan te scherpen! Hartelijk
dank voor je inzet en voor het snel en doeltreffend corrigeren van mijn manuscripten. Frans
Trijbels, mijn tweede promotor, jij was letterlijk en figuurlijk wat verder van de materie van
mijn proefschrift verwijderd. Dat nam echter niet weg dat je altijd mijn stukken punctueel las en
ze op tijd weer terugstuurde, zelfs als dat moest gebeuren tijdens je vakantie of vrije avonden.
Bedankt voor je inspanning.
Petra, officieel was je niet betrokken bij mijn project maar meerdere malen heb je je
belangeloos ingezet om met mij vraagstukken onder de loep te nemen. Je weet dat je mijn
“Grote Voorbeeld” bent en daarom ben ik erg blij dat je in mijn promotiecommissie hebt willen
plaatsnemen!
Mijn onderzoek had nooit plaats kunnen vinden zonder deelnemers en medewerkers van het
MORGEN- en Peilstationsproject. Ik ben ook dank verschuldigd aan de RIVM-medewerkers die
als vrijwilligers meededen aan mijn stabiliteitsstudie. Daarnaast wil ik Maria van Hemert-Jansen
en Saskia Houterman bedanken, die mij hielpen bij het uitvoeren van de laatstgenoemde studie.
Voor de onderzoeken die beschreven zijn in dit proefschrift zijn ruim tienduizend bloedjes
gelicht uit diverse vriezers. Om dit helse karwei te klaren heb ik hulp gehad van veel collega’s:
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hartstikke bedankt! De koningin onder de lichters verdient het om persoonlijk genoemd te
worden: Jolanda, dank je wel dat je keer op keer meeging naar de vriezers in Nieuw Vennep
om er onder andere voor te zorgen dat ik niet ingevroren tussen de Friko-frietjes achterbleef.
In het grote aantal bloedmonsters zijn meerdere bepalingen gedaan, en voor hulp en inzet
daarbij wil ik graag de volgende mensen heel hartelijk danken. Allereerst de ‘homocysteïne-
dames’ uit Nijmegen. Addy, Dinny, Maria en Stephanie zonder jullie was er geen proefschrift
geweest! Ten tweede wil ik Barbara Hoebee en de vele medewerkers van LEO bedanken voor
de ontelbare DNA-isolaties. Daarnaast hebben in Nijmegen verschillende mensen zich naast hun
normale werk ingezet om voor mijn project mutatie-analyses te doen. Nathalie, Sandra,
Henriëtte en Alexandra: mijn dank is groot. Voor enkele vitaminebepalingen ben ik zelf naar
laboratoria in Noorwegen en Amerika gegaan. Dear Per Ueland, Helga Refsum and Jacob
Selhub, thank you so much for having me over in your laboratories. As I have no laboratory
background, the kind and patient daily supervision of Anne-Lise and Gre in Bergen and of Marie
in Boston was indispensable. Thank you! Karin Wichers, dankjewel voor je hulp en je
gezelschap in Bergen! Als laatste ben ik Siem Klaver en Doriene Swinkels van het CKCL in
Nijmegen erkentelijk voor de gestroomlijnde aanlevering van de resultaten van de vitamine B6
en kreatinine bepalingen.
Voor secretariële, automatiserings- en statistische ondersteuning ben blij dat ik terug kon
vallen op Cécile, Lydia, Els, Hans, Jan, Ruud, Nico, Cor en Hendriek. Nog even speciaal wil ik
Anita, de secretaresse van Henk, en Anke, de secretaresse van Daan noemen. Anita, dankjewel
voor je niet aflatende meedenken, meeleven en hulp terwijl Henk in Amerika zat. Anke, als iets
in jouw handen terecht kwam dan wist ik dat het goed kwam!
Natuurlijk wil ik ook alle collega’s van het RIVM en Nijmegen bedanken voor hun bijdrage -op
welke manier dan ook- aan mijn proefschrift! Een aantal wil ik met name bedanken. Als eerste
mijn kamergenootjes Claudia en Margje. Ik heb het echt getroffen met zulke leuke meiden als
jullie. Ik heb de afgelopen maanden langzaam kunnen wennen aan jullie afwezigheid, maar ik
zal jullie nog vaak missen. Het was heerlijk om jullie als klankbord te hebben voor vraagstukken
waar ik soms niet uitkwam. Tegen de tijd dat ik in staat was onder woorden te brengen waar ik
mee zat, was ik er meestal al voor een groot deel uit. Bedankt voor jullie geduldige luisterende
oren! Maar bovenal bedankt voor jullie vriendschap. De vriendschap van Jantine, Jean, Sandra,
Susan en Saskia zal ik ook missen. Ten tijde van regen en van zonneschijn stonden jullie voor
mij klaar en dat heeft heel erg veel voor mij betekend! Naast ‘bijstand’ op het persoonlijke vlak,
heeft een aantal van jullie in de eindfase van mijn proefschrift mij met raad en daad bijgestaan
en mijn stukken gelezen plus becommentarieerd. Hartelijk dank. Tommy, Rob, Caroline, Ilja,
Marga, Edith, Ina, Peggy, Jolanda, Wanda, Wil en Cora: bedankt voor de gezelligheid op en
buiten het werk. Van de Nijmeegse collega’s wil ik Nathalie, Sandra, Karin, Lydia, Maarten, en
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Leo bedanken. Dankzij jullie waren de homocysteïne-congressen en –bijeenkomsten naast
leerzaam ook een feest om naar uit te kijken!
Vele vrienden hebben belangstelling gehad in wat ik deed en stonden onvoorwaardelijk voor
mij klaar. Speciaal wil ik Louise, Leone, Laura, Erica, Melanie, Marjakke, Menrike, Mirjam W. en
Mirjam Z. noemen: jullie zijn echte schatten! Lieve Carin, jou wil ik bedanken voor je niet
aflatende opgewektheid, je goede zorgen en je grote geduld met die huisgenoot met een
ochtendhumeur en allerlei andere afwijkingen. Lieve Mariek, toen we samenwoonden scherpten
we elkaar door discussies over functional foods (Goede Morgen) en vele andere onderwerpen.
Ik vond het een uitdaging steeds weer antwoorden te vinden op de vragen die je stelde over
mijn werk. Ik ben heel blij dat jij me wilt bijstaan als paranimf. Lieve Jen, onze vriendschap
gaat al heel lang terug en betekent veel voor mij. Promoveren zonder jou aan mijn zijde is voor
mij niet denkbaar. Dankjewel dat je zo’n schat voor mij bent.
Dan wil ik graag mijn ouders bedanken voor alles wat ze voor mij betekenen. Zonder jullie
was ik er niet geweest en aan jullie draag ik dan ook mijn proefschrift op! Lieve mamma, ik wil
jou verder bedanken voor het prachtige schilderij dat de omslag van mijn proefschrift siert.
Lieve broer, bedankt voor jouw heldere kijk op de wereld. Met jouw relativeringsvermogen,
scherpe analyses en humor heb je mij heb je mij keer op keer op weg geholpen. Lieve Freek,
de laatste woorden van dit dankwoord zijn voor jou. Jij maakt het verschil! Dankjewel dat je
met mij mee naar Parijs gaat.
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